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AbsTrACT
background: Risk assessment can potentially be improved by closely linked experiments in 
the disciplines of epidemiology and toxicology. This was explored for isoflavones in a case 
study. Isoflavones are suggested to have potential beneficial effects, but discussions on their 
safety are ongoing as well.
Aims and methods: Effects of isoflavone supplements on gene expression were studied 
in white blood cells (PBMCs) and adipose tissue, among postmenopausal women in two 
human intervention studies. To advance risk assessment, the dose-response relation between 
isoflavone intake and plasma concentrations was studied with a log-linear regression model. 
Furthermore, human gene expression profiles after isoflavone supplementation were 
quantified and compared to results from a rat experiment using multivariate analysis. 
results: In both PBMCs and adipose tissue, changes in gene expression profiles pointed 
at effects of isoflavones on energy metabolism, inflammation and cell cycle; these effects 
were modified by supplement composition and equol-producing phenotype. Hypothesized 
estrogen-responsive effects were not observed. For the intake range of 0-100 mg/day, the 
plasma concentrations of daidzein, equol, genistein and total isoflavones were quantified, but 
a large degree of inter-individual variation was observed. Effect sizes of estrogen-responsive 
gene profiles and other biological pathways could be quantitatively compared between 
PBMCs and adipose tissue, as well as between humans and rats. 
Conclusion: Effects of isoflavone supplementation on gene expression in PBMCs and 
adipose tissue of postmenopausal women suggested mainly beneficial effects of a dose of 
~100 mg/day. The absence of a distinct estrogen-like response suggested a limited role of 
the estrogen receptor in isoflavone induced gene expression in postmenopausal women. 
Modelling exposure marker and gene expression data from human and animal studies 
provided important tools for further exploration of intertissue and interspecies similarities 
and for the use of transcriptomics in improving risk assessment.
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Improvement of rIsk assessment wIth Isoflavones as 
a case study
The idea of this project originated from the need to improve risk assessment in the 
domain of food, nutrition and health. To this end, the Netherlands Food Safety Authority 
funded a study in 2009 on the improvement of risk assessment. This resulted in a Dutch 
report, representing an inventory of views of experts in toxicology and epidemiology on 
the current risk assessment process and on how toxicology and epidemiology can work 
together to improve risk assessment (1). It was concluded that both disciplines could 
complement each other in the risk assessment process with regard to research on dietary 
intake, exposure markers, early effect markers and disease endpoints (Figure 1.1). In this 
approach, measurement of exposure markers and early effect markers would need to be 
further standardized and aligned in a collaboration between the two disciplines, for instance 
with human intervention studies and animal experiments. Furthermore, epidemiology 
would provide insight in dietary intake across the population. While in toxicology, data on 
health endpoints could be obtained in animal experiments (Figure 1.1).
figure 1.1 The concept of integrating toxicological and epidemiological approaches to improve 
risk assessment.
Epidemiology 
Two human intervention studies
Toxicology 
One rat experiment
Intake
Exposure 
markers
Early effect 
markers
Health 
endpoints
In this thesis, the practical application of this concept was further developed using 
isoflavones as a case study. This topic was chosen, because safety of isoflavone consumption 
at higher doses was under debate and concerns existed on effects of isoflavones on tumour 
promotion and thyroid function (2-4).
rIsk assessment
assessment of risks and benefits in nutritional toxicology
Risk assessment has been defined by the EU as: ‘a scientifically based process consisting 
of four steps; hazard identification, hazard characterisation, exposure assessment and 
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risk characterisation’ (EC No 178/2002 (5)). These four steps are a framework in which 
scientific data on health risks are evaluated and translated for risk management (6). Ideally, 
information on associations with human health endpoints, like cancer risk, are derived 
from observational studies, as done for chromium by Goldbohm et al. (7, 8). In practice, 
human data on hard endpoints is often lacking or incomplete and instead data from animal 
experiments is extrapolated to the human situation with the use of uncertainty factors, 
typically one for intraspecies variability and one for interspecies variability (9). The traditional 
uncertainty factors – 10 for intraspecies and 10 for interspecies – were applied to a reference 
dose at which adverse health effects are considered absent in animal experiments. These 
uncertainty factors have been updated over the years starting with separate uncertainty 
factors for pharmacokinetics and pharmacodynamics (9). More recently, the concept of 
allometric scaling of metabolic rate between species was further developed, in which an 
interspecies factor of 4 for rat to human and 7 for mouse to human was derived (10). Other 
initiatives derived similar interspecies factors from No Observed Effect Level (NOEL) or 
Benchmark Dose (BMD) comparisons together with their factor distribution from different 
databases, like RepDose and technical reports from the National Toxicology Program (11, 
12). The uncertainty caused by extrapolation is only one of several sources of uncertainty 
and variability in all steps of the risk assessment process (13) and underlines the need for 
improvement of this process.
parallelogram approach for improvement of risk assessment
The Dutch report concluded that risk assessment could be improved by concentrating 
research on intake and health endpoints, along with further standardization of exposure 
markers and early effect markers measured in both human intervention studies and 
animal experiments (Figure 1.1 (1)). In a practical setting, this would imply the design of 
an animal experiment completely aligned to a human intervention study with regard to 
dose, duration and target group. This way, observed effects can be evaluated between 
species using a parallelogram approach with intake, exposure markers, early effect markers 
and hard endpoints as ‘linking pins’ enabling a comparison between species (Figure 
1.2). With regard to early effects markers, toxicological research is currently exploiting 
high throughput techniques and computational models to detect early perturbations in 
biological systems to reduce animal experiments on disease endpoints (14). Detection 
of early perturbations of health is also key in human intervention studies (15), because 
toxicological studies on disease endpoints are not ethical in humans. Therefore, this 
detection of early perturbations, for instance by transcriptomics, represents a potentially 
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new opportunity to fill a knowledge gap in risk assessment by comparing gene expression 
effects between animals and humans.
This practical setting for improvement of risk assessment was applied in a case study with 
isoflavones, in which two human intervention studies were conducted at the department 
of Human Nutrition (this thesis) as well as a rat experiment by the sub-department of 
Toxicology of Wageningen University.
Isoflavones
from soy plants to the systemic circulation
The three major isoflavones, daidzein, genistein and glycitein, are phytoestrogens that are 
naturally present in soy and soy products. The soy plant (Glycine max) consists of different 
parts in which the isoflavone content and ratio between the individual isoflavones vary 
(16). The composition is further influenced by plant genotype and environmental factors 
during growth (17). Isoflavone molecules in soy plants are often bound to glucose and 
therefore denoted as daidzin, genistin and glycitin. These glucosides can be also be present 
figure 1.2 The practical parallelogram approach for improvement of risk assessment. Uncertainty 
in extrapolating human health endpoint from animal studies depends on the comparability of 
pathways from intake to health endpoints in both species. In the current thesis, this was estimated 
using similar markers and comparable methodologies.
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in esterified form, with either malonyl or acetyl groups (18). Methylated forms of daidzein 
and genistein, like formononetin and biochanin A, occur mainly in red clover and alfalfa 
sprouts (19).
Mean intake of isoflavones in European countries is estimated to be 0.5-0.8 mg/day for the 
general population, while vegetarians and vegans in the UK are reported to consume on 
average 22.4 mg isoflavones/day (20). In Japan, mean intakes of daidzein and genistein 
of respectively 18.3 and 31.4 mg/day have been observed (21). In Western countries, 
supplement users are reported to consume 50 mg isoflavones/day on average, but soy-
based dietary supplements can contain up to 107 mg aglycone equivalents of isoflavones 
(22-24). Although exact market figures are lacking, a recent review of surveys indicated 
that about 50% of the women are seeking alternative therapies for their menopausal 
symptoms and that phytoestrogen supplements are the second most popular alternative 
after herbal medicine (25).
After consumption of soy isoflavones, the isoflavone glucosides are deglycosylated during 
their journey through the gastro-intestinal tract by lactase phlorizin hydrolase (LPH) in the 
enterocyte brush border (26). Isoflavone glucosides are more bioavailable than aglycones 
due to their water solubility and stability, but aglycones can be more rapidly absorbed 
because they do not need to undergo deglycosylation (27). Uptake of the aglycone 
isoflavones occurs in the small intestine and the colon via passive diffusion (28), after which 
the isoflavones are conjugated by intestinal P450 enzymes with glucuronides or sulfonate 
esters and enter the bloodstream (27).
One of the isoflavones, daidzein, can be converted into equol by intestinal bacteria present 
in 25-30% of the Western population and 50-60% of the Asian population (29). These 
people are called equol producers and this is known as a relatively stable phenotype (30). 
In intervention and cross-sectional studies, equol production was shown to be associated 
with intake of several nutrients (31-33). Furthermore, the equol-producing phenotype was 
suggested to be affected by antibiotic treatment in an observational study (33), but this 
effect was not found in an intervention study (34). Next to equol, O-desmethylangolensin 
(O-DMA) is also a gut metabolite of daidzein, which is found to be produced in 92% of the 
Caucasian and 84% of the Korean American population of Seattle (35). 
from the systemic circulation to molecular effects of isoflavones
Isoflavones resemble the molecular structure of 17β estradiol (E2) and are known to bind 
to the estrogen receptors (ER) α and β, hence the name phytoestrogens (36). When ligands 
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bind to the ERs, homo- or heterodimers are formed with other ligand-bound ERs and this 
complex binds to the estrogen-responsive element (ERE) on the DNA and induces mRNA 
transcription. Moreover, the isoflavone-bound ERs can heterodimerize with specificity 
protein 1 (SP1) and activator protein-1 (AP-1) and bind to other promotor sequences to 
induce gene expression. Lastly, isoflavones can potentially induce non-genomic, rapid 
effects of membrane-bound ERs. These effects include changes in calcium and potassium 
signalling, increase in cAMP and phosphorylation of the cAMP response element binding 
protein (CREB) as well as activation of MAPK signalling (37). 
In addition to the ERα and ERβ, the G-protein coupled receptor 30 (GPR30) was recently 
established to be an ER and is now denoted as G-protein coupled ER (GPER, (38)). Although 
the structure of the isoflavones allows binding to all three ERs, they preferentially bind 
to the ERβ. Genistein has the highest binding affinity for ERβ and equol is suggested 
to have a similar or slightly lower binding affinity to this receptor. Daidzein has a lower 
binding affinity than genistein and equol, but has a higher binding affinity than glycitein 
and O-DMA (39-41). 
Isoflavones can also induce effects on gene expression via other nuclear receptors and 
pathways. For instance, they are known to activate the progesterone receptor (PR), androgen 
receptor (AR), peroxisome proliferator-activated receptors (PPARs), aryl-hydrocarbon 
receptor (AhR), but also the Vitamin D receptor (VDR) and Retinoic acid receptor (RAR) 
(42, 43). 
Because of their estrogen-like structure, effects of isoflavones are expected to be 
predominantly mediated via the ERs, and tissues expressing these receptors are potential 
target tissues of isoflavone action. Thus, the main target tissues of interest are in the 
reproductive system, like breast, uterus and prostate tissue. However, other tissues like 
bone, liver and adipose tissue, and tissues in the cardiovascular and central nervous system 
are also known to express ERs (44, 45). 
Beneficial effects of isoflavones
Adlercreutz et al. (46) suggested in 1992 that higher isoflavone concentrations in urine of 
Japanese compared to American and Finnish women could explain the lower frequency 
of hot flushes observed in Japan by Lock et al. (47). Other beneficial effects of isoflavone 
consumption suggested from epidemiological research were reduced incidence of 
osteoporosis, cardiovascular disease, and certain cancers (48). Because of these suggested 
beneficial effects, soy products are more often consumed in Western countries in recent 
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years and a market for isoflavone supplements has emerged, especially for women 
experiencing menopausal complaints (25). A recent meta-analysis on the efficacy of 
isoflavone supplements on hot flushes indicated that these supplements potentially reduce 
the severity and the frequency of hot flushes (49). 
Another possible consequence of menopause is osteoporosis, which is enhanced by the 
decline in the production of endogenous estrogen (52). In epidemiological studies in Asian 
populations, isoflavone intake was suggested to decrease hip fracture risk and increase 
bone mineral density (53, 54). However, the effects of isoflavone supplementation in bone 
mineral density measured in a 3-year randomized controlled trial (RCT) suggested a modest 
protective effect only for neck bone mineral density (55). On the other hand, a meta-analysis 
showed protective effects only on lumbar spine bone mineral density after isoflavone 
supplementation (56). Finally, a recent systematic review showed a statistically significant 
increase in bone mineral density and the urinary bone resorption marker deoxypyridinoline 
(DPD), but these effects were dependent on menopausal status, supplement type, dose 
and duration of intervention (57).
Effects of isoflavones on cardiovascular disease (CVD) in RCTs point also towards beneficial 
effects, like a modest effect of isoflavones on flow mediated dilation (FMD) detected in 
a meta-analysis of RCTs (58). Another meta-analysis confirmed these effects, but only 
in women with low baseline FMD (59). Next to markers for endothelial function, effects 
on lipid profile and inflammation markers are often used as early cardiovascular health 
endpoints. A systematic review found lowering of triglycerides after isoflavone consumption, 
but no effects on other markers in the lipid profile (60). Furthermore, reported effects 
on inflammation markers related to CVD were not consistent, for instance lowering of 
C-reactive protein (CRP) was found in one study (61), while other studies reported positive 
effects on serum adiponectin concentrations (62), or found no effect on any of the markers 
measured (63).
Epidemiological studies in Asia showed that cancer incidence is lower in countries with 
higher isoflavone intake (64). Indeed, also a recent meta-analysis showed that soy food 
intake as consumed by the Asian population might be protective for breast cancer (65). 
It has been suggested that this protective effect mainly occurs due to soy consumption 
during childhood (3, 66). Although most of the research focusses on breast cancer, 
one observational study suggested that isoflavone intake also has beneficial effects on 
endometrial cancer occurrence (67). Suggestions of beneficial effects on other cancers, 
like in other tissues of the reproductive system, are limited (4).
IntroductionChapter 1
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potential harmful effects of isoflavones
Epidemiological studies suggest that breast cancer incidence is lower in Asian countries 
due to isoflavone intake. On the other hand, isoflavones are hypothesized to activate ERs 
in the same way as estrogens and these are known to increase breast cancer risk (2). This 
contradiction raises concern about potential adverse effects of isoflavones on breast cancer 
risk at higher doses (4). In this respect, a recent meta-analysis of eight RCTs found no effect 
of isoflavone intake on breast density in postmenopausal women, as a surrogate marker 
for breast cancer risk, although an increase was suggested in premenopausal women 
(68). Similarly, concerns exist on the effect of isoflavones on endometrial cancer risk (3), 
supported by results from animal experiments and from one human study (69). However, 
in two recent 2- and 3-year human intervention studies, no effects of isoflavone intake 
on endometrial thickness, as an intermediate marker for endometrial cancer risk, were 
found (55, 70). The last issue of concern regarding isoflavones is their suggested effect 
on thyroid function; isoflavone intake might interfere with thyroid metabolism and with 
synthetic thyroid hormone in patients suffering from hypothyroidism. This makes isoflavone 
intake of concern for vulnerable groups, like infants with hypothyroidism consuming 
soy milk (71).
rationale for human intervention studies
Altogether, beneficial and adverse effects of isoflavone intake are not yet established. 
Safety issues are of importance for subpopulations consuming high doses, like peri- and 
postmenopausal women consuming isoflavone supplements. Especially postmenopausal 
women, who do not produce endogenous estradiol to compete with isoflavones for the 
ERs, and those who produce equol, which is more active than daidzein, might be groups 
at risk of adverse effects of isoflavones. 
Potential beneficial effects are also relevant in this age group. During menopause, the 
decline in endogenous estrogen production induces adipose tissue distribution changes, 
which may eventually lead to the development of the metabolic syndrome (45). The 
metabolic syndrome co-exists with a pro-inflammatory state of the adipose tissue (72) and 
is associated with a two-fold increased risk of cardiovascular disease (73). It is hypothesized 
that isoflavones may have positive effects on these unfavorable body fat distribution 
changes (74, 75), but also on glucose metabolism, lipid metabolism and inflammation 
markers. 
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thesIs outlIne
To study the potential adverse and beneficial effects of isoflavones, two intervention studies 
were conducted, in which effects were assessed using whole-genome gene expression. The 
first intervention study focussed on the most vulnerable population of equol-producing 
postmenopausal women; in this study gene expression effects of isoflavones were measured 
in peripheral blood mononuclear cells (PBMCs, chapter 2). The second intervention 
study included the general postmenopausal population, both equol producers and non-
producers; in this study the effects of two different isoflavone supplements were studied 
in an estrogen-responsive tissue, i.e. adipose tissue (chapter 3).
The basic concept underlying this thesis was that alignment of human intervention 
studies and animal experiments would enable assessment of similar exposure markers 
and early effect markers (Figure 1.2), which would enable an integrated approach between 
epidemiology and toxicology for improvement of risk assessment (Figure 1.1). Therefore, 
in chapter 4, the relation between isoflavone intake and exposure markers was modelled 
using data from the two human intervention studies together with a third intervention 
study with a lower dose of isoflavones from soy foods. Finally, in chapter 5, data from 
the two human intervention studies was connected to a rat experiment conducted by 
the sub-department of Toxicology. In this last chapter, the similarity of isoflavone effects 
on early effect markers in PBMCs and adipose tissue of humans and rats was studied for 
improvement of risk assessment.
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ABSTRACT
Background: Isoflavones (genistein, daidzein, and glycitein) are suggested to have 
benefits as well as risks for human health. Approximately one-third of the Western 
population is able to metabolize daidzein into the more potent metabolite equol. 
Having little endogenous estradiol, equol-producing postmenopausal women who use 
isoflavone supplements to relieve their menopausal symptoms could potentially be at 
high risk of adverse effects of isoflavone supplementation. 
Objective: The current trial aimed to study the effects of intake of an isoflavone 
supplement rich in daidzein compared with placebo on whole-genome gene 
expression profiles of peripheral blood mononuclear cells (PBMCs) in equol-producing, 
postmenopausal women. 
Design: Thirty participants received an isoflavone supplement or a placebo for 8 wk 
each in a double-blind, randomized crossover design. The isoflavone supplement was 
rich in daidzein (60%) and provided 94 mg isoflavones (aglycone equivalents) daily. 
Results: Gene expression in PBMCs was significantly changed (P < 0.05) in 357 genes 
after the isoflavone intervention compared with placebo. Gene set enrichment analysis 
revealed downregulated clusters of gene sets involved in inflammation, oxidative 
phosphorylation, and cell cycle. The expression of estrogen receptor (ER) target genes 
and gene sets related to ER signaling were not significantly altered, which may be 
explained by the low ERα and ERβ expression in PBMCs. 
Conclusion: The observed downregulated gene sets point toward potential beneficial 
effects of isoflavone supplementation with respect to prevention of cancer and 
cardiovascular disease. However, whether ER-related effects of isoflavones are beneficial 
or harmful should be studied in tissues that express ERs.
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INTRODUCTION
Isoflavones are phytoestrogens present in soy and red clover. The main isoflavones 
in these plants are the glucosides genistin, daidzin, and glycitin. Their aglycones are 
known as genistein, daidzein, and glycitein. A potent metabolite of daidzein, equol, can 
be produced by certain intestinal bacteria that are present in 20–30% of the Western 
population (1). Positive health effects of isoflavones include a reduced risk of cancer and 
cardiovascular disease, as suggested by epidemiologic research in Asian populations 
who daily consume soy products (2). Other beneficial effects of isoflavones, relevant for 
peri- and postmenopausal women, relate to diminishing menopausal symptoms and 
osteoporosis. Due to these advocated effects of isoflavones, isoflavone supplementation is 
becoming more common in Western countries (3). However, the daily doses recommended 
by the suppliers of these supplements are relatively high compared with the traditional 
Asian soy diet; therefore, the safety of these supplements requires investigation. In this 
regard, recent reviews state that human, animal, and cell experimental studies remain 
inconclusive on whether isoflavones, especially as food supplements, are beneficial 
or potentially harmful (4, 5). Suggested adverse effects relate to cancer promotion in 
hormone-sensitive cancers, such as breast and uterus cancer, and effects on the thyroid 
gland when iodine intake is insufficient (4). With the positive and negative effects of 
isoflavone supplementation still under debate, we hypothesized that postmenopausal 
equol-producing women are particularly susceptible to the possible effects of isoflavone 
supplementation. Postmenopausal women produce little endogenous estradiol to 
compete with isoflavones for the estrogen receptor (ER) (6), therefore isoflavones could 
theoretically induce estrogen-responsive effects. Moreover, equol is a more potent 
activator of ERs than its precursor daidzein (7), and could therefore potentially be 
responsible for adverse effects of isoflavone supplementation. Effects of isoflavones are 
induced via ERα and ERβ, which are differentially distributed in different tissues (5, 8). 
Isoflavones may regulate transcription of ER target genes via the estrogen-responsive 
elements (EREs) present within gene promoter regions but may also have ER- and ERE-
independent effects. A good tool to study these isoflavone supplementation-induced 
pathways and signaling routes is whole-genome gene expression. Peripheral blood 
mononuclear cells (PBMCs) are easily accessible, and previous studies have shown that 
those cells can be used to study nutrition-induced effects on gene expression (9). A 
previous 84-d parallel intervention study demonstrated differential gene expression 
changes in PBMCs upon isoflavone supplementation (approximately 900 mg daily) in 
equol producers and non-producers, also on estrogen-responsive genes (10). These effects 
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were observed with a 16K oligo array upon consumption of a genistein-rich isoflavone 
supplement in 10 postmenopausal women receiving placebo treatment compared with 
11 postmenopausal women receiving isoflavone treatment, 2 and 5 of whom, respectively, 
were equol producers.
The current study aimed to determine effects on PBMC whole-genome gene expression 
of an isoflavone supplement rich in daidzein in a common dose for supplement users. For 
this study, 30 equol-producing, postmenopausal women were selected (i.e., those who 
convert the daidzein in this supplement to the more potent equol).
PARTICIPANTS AND meThODS
Participants
A total of 30 postmenopausal, equol-producing women were recruited for the trial. Equol 
producer status was tested following the protocol of Setchell and Cole (11). In short, the 
potential participants took 75 mg (aglycone equivalents) isoflavones as supplements daily 
for 3 d and delivered morning urine on the fourth day. Participants were designated as 
equol producers when the log10-transformed urinary S-equol:daidzein ratio was higher 
than 1.75. The participants were defined as postmenopausal when they had had their last 
menses > 1 y before the start of the study. When the participants’ last menses was between 
3 mo and 1 y ago, or when the potential participant had undergone a hysterectomy, 
the inclusion criterion was a follicle-stimulating hormone (FSH) concentration > 40 
IU/L. Exclusion criteria were as follows: regular use of soy products or regular intake of 
isoflavone supplements (more than once a week), current use of contraceptives containing 
hormones or hormone replacement therapy, current use of medication containing sex 
hormones or sex hormone–triggering compounds, current use of anti-inflammatory 
medicines, and use of antibiotics in the past 3 mo. Furthermore, women with severe heart 
disease, thyroid disorders, a removed thyroid gland, removed ovaries or prior diagnosis 
of cancer could not participate. Lifestyle-related exclusion criteria included alcohol and 
drug abuse, smoking, a BMI > 35 kg/m2, and allergy to soy. All participants consented to 
participate in the study. The study was approved by the medical ethical committee of 
Wageningen University.
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Study design
This randomized, double-blind, crossover, placebo-controlled study included two 8-wk 
intervention periods with one 8-wk washout period in between. A sample size of 30 
participants was postulated to be sufficient on the basis of previous nutritional intervention 
studies using whole-genome transcriptomics that found significant effects on gene 
expression profiles (9, 12). The participants were randomly allocated to receive either the 
isoflavone supplement or the placebo supplement in the first intervention period of 8 wk 
and the other treatment in the second intervention period. Stratified randomization was 
performed by an independent research assistant by using a computer-generated table of 
random numbers. Researchers as well as participants were blinded to randomization until 
after data analysis. The participants were asked to consume 4 capsules/d, 2 in the morning 
and 2 in the evening. The participants consumed 94 mg isoflavones (aglycone equivalents) 
daily (56 mg daidzein, 26 mg glycitein, and 12 mg genistein as analyzed in our laboratory). 
There was a run-in period of 4 wk before the start of the experimental treatments. The 
participants were asked not to eat soy foods during this period as well as during the trial. 
To aid in this, a detailed list of isoflavone-containing foods was provided to direct the 
participants. At the end of each 8-wk intervention period, the participants were asked to 
fill out an FFQ in order to monitor their eating habits during these periods (13).
Isoflavone supplement and placebo
The isoflavone supplement in capsules was commercially available (Phytosoya Forte, 35 mg) 
and manufactured and purchased from Arkopharma. For the placebo supplement, identical 
empty capsules and capsule bottles were purchased from Arkopharma and filled by Fagron. 
The placebo capsules were filled with microcrystalline cellulose; this was also the filler 
component of the isoflavone supplement. The capsules were made of hydroxypropylmethyl 
cellulose and dyed with iron oxide and titanium oxide.
Blood sampling and PBmC isolation
During each intervention period, the participants arrived in a fasted state at the research 
venue, at Wageningen University, at the start of the study, after 4 wk, and after 8 wk (6 visits 
in total). At each visit, fasting venous blood samples were obtained. Plasma was collected 
into 6-mL EDTA Vacutainers [Becton Dickinson (BD)], centrifuged for 10 min at 1190 g at 
a temperature of 4°C. Serum was collected in 8-mL BD SST tubes, centrifuged for 10 min 
at 1580 g at 20°C. For PBMC isolation, 8 mL of blood was collected in BD Vacutainer cell 
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preparation tubes. PBMCs were isolated immediately after blood collection according to 
the manufacturer’s instructions, dissolved in RLT buffer (Qiagen). All samples were stored 
until further analysis at 80°C.
RNA extraction and microarray processing
RNA was isolated from all PBMC samples by using Qiagen RNeasy Micro Kit (Qiagen). RNA 
yield was quantified on a Nanodrop ND 1000 spectophotometer (Nanodrop Technologies), 
and integrity was measured on an Agilent 2100 Bioanalyzer with RNA 6000 Nanochips 
(Agilent Technologies). PBMC samples from all 30 participants, after both placebo and 
isoflavone supplementation, yielded enough RNA of sufficient quality to perform microarray 
analysis. Microarray analysis was performed on samples from each individual obtained 
after 8 wk of isoflavone supplementation and 8 wk of placebo supplementation, resulting 
in a total of 60 microarrays. Total RNA was labeled by using a 1-cycle cDNA labeling kit 
(MessageAmp II-Biotin Enhanced Kit; Ambion) and hybridized to GeneChip Human 
Gene 1.1 ST Array targeting 19,738 unique gene identifiers (Affymetrix). Sample labeling, 
hybridization to chips, and image scanning were performed according to the manufacturers’ 
instructions.
cDNA synthesis and qPCR were performed to confirm the microarray data for ERα and ERβ 
expression. First, 500 ng of total RNA was reverse-transcribed with a Promega cDNA synthesis 
kit (Promega Benelux BV). cDNA was PCR-amplified with Platinum Taq DNA polymerase 
(Invitrogen) on a Biorad I-cycler PCR machine (Bio-Rad Laboratories BV). Primer sequences 
of ERα and ERβ were chosen on the basis of the sequences available in the National Center 
for Biotechnology Information’s BLAST (Basic Local Alignment Search Tool) (14). The mRNA 
expression of all genes was normalized to human ribosomal protein LP0 expression and 
expressed as 2-log ratios.
hPLC analysis of isoflavones in supplements and plasma
HPLC analyses were carried out with a CoulArray electrochemical detector equipped with a 
high-sensitivity analytical cell (model 6210, 4-sensor cell; ESA). CoulArray for Windows (ESA) 
was used for controlling the instrument and collecting the data from the electrochemical 
detector.
The isoflavone content of the supplements was analyzed on the basis of the method 
described by Penalvo et al. (15) with a platinum C18 column (Waters). Sample preparation 
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for the analysis of isoflavones in plasma was performed following the method proposed by 
Saracino and Raggi (16) and measured with a Symmetry Shield C18 column (150 mm x 4.6 
mm, 5µm) from Waters. For all analyses, a Brownlee Newguard precolumn (7µm; Shelton) 
was used. The isoflavones (daidzein, equol, genistein, and glycitein) were measured on 4 
channels; 300, 500, 550, and 600 mV. Daidzein, equol, and genistein were quantified at 500 
mV, whereas glycitein was quantified at 300 mV. The limit of detection for all isoflavones, 
except for glycitein, was 0.01 µg/mL, whereas the limit of quantification was 0.02µg/mL. 
For glycitein, these values were 0.03 and 0.06 µg/mL, respectively.
Serum hormone concentrations
To monitor the postmenopausal state of the participants, estradiol and FSH were measured 
in serum samples with an electrochemiluminescence immunoassay.
Data analysis
Two arrays for 2 different participants did not meet the quality criteria; therefore, arrays 
for 28 participants were analyzed by using MADMAX (Management and Analysis Database 
for Multiplatform Microarray Experiments) (17). Expression values were calculated with the 
Robust Multichip Average method and normalized by using quantile normalization (18, 
19). Genes with normalized expression values of > 20 on > 5 different arrays were defined 
as expressed and selected for further analysis. Filtered data were further analyzed with 
gene set enrichment analysis (GSEA) (20-22). Significantly regulated gene sets were defined 
with a false discovery rate of < 0.25. The gene sets were visualized and clustered by using 
Cytoscape (23) which enabled the identification of clusters of gene sets.
A list of estrogen-responsive genes was derived from the Dragon Estrogen-Responsive 
Gene Database comprising 1069 genes from Homo sapiens [data downloaded December 
2011 (24)]. This list was compared with the significantly changed genes in our study and 
visualized using a Venn diagram (25).
The statistical package SAS (version 9.2; SAS Institute) was used for statistical analysis of the 
data. Changes in plasma isoflavone concentrations after isoflavone supplementation and 
placebo were analyzed by paired t-tests. Changes in macronutrient intake, as measured 
by FFQs, after both intervention periods were expressed as percentages of total energy 
intake and compared by paired t-tests. All data were presented as means ± SDs unless 
indicated otherwise.
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ReSULTS
In total, 30 postmenopausal, equol-producing women participated in the study, and all 
participants finished the study. To recruit this number of equol producers, initially 150 
postmenopausal women were screened between September 2010 and March 2011. Forty-
two women (27%) were equol producers according to their urinary log10-transformed 
equol:daidzein ratio of > 1.75 after a 3-d isoflavone challenge. After application of the 
exclusion criteria, 30 participants entered the study between October 2010 and October 
2011. The participants were 61.1 ± 5.8 y old and had a BMI of 25.1 ± 3.7 kg/m2 at the 
start of the study. FSH concentrations, measured after 8 wk of isoflavone and placebo 
supplementation, were above the cutoff for postmenopause of 40 IU/L for all participants; 
therefore, we regarded all women as postmenopausal (26). Estradiol concentrations 
at baseline were below the postmenopausal cutoff of 110 pmol/L (27) for all except 
for 1 participant. After the 8-wk isoflavone supplementation, estradiol concentrations 
in all participants were below the cutoff; after the placebo period, 1 participant had a 
concentration > 110 pmol/L. Dietary habits were measured by FFQ, and a paired t-test 
revealed that intakes of energy, fat, protein, and carbohydrate did not differ significantly 
between the isoflavone and placebo periods. During the isoflavone intervention, the 
participants consumed 36 ± 8% of their energy as fat, 15 ± 3% as protein, and 45 ± 8% as 
carbohydrates. During the placebo period, the corresponding figures were 36 ± 6 en% as 
fat, 15 ± 3 en% protein, and 45 ± 7 en% as carbohydrates.
Plasma concentrations of all 4 isoflavones were significantly higher after the 8-wk 
intervention compared with placebo (P < 0.05; Figure 2.1). At the end of the placebo period, 
the concentrations of all isoflavones, except for daidzein (0.01 µg/mL), were below the 
detection limit of the method. As expected, daidzein and equol concentrations contributed 
most to the total plasma isoflavone concentrations after the isoflavone intervention. All 
participants remained equol producers during the study. The compliance based on returned 
pill counts after isoflavone supplementation was 97%, whereas in the placebo period the 
compliance was 95%.
Microarray analysis of the PBMC samples of 28 participants revealed that expression of a 
total of 357 genes was significantly changed after 8 wk of isoflavone treatment compared 
with placebo (Figure 2.2). Of those genes, the expression of 170 genes was upregulated 
and the expression of 187 genes was downregulated after isoflavone supplementation 
(Supplemental Tables 2.1 and 2.2). To elucidate which gene sets were regulated, GSEA 
was performed and revealed 1 gene set to be significantly upregulated and 91 gene sets 
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Figure 2.1 Plasma isoflavone concentrations in postmenopausal, equol-producing women after 
8-wk exposure to placebo and isoflavone supplementation. Values are means ± SEMs, n = 30; 
* Different from placebo, P < 0.05. conc., concentration.
Figure 2.2 Flow chart of microarray analysis indicating significantly changed genes and results of 
gene set enrichment analysis (RMA, robust multichip average; expression level in arbitrary units; 
FDR, false discovery rate).
Human Affymetrix Whole genome 
array: 19,738 genes
RMA normalization and filtering > 5 arrays with 
signal > 20: 13,376 genes
357 genes 
significantly changed, 
P < 0.05
170 upregulated
genes
187 downregulated 
genes
Gene set enrichment 
analysis
1 gene set 
significantly upregulated
at FDR < 0.25
91 gene sets
significantly downregulated
at FDR < 0.25
to be significantly downregulated upon 8-wk isoflavone supplementation compared 
with placebo. The only upregulated gene set was the generic transcription pathway, 
which is based on positive enrichment of zinc finger (ZNF) genes. The 91 downregulated 
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gene sets were grouped together with Cytoscape by means of overlapping genes. The 
clusters formed were related to inflammation (including complement and coagulation), 
oxidative phosphorylation (OXPHOS), and cell cycle (Figure 2.3). Furthermore, some other 
significantly downregulated gene sets were of interest because of their high ranking in 
the GSEA, such as PPARα (peroxisome proliferator receptor α; false discovery rate q value 
= 0.029), oxidative stress (q = 0.034), FOXM1 (forkhead box protein M1; q = 0.034), and 
nuclear receptor gene sets (q = 0.046), although expression of only a few genes within 
Figure 2.3 Enrichment maps of downregulated gene sets after 8-wk isoflavone supplementation 
compared with placebo in postmenopausal, equol-producing women identified with gene set 
enrichment analysis. Three main clustered gene sets were identified: (A) inflammation, complement, 
and coagulation; (B) oxidative phosphorylation; and (C) cell cycle. Panel D represents other gene 
sets. Nodes represent gene sets, whereas edges represent overlapping genes. Clusters of related 
gene sets were assigned a label on the basis of gene sets present in the cluster. BIOC, BioCarta 
Pathway Diagrams; CENPA, centromere protein A; FOXM1, forkhead box protein M1; KEGG, Kyoto 
Encyclopedia of Genes and Genomes database; NCI, Nature Pathway Interaction database; REACT, 
Reactome knowledgebase; WIP_HS, WikiPathways Homo Sapiens.
A
DC
BInflammation, complement and coagulation Oxidative phosphorylation
Cell cycle Other pathways
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these gene sets was significantly changed. Individual changes in gene expression of the 
genes that significantly changed upon isoflavone supplementation are visualized per 
cluster in Figure 2.4. In summary, the inflammation cluster of gene sets mainly consisted of 
a reduced expression of Toll-like receptors (TLRs) and genes expressed in the complement 
and coagulation cascades such as PLAUR (plasminogen activator, urokinase receptor). 
Downregulation of several NADH dehydrogenase ubiquinone flavoprotein (NDUF) genes 
directed the downregulation of the OXPHOS cluster. The cell cycle cluster was directed by 
downregulation of the gene expression of histones in several gene sets.
Gene sets related to ERα and ERβ activation were not changed after isoflavone supplemen-
tation compared with placebo. Subsequent checking of the expression level of ERα and 
ERβ revealed that expression levels of ERα were just sufficient to pass the filtering criteria, 
Figure 2.4 Heat map of significantly changed genes in peripheral blood mononuclear cells of 
postmenopausal, equol-producing women after 8 wk of isoflavone supplementation compared 
with placebo. Each column represents a participant; each row represents a single gene within the 
clusters of gene sets indicated in the blocks. Mean changes in expression (signal log ratios) are 
shown, ranging from ≤ -0.25 (green squares) to ≥ 0.25 (red squares). CD14, monocyte differentiation 
antigen CD14; CLTA, clathrin light chain A; FCGR2B, low affinity IG gFc region receptor II-b; HIST1H4I, 
histone cluster 1, H4i; IL1β, interleukin 1β; NDUF (B3 and S6), NADH dehydrogenase ubiquinone 
flavoprotein (B3 and S6); OXPHOS, oxidative phosphorylation; PLAUR, plasminogen activator, 
urokinase receptor; PPARA, peroxisome proliferator receptor α; SLC25A5, solute carrier family 25 
member 5; TIRAP, Toll–interleukin 1 receptor domain containing adaptor protein; TLR4, Toll-like 
receptor 4; ZNF (331, 189, and 257), zinc finger (331, 189, and 257).
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whereas the levels of ERβ were not. The low expression was confirmed by qPCR analysis; 
after normalization to human ribosomal protein LP0 expression, the 2-log ratio of ERα was 
20.05 after isoflavone treatment and 20.14 after placebo treatment. For ERβ, this was 20.41 
and 20.20, respectively, meaning that both ERα and ERβ expression was low in PBMCs of 
postmenopausal women.
To test the hypothesis of lack of isoflavone-induced ER signaling in PBMCs, we compared 
significantly changed genes in this study to estrogen-responsive genes from the Estrogen- 
Responsive Gene Database data set (24). Of the 1069 estrogen-responsive genes present 
in this database, we found an expression of only 17 estrogen-responsive genes to be 
significantly changed in our study (Table 2.1).  
Table 2.1 List of 7 significantly upregulated and 10 downregulated estrogen-responsive genes 
in PMBCs of postmenopausal, equol-producing women after 8 wk of isoflavone supplementation 
compared with placebo1
Gene Description Regulation in 
current study2
BCL2L1 BCL2-like 1 ↑
CACYBP calcyclin binding protein ↓
EDEM1 ER degradation enhancer, mannosidase alpha-like 1 ↑
ERBB2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/
glioblastoma derived oncogene homolog (avian)
↑
FKBP5 FK506 binding protein 5 ↑
FOXP1 forkhead box P1 ↑
HSPA1A heat shock 70kDa protein 1A ↓
MYB v-myb myeloblastosis viral oncogene homolog (avian) ↑
NME2 NME/NM23 nucleoside diphosphate kinase 2 ↓
NRP1 neuropilin 1 ↓
PSMD8 proteasome (prosome, macropain) 26S subunit, non-ATPase, 8 ↓
PTPRO protein tyrosine phosphatase, receptor type, O ↓
SLC25A5 solute carrier family 25 (mitochondrial carrier; adenine nucleotide 
translocator), member 5
↓
SPRED1 sprouty-related, EVH1 domain containing 1 ↓
STAB1 stabilin 1 ↓
STXBP1 syntaxin binding protein 1 ↑
TIMELESS timeless homolog (Drosophila) ↓
1 As compared to the Estrogen-Responsive Gene Database (24). BCL2, B-cell CLL/lymphoma; ↓, downregulated; 
↑, upregulated.
2 P < 0.05.
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DISCUSSION
With this 8-wk double-blind, randomized, placebo-controlled, crossover trial we showed 
that a daidzein-rich isoflavone supplement compared with placebo downregulated 
expression of genes involved in inflammation, OXPHOS, and cell cycle processes in PBMCs. 
The observed effects were not mediated by ERα and ERβ. The observed downregulation of 
gene sets related to inflammation are driven by diminished gene expression of TLR4 (Toll-
like receptor 4), TIRAP (Toll–interleukin 1 receptor domain containing adaptor protein), and 
IL1β (interleukin 1β) and downregulation of complement and coagulation gene sets. TLR 
and TIRAP proteins play a role in inflammation by enabling production of cytokines such as 
IL1β (28). Downregulation of inflammation by isoflavones in general has been repeatedly 
shown in animal and cell studies in a carcinogenic context (29). 
In human studies, the results on inflammatory cytokines are inconsistent (30), but 
isoflavones have been shown to decrease concentrations of TNF-α (tumor necrosis factor α) 
and to a lesser extent IL-6 (interleukin 6) (31, 32). The observed reduction in inflammation 
in the present study can be considered beneficial because it is known that chronic 
inflammation can potentially induce as well as promote cancer (33) and initiate diseases 
such as cardiovascular disease (34) and osteoporosis (35).
The regulation of OXPHOS was mainly driven by gene expression changes of several NDUF 
genes. The proteins encoded by NDUFs belong to the complex I molecules in mitochondria, 
which regulate mitochondrial function and can produce reactive oxygen species (ROS) 
(36). Downregulation of NDUF gene expression might result in reduced ROS production, 
and hence reduced oxidative stress. Interestingly, expression of superoxide dismutase 1 
(SOD1), needed to discharge ROS, was also (borderline significantly) reduced after 8 wk of 
isoflavone supplementation. Both ROS and oxidative stress have the potential to induce 
DNA damage as a precursor for cancer (37). 
In this study, the expression of histones and histone-like genes was downregulated within 
cell cycle–related gene sets. Histones are typically upregulated during the S phase of the 
cell cycle starting from the G1-S checkpoint (38). Because downregulation of histone 
transcription was observed, this could mean that many cells remain in arrest at some point 
in the cycle, for instance at G0/G1 (39), after exposure to isoflavone supplementation. This 
was supported by the significantly downregulated enrichment of gene sets associated with 
mitotic G1-S phase and G1-S transition in this study. The results of the present study are in 
line with the review by Medjakovic et al. (40), who discussed effects of isoflavones on cell 
cycle arrest in several cell lines and concluded that daidzein seems to cause an arrest in the 
G0/G1 phase, whereas genistein induces G2/M arrest. In addition, the observation that the 
FOXM1 pathway, which plays an important role in regulating histones and cell cycle (41), 
was downregulated in our study, strengthens the theory of cell cycle arrest after exposure 
to isoflavones (42). The observed cell cycle arrest provides time for the cell to repair any 
damaged DNA or to go into apoptosis and consequently prevents replication of cells with 
DNA damage and formation into tumors (43).
There are several strengths regarding the study design and results. First, a sample size of 
28 participants is appropriate and larger than previous nutritional intervention studies 
that used whole-genome transcriptomics (9, 12). Second, compliance to the study was 
good because the plasma concentrations of isoflavones showed a significant difference 
between the intervention and the placebo period, as supported by the capsule counts. An 
additional strength is that we used a commercially available supplement rich in daidzein for 
this study, which is representative in composition of the majority of isoflavone supplements 
on the market. Many supplements are made from soy germ, which contains relatively 
more daidzein than genistein and glycitein (daidzein:genistein:glycitein ratio of 4:1:3) (44). 
Furthermore, the used dosage was at the high end of the manufacturers’ recommendations 
on isoflavone supplements. Finally, for this study a homogenous group of postmenopausal, 
equol-producing women was preselected by criteria such as absence of menstrual cycle 
and FSH concentrations for postmenopausal status and urinary equol concentrations after 
an isoflavone challenge for equol-producing capacity. These characteristics were stable 
in the participants during the trial, as monitored by FSH and equol concentrations in the 
blood. The stable features of the participants make the results of this study applicable to 
a very relevant potential risk group, but limit the extrapolation to other groups of people. 
The exposure time of 8 wk was chosen because we were interested in moderate to long-
term effects.
In the current study, the expression of 357 genes (1.8%) was significantly changed after 
isoflavone supplementation versus placebo on a gene chip encoding 19,738 gene identifiers. 
This indicates that small effects were observed, compared with results from nutritional 
intervention studies with other compounds performed in PBMCs at the same laboratory with 
similar analysis techniques (9, 12). Also, in a previous study with an isoflavone supplement 
(900 mg/d, high genistein) with a parallel design, only a limited number of genes [319 genes 
(2.0%)] were significantly changed on a 16K oligo array in PBMCs of postmenopausal equol 
producers compared with all participants (n = 10, of whom 2 were equol producers) who 
received placebo treatment (10). However, in that study, in total only 7 equol producers were 
included and therefore low numbers of significantly expressed genes could be expected, 
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whereas our study included 28 participants and used a crossover design. In the previous 
study, 11 estrogen-responsive genes were found in equol-producing women that did not 
overlap with the 17 significantly expressed estrogen-responsive genes in the current study. 
Because of the use of PBMCs in the current study, the observed effects cannot easily be 
extrapolated to, for example, healthy breast or uterus tissue, mainly because of the difference 
in ERα and ERβ occurrence (45). Gene expression measured by microarrays and confirmed 
by qPCR revealed that, in our study, the expression of both ERα and ERβ in PBMCs was very 
low. Also, well-known estrogen-responsive genes, such as the progesterone receptor (PR), 
presenelin-2 (pS2), B-cell CLL/lymphoma (BCL2), and cyclin D1 (CCND1) genes (46), were 
not significantly expressed, which supports the lack of isoflavone-induced ER signaling. 
The lack of expression of ERα and ERβ in PBMCs contradicts recent literature in which these 
genes were found to be expressed in these cells (47-49). This might be explained by the 
postmenopausal status of the participants in this study. Postmenopausal women do not 
produce endogenous estradiol; therefore, expression of ERs might be less necessary and 
might even be silenced by mechanisms such as DNA methylation. However, expression 
levels of ERα and ERβ were not significantly different between premenopausal women and 
postmenopausal women (unpublished results).
It is possible that other nuclear receptors known to be affected by isoflavones are involved 
in the regulation of the observed effects. Likely candidates from literature are PPARα, aryl 
hydro-carbon receptor (AhR), and G protein-coupled ER (GPER) (40, 50). In the current study, 
the expression of AhR and GPER was observed in PBMCs, but was not significantly changed 
after exposure. On the other hand, expression of PPARα was significantly decreased after 
the 8-wk exposure to isoflavones compared with placebo. Another nuclear receptor, LXR 
(liver X receptor), was significantly changed in this study and therefore also a candidate 
for the regulation of the observed effects. Because the expression of target genes of these 
receptors was not significantly changed, it is not likely that effects were mediated by these 
nuclear receptors. Interpretation of the effects on gene expression in this study might have 
been facilitated by measuring circulating biomarkers for the observed effects. However, the 
gene expression results did not point to a specific marker that would have differentiated 
between either beneficial or harmful effects of isoflavones. Although PBMCs might not be 
the preferred model to study isoflavone-induced estrogenic effects, these cells circulate 
through the whole body and pervade tissues; therefore, they may reflect systemic changes 
(51). The observed effects on inflammation, OXPHOS, and cell cycle may be caused by direct 
effects on gene expression by the isoflavones itself but might also be systemic as result of 
effects in other tissues.
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Together, the observed downregulation of inflammation, OXPHOS, and cell cycle gene sets 
point toward beneficial effects of isoflavone supplementation with respect to prevention of 
cancer and cardiovascular disease. However, whether ER-related effects of isoflavones can 
be expected to be beneficial or harmful should be studied in tissues that are more likely 
to express ERs, such as breast, uterus, or adipose tissue.
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Supplemental Table 2.1 Significantly downregulated genes after isoflavone supplementation 
compared to placebo
Gene Description
AAMP angio-associated, migratory cell protein
ABCB8 ATP-binding cassette, sub-family B (MDR/TAP), member 8
AFMID arylformamidase
AKR1C1 aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1 /// 20-alpha 
(3-alpha)-hydroxysteroid dehydrogenase)
AMPD2 adenosine monophosphate deaminase 2
ANKRD57 ankyrin repeat domain 57
ARPC3 actin related protein 2/3 complex, subunit 3, 21kDa
B4GALT2 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 2
C12orf45 chromosome 12 open reading frame 45
C14orf109 chromosome 14 open reading frame 109
C16orf87 chromosome 16 open reading frame 87
C19orf59 chromosome 19 open reading frame 59
C1orf53 chromosome 1 open reading frame 53
C21orf70 chromosome 21 open reading frame 70
C2orf76 chromosome 2 open reading frame 76
C6orf115 chromosome 6 open reading frame 115
C8orf76 chromosome 8 open reading frame 76
C9orf139 chromosome 9 open reading frame 139
C9orf24 chromosome 9 open reading frame 24
CACYBP calcyclin binding protein
CALCRL calcitonin receptor-like
CD101 CD101 molecule
CD14 CD14 molecule
CDC42EP1 CDC42 effector protein (Rho GTPase binding) 1
CHAF1A chromatin assembly factor 1, subunit A (p150)
CIB2 calcium and integrin binding family member 2
CKB creatine kinase, brain
CLEC4A C-type lectin domain family 4, member A
CLTA clathrin, light chain A
CRK v-crk sarcoma virus CT10 oncogene homolog (avian)
CSF1R colony stimulating factor 1 receptor
CSTA cystatin A (stefin A)
CTF1 cardiotrophin 1
CTIF CBP80/20-dependent translation initiation factor
CYP2S1 cytochrome P450, family 2, subfamily S, polypeptide 1
DAPK3 death-associated protein kinase 3
DCP2 DCP2 decapping enzyme homolog (S. cerevisiae)
DDX21 DEAD (Asp-Glu-Ala-Asp) box polypeptide 21
DEPDC1B DEP domain containing 1B
DKFZP434F142 hypothetical DKFZp434F142
DNTTIP1 deoxynucleotidyltransferase, terminal, interacting protein 1
Isoflavone effect on PBM
C gene expression
Chapter 2
43
2
Supplemental Table 2.1 continues on next page
Gene Description
DOC2B double C2-like domains, beta
E2F6 E2F transcription factor 6
EIF2C1 eukaryotic translation initiation factor 2C, 1
EIF4A1 eukaryotic translation initiation factor 4A1
ELOVL1 elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 1
EMR3 egf-like module containing, mucin-like, hormone receptor-like 3
FAM108A1 family with sequence similarity 108, member A1
FAM70B family with sequence similarity 70, member B
FBXO42 F-box protein 42
FCGR2B Fc fragment of IgG, low affinity IIb, receptor (CD32)
FDXR ferredoxin reductase
FGD6 FYVE, RhoGEF and PH domain containing 6
FSCN2 fascin homolog 2, actin-bundling protein, retinal (Strongylocentrotus purpuratus)
FTL ferritin, light polypeptide
FTSJ2 FtsJ homolog 2 (E. coli)
FZD1 frizzled homolog 1 (Drosophila)
FZD5 frizzled homolog 5 (Drosophila)
GAS2L3 growth arrest-specific 2 like 3
GINS1 GINS complex subunit 1 (Psf1 homolog)
GLTP glycolipid transfer protein
GNG5 guanine nucleotide binding protein (G protein), gamma 5
HAGH hydroxyacylglutathione hydrolase
HIST1H4I histone cluster 1, H4i
HK3 hexokinase 3 (white cell)
HLA-DQB2 major histocompatibility complex, class II, DQ beta 2
HSPA1A heat shock 70kDa protein 1A
HTRA1 HtrA serine peptidase 1
IL1B interleukin 1, beta
ISG20L2 interferon stimulated exonuclease gene 20kDa-like 2
ITPRIP inositol 1,4,5-triphosphate receptor interacting protein
JPH4 junctophilin 4
KCNH3 potassium voltage-gated channel, subfamily H (eag-related), member 3
KIAA1143 KIAA1143
KIF1C kinesin family member 1C
KLF4 Kruppel-like factor 4 (gut)
KLK5 kallikrein-related peptidase 5
KRTAP12-3 keratin associated protein 12-3
KRTAP5-10 keratin associated protein 5-10
LAMB2 laminin, beta 2 (laminin S)
LDLRAD3 low density lipoprotein receptor class A domain containing 3
LGALS2 lectin, galactoside-binding, soluble, 2
LMNB2 lamin B2
LOC100505818 afadin-like
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Gene Description
LOC283392 hypothetical LOC283392
LOC401127 WD repeat domain 5 pseudogene
LRG1 leucine-rich alpha-2-glycoprotein 1
LRRC56 leucine rich repeat containing 56
LRRC69 leucine rich repeat containing 69
MAFB v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (avian)
MCART1 mitochondrial carrier triple repeat 1
MIA melanoma inhibitory activity
MICAL2 microtubule associated monoxygenase, calponin and LIM domain containing 2
MIR330 microRNA 330
MMP25 matrix metallopeptidase 25
MRGPRE MAS-related GPR, member E
MRPL54 mitochondrial ribosomal protein L54
MTMR11 myotubularin related protein 11
NDUFAF2 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, assembly factor 2
NDUFB3 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 3, 12kDa
NDUFS6 NADH dehydrogenase (ubiquinone) Fe-S protein 6, 13kDa (NADH-coenzyme Q 
reductase)
NEURL neuralized homolog (Drosophila)
NME2 non-metastatic cells 2, protein (NM23B) expressed in
NR1H3 nuclear receptor subfamily 1, group H, member 3
NRP1 neuropilin 1
NTAN1 N-terminal asparagine amidase
OAZ2 ornithine decarboxylase antizyme 2
PAQR4 progestin and adipoQ receptor family member IV
PDCD6 programmed cell death 6
PDE8B phosphodiesterase 8B
PGM2 phosphoglucomutase 2
PID1 phosphotyrosine interaction domain containing 1
PIK3R6 phosphoinositide-3-kinase, regulatory subunit 6
PLAUR plasminogen activator, urokinase receptor
PLB1 phospholipase B1
PLEKHJ1 pleckstrin homology domain containing, family J member 1
PMM1 phosphomannomutase 1
PNO1 partner of NOB1 homolog (S. cerevisiae)
PNPLA6 patatin-like phospholipase domain containing 6
PODXL podocalyxin-like
POM121L9P POM121 membrane glycoprotein-like 9, pseudogene
POU2F2 POU class 2 homeobox 2
PPARA peroxisome proliferator-activated receptor alpha
PRDX1 peroxiredoxin 1
PRR11 proline rich 11
PSMD8 proteasome (prosome, macropain) 26S subunit, non-ATPase, 8
PSMG2 proteasome (prosome, macropain) assembly chaperone 2
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Supplemental Table 2.1 continues on next page
Gene Description
PSMG3 proteasome (prosome, macropain) assembly chaperone 3
PTPLB protein tyrosine phosphatase-like (proline instead of catalytic arginine), member b
PTPRE protein tyrosine phosphatase, receptor type, E
PTPRO protein tyrosine phosphatase, receptor type, O
PTX3 pentraxin 3, long
QPRT quinolinate phosphoribosyltransferase
RASSF4 Ras association (RalGDS/AF-6) domain family member 4
RELT RELT tumor necrosis factor receptor
RLN3 relaxin 3
RNF139 ring finger protein 139
RNF215 ring finger protein 215
RPL13AP5 ribosomal protein L13a pseudogene 5
RPRD1B regulation of nuclear pre-mRNA domain containing 1B
RPS26 ribosomal protein S26
RRP12 ribosomal RNA processing 12 homolog (S. cerevisiae)
S100A12 S100 calcium binding protein A12
SCAMP5 secretory carrier membrane protein 5
SCARF2 scavenger receptor class F, member 2
SDF2 stromal cell-derived factor 2
SDF4 stromal cell derived factor 4
SERPINB10 serpin peptidase inhibitor, clade B (ovalbumin), member 10
SERPINB2 serpin peptidase inhibitor, clade B (ovalbumin), member 2
SERPINB8 serpin peptidase inhibitor, clade B (ovalbumin), member 8
SGK1 serum/glucocorticoid regulated kinase 1
SH3D21 SH3 domain containing 21
SHISA9 shisa homolog 9 (Xenopus laevis)
SIGLEC10 sialic acid binding Ig-like lectin 10
SIRPA signal-regulatory protein alpha
SLC25A5 solute carrier family 25 (mitochondrial carrier /// adenine nucleotide translocator), 
member 5
SLC46A1 solute carrier family 46 (folate transporter), member 1
SLC46A2 solute carrier family 46, member 2
SNORA5B small nucleolar RNA, H/ACA box 5B
SNORA62 small nucleolar RNA, H/ACA box 62
SNX30 sorting nexin family member 30
SPATA6 spermatogenesis associated 6
SPC24 SPC24, NDC80 kinetochore complex component, homolog (S. cerevisiae)
SPRED1 sprouty-related, EVH1 domain containing 1
SRGAP3 SLIT-ROBO Rho GTPase activating protein 3
STAB1 stabilin 1
STRAP serine/threonine kinase receptor associated protein
STYXL1 serine/threonine/tyrosine interacting-like 1
SUCLG1 succinate-CoA ligase, alpha subunit
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Supplemental Table 2.1 Continued
Gene Description
TCF24 transcription factor 24
TIGD5 tigger transposable element derived 5
TIMELESS timeless homolog (Drosophila)
TIRAP toll-interleukin 1 receptor (TIR) domain containing adaptor protein
TLR4 toll-like receptor 4
TNFRSF10B tumor necrosis factor receptor superfamily, member 10b
TNIP3 TNFAIP3 interacting protein 3
TP53I11 tumor protein p53 inducible protein 11
TP53I3 tumor protein p53 inducible protein 3
TRIAP1 TP53 regulated inhibitor of apoptosis 1
TRIB1 tribbles homolog 1 (Drosophila)
TUBA1A tubulin, alpha 1a
UCK2 uridine-cytidine kinase 2
USP46 ubiquitin specific peptidase 46
WBSCR16 Williams-Beuren syndrome chromosome region 16
ZNF324B zinc finger protein 324B
ZNF697 zinc finger protein 697
ZNF710 zinc finger protein 710
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Supplemental Table 2.2 Significantly upregulated genes after isoflavone supplementation 
compared to placebo
Gene Description
A2LD1 AIG2-like domain 1
ABCF3 ATP-binding cassette, sub-family F (GCN20), member 3
ADD1 adducin 1 (alpha)
ADD3 adducin 3 (gamma)
AGGF1 angiogenic factor with G patch and FHA domains 1
AK3 adenylate kinase 3
AK5 adenylate kinase 5
AKIRIN1 akirin 1
AMIGO2 adhesion molecule with Ig-like domain 2
ANKRD55 ankyrin repeat domain 55
APITD1 apoptosis-inducing, TAF9-like domain 1
APOBEC3F apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F
ARHGEF9 Cdc42 guanine nucleotide exchange factor (GEF) 9
ASPSCR1 alveolar soft part sarcoma chromosome region, candidate 1
B3GNT1 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 1
BACH2 BTB and CNC homology 1, basic leucine zipper transcription factor 2
BAG5 BCL2-associated athanogene 5
BBS4 Bardet-Biedl syndrome 4
BCL2L1 BCL2-like 1
BPHL biphenyl hydrolase-like (serine hydrolase)
C10orf111 chromosome 10 open reading frame 111
C12orf41 chromosome 12 open reading frame 41
C17orf28 chromosome 17 open reading frame 28
C21orf128 chromosome 21 open reading frame 128
C21orf49 chromosome 21 open reading frame 49
C21orf63 chromosome 21 open reading frame 63
C22orf36 chromosome 22 open reading frame 36
C3orf39 chromosome 3 open reading frame 39
C9orf78 chromosome 9 open reading frame 78
CA11 carbonic anhydrase XI
CABP5 calcium binding protein 5
CACNA1H calcium channel, voltage-dependent, T type, alpha 1H subunit
CDC14A CDC14 cell division cycle 14 homolog A (S. cerevisiae)
CDHR1 cadherin-related family member 1
CDNF cerebral dopamine neurotrophic factor
CLEC17A C-type lectin domain family 17, member A
CLK2P CDC-like kinase 2, pseudogene
CORT cortistatin
CSRP2BP CSRP2 binding protein
CYP2D7P1 cytochrome P450, family 2, subfamily D, polypeptide 7 pseudogene 1
DDX51 DEAD (Asp-Glu-Ala-Asp) box polypeptide 51
DENND2C DENN/MADD domain containing 2C
Supplemental Table 2.2 continues on next page
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Supplemental Table 2.2 Continued
Gene Description
DHX34 DEAH (Asp-Glu-Ala-His) box polypeptide 34
DHX38 DEAH (Asp-Glu-Ala-His) box polypeptide 38
DSEL dermatan sulfate epimerase-like
DUS4L dihydrouridine synthase 4-like (S. cerevisiae)
EDAR ectodysplasin A receptor
EDEM1 ER degradation enhancer, mannosidase alpha-like 1
EPB41 erythrocyte membrane protein band 4.1 (elliptocytosis 1, RH-linked)
ERBB2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived 
oncogene homolog (avian)
ERCC5 excision repair cross-complementing rodent repair deficiency, complementation group 5
EXT2 exostosin 2
FAM134C family with sequence similarity 134, member C
FITM2 fat storage-inducing transmembrane protein 2
FKBP11 FK506 binding protein 11, 19 kDa
FKBP5 FK506 binding protein 5
FLJ36031 hypothetical protein FLJ36031
FLJ44606 glutaredoxin-like protein YDR286C homolog
FOXP1 forkhead box P1
FUBP1 far upstream element (FUSE) binding protein 1
GALNT12 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 
12 (GalNAc-T12)
GATAD2B GATA zinc finger domain containing 2B
GOLGA8A golgin A8 family, member A
GPA33 glycoprotein A33 (transmembrane)
GPATCH2 G patch domain containing 2
GUSBL1 glucuronidase, beta-like 1
HEMK1 HemK methyltransferase family member 1
HINFP histone H4 transcription factor
HIST1H2BO histone cluster 1, H2bo
IGLV3-10 immunoglobulin lambda variable 3-10
IGLV7-46 immunoglobulin lambda variable 7-46 (gene/pseudogene)
IKZF5 IKAROS family zinc finger 5 (Pegasus)
KCTD9 potassium channel tetramerisation domain containing 9
KIAA0319L KIAA0319-like
KIAA0748 KIAA0748
KLC4 kinesin light chain 4
LOC100133207 hypothetical LOC100133207
LOC100286979 anaphase-promoting complex subunit 1-like
LOC100289388 hypothetical LOC100289388
LOC100499177 hypothetical LOC100499177
LOC100507418 hypothetical LOC100507418
LOC100507457 hypothetical LOC100507457
LOC145757 hypothetical LOC145757
LOC158572 hypothetical LOC158572
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Supplemental Table 2.2 continues on next page
Gene Description
LOC441208 zinc and ring finger 2 pseudogene
LOC646813 DEAH (Asp-Glu-Ala-His) box polypeptide 9 pseudogene
LOC93622 hypothetical LOC93622
LONRF3 LON peptidase N-terminal domain and ring finger 3
LUC7L2 LUC7-like 2 (S. cerevisiae)
MAGED1 melanoma antigen family D, 1
MAX MYC associated factor X
MOB2 Mps one binder kinase activator-like 2
MPHOSPH10 M-phase phosphoprotein 10 (U3 small nucleolar ribonucleoprotein)
MYB v-myb myeloblastosis viral oncogene homolog (avian)
NAPG N-ethylmaleimide-sensitive factor attachment protein, gamma
NECAB3 N-terminal EF-hand calcium binding protein 3
NELL2 NEL-like 2 (chicken)
NEURL3 neuralized homolog 3 (Drosophila) pseudogene
NLRP6 NLR family, pyrin domain containing 6
NMB neuromedin B
NUB1 negative regulator of ubiquitin-like proteins 1
NUDT6 nudix (nucleoside diphosphate linked moiety X)-type motif 6
OCRL oculocerebrorenal syndrome of Lowe
ODF2L outer dense fiber of sperm tails 2-like
PARK2 parkinson protein 2, E3 ubiquitin protein ligase (parkin)
PDE3B phosphodiesterase 3B, cGMP-inhibited
PDE4D phosphodiesterase 4D, cAMP-specific
PDE7A phosphodiesterase 7A
PDIK1L PDLIM1 interacting kinase 1 like
PIGC phosphatidylinositol glycan anchor biosynthesis, class C
PKIG protein kinase (cAMP-dependent, catalytic) inhibitor gamma
PM20D2 peptidase M20 domain containing 2
PPAT phosphoribosyl pyrophosphate amidotransferase
PPCS phosphopantothenoylcysteine synthetase
PPP2R5C protein phosphatase 2, regulatory subunit B', gamma
PRH1 proline-rich protein HaeIII subfamily 1
RASGRF2 Ras protein-specific guanine nucleotide-releasing factor 2
RCC2 regulator of chromosome condensation 2
RFC1 replication factor C (activator 1) 1, 145kDa
RINL Ras and Rab interactor-like
RNF144A ring finger protein 144A
RNF157 ring finger protein 157
RNF165 ring finger protein 165
RNY4P8 RNA, Ro-associated Y4 pseudogene 8
RPL10 ribosomal protein L10
RPL34 ribosomal protein L34
RPLP2 ribosomal protein, large, P2
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Supplemental Table 2.2 Continued
Gene Description
RUFY4 RUN and FYVE domain containing 4
SAMD10 sterile alpha motif domain containing 10
SBDS Shwachman-Bodian-Diamond syndrome
SDC4 syndecan 4
SEL1L3 sel-1 suppressor of lin-12-like 3 (C. elegans)
sep06 septin 6
SERPINE2 serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), 
member 2
SLC10A7 solute carrier family 10 (sodium/bile acid cotransporter family), member 7
SLC35B4 solute carrier family 35, member B4
SPRR2G small proline-rich protein 2G
STXBP1 syntaxin binding protein 1
SUMO1 SMT3 suppressor of mif two 3 homolog 1 (S. cerevisiae)
SVIP small VCP/p97-interacting protein
SYTL3 synaptotagmin-like 3
TBC1D25 TBC1 domain family, member 25
TC2N tandem C2 domains, nuclear
THEM4 thioesterase superfamily member 4
TLK1 tousled-like kinase 1
TMEM161A transmembrane protein 161A
TRIM22 tripartite motif containing 22
TRIM33 tripartite motif containing 33
TRIM39 tripartite motif containing 39
TRIM4 tripartite motif containing 4
TRIM40 tripartite motif containing 40
TSEN2 tRNA splicing endonuclease 2 homolog (S. cerevisiae)
TTC16 tetratricopeptide repeat domain 16
TUBG2 tubulin, gamma 2
TXNDC16 thioredoxin domain containing 16
USP18 ubiquitin specific peptidase 18
ZCCHC17 zinc finger, CCHC domain containing 17
ZFP161 zinc finger protein 161 homolog (mouse)
ZMYM3 zinc finger, MYM-type 3
ZNF189 zinc finger protein 189
ZNF257 zinc finger protein 257
ZNF329 zinc finger protein 329
ZNF331 zinc finger protein 331
ZNF470 zinc finger protein 470
ZNF549 zinc finger protein 549
ZNF569 zinc finger protein 569
ZNF674 zinc finger protein 674
ZNF681 zinc finger protein 681
ZNF84 zinc finger protein 84
ZNF880 zinc finger protein 880
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ABSTRACT
Background: Isoflavone supplements, consumed by women experiencing menopausal 
complaints, are suggested to positively affect menopause-related adiposity and 
cardiovascular risk profile but discussions about their safety are still ongoing.
Objective: To study the effects of 8 wk consumption of two different isoflavone 
supplements compared to placebo on whole-genome gene expression in adipose 
tissue of postmenopausal women. 
Design: This randomized double-blind placebo-controlled crossover intervention 
consisted of two sub studies; one with a low genistein supplement (LG, 56% daidzein, 
16% genistein), the other with a high genistein supplement (HG, 49% daidzein, 41% 
genistein). Both supplements provided ~100 mg isoflavones/day (aglycone equivalents). 
After the 8 wk isoflavone and placebo period, whole-genome arrays were performed in 
subcutaneous adipose tissue of postmenopausal women (n = 24 after LG, n = 31 after 
HG). Data was analysed per sub study for equol producers and non-producers separately.
Results: GSEA showed downregulation of expression of energy metabolism-related 
genes after LG supplementation in both equol-producing phenotypes and oppositely 
regulated expression for equol producers (down) and non-producers (up) after HG 
supplementation. Expression of inflammation-related genes was upregulated in equol 
producers, while downregulated in non-producers, independent of supplement type. 
Body weight, adipocyte size and plasma lipid profile were not affected by isoflavone 
supplementation.
Conclusion: Effects of isoflavones on adipose tissue gene expression were influenced by 
supplement composition and equol-producing phenotype, while estrogen-responsive 
effects were limited. LG isoflavone supplementation resulted in a caloric restriction-like 
gene expression profile for both producer phenotypes and pointed towards a potential 
beneficial effect, while both supplements induced anti-inflammatory gene expression 
in equol producers. 
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INTRODUCTION
Isoflavones, naturally present in soy, are known for their alleged positive health effects in 
the Asian, predominantly soy-consuming, population (1). The potential positive effects 
on menopausal complaints makes isoflavones interesting for Western postmenopausal 
women and therefore for the supplement industry (2). Soy isoflavone supplements are on 
the market in different compositions (3, 4) in which the ratio between daidzein, genistein 
and glycitein is depending on the part of the soy plant used for isoflavone extraction 
(5). Next to the variation in composition, a large variation in doses exists of 5 to 107 mg/
day (3, 4). This raises questions regarding the safety and functionality of the different 
isoflavones (6) at higher doses. Because isoflavones resemble the molecular structure 
of 17β estradiol, part of the health effects of isoflavones are hypothesized to be induced 
via α, β or G-coupled estrogen receptor (ER)-mediated gene expression (7, 8). Isoflavones 
may also affect processes independent of ERs, as we demonstrated in our previous study 
with peripheral blood mononuclear cells (PBMC), where we found no changes related to 
activation of the ER. We did observe a downregulation in expression of genes related to 
oxidative phosphorylation (OXPHOS), inflammation and cell cycle (9). To unravel the total 
and ER-mediated effects of isoflavone supplementation in postmenopausal women, studies 
are needed in estrogen-responsive tissues such as adipose tissue. Adipose tissue is of interest 
because its distribution changes during menopause due to the decline in endogenous 
estrogen production and it is hypothesized that isoflavones may have positive effects on 
these unfavourable body fat distribution changes (10, 11). The potential mechanisms have 
not been evaluated in humans, but results from animal studies suggest that isoflavones 
may affect glucose and lipid metabolism, for instance via increased energy expenditure 
as demonstrated in mice (12) and decreased release of adipokines as found in Huanjiang 
minipigs (13). It has also been suggested that in this respect activation of PPAR (14) and 
AMPK signaling (15) might play an important role. 
It is not yet elucidated whether individual isoflavones have differential effects, or whether 
the total isoflavone content is responsible for the health effects. In addition, it has been 
suggested that equol, the more active metabolite of daidzein produced by gut bacteria of 
20 to 30% of the general Western population (16), affects gene expression response (17). 
In the current study, we aimed to identify the effects of two different types of isoflavone 
supplements on whole-genome gene expression in adipose tissue of postmenopausal 
women, taking into account the potential influence of the equol-producing phenotype.
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PARTICIPANTS AND meThODS
Subjects
Fifty-eight postmenopausal women were recruited for the intervention study at Wageningen 
University from November 2011 to January 2012. Equol producer phenotype was 
determined before the start of the study according to the protocol of Setchell et al. (18) and 
performed as previously described (9). The participants were defined as postmenopausal 
when they had their last menses more than one year before the start of the study. Exclusion 
criteria were regular intake of soy products or isoflavone supplements (> 1x/wk), current 
use of hormone-containing contraceptives, hormone replacement therapy, sex hormones-
containing or sex hormone-triggering medication, anti-inflammatory medicines, and use 
of antibiotics in the past 3 months. Furthermore, women with severe heart disease, thyroid 
disorders, a removed thyroid gland, removed ovaries or prior diagnosis of cancer were 
excluded. Lifestyle-related exclusion criteria included alcohol and drug abuse, smoking, a 
BMI above 35 kg/m2 and self-reported allergy to soy. All subjects consented to participate 
in the study after oral and written information was provided. The study was approved by 
the Medical Ethical Committee of Wageningen University and registered at clinicaltrials.
gov under NCT01556737.
Study design
This randomized double-blind crossover placebo-controlled study included two 8 wk 
intervention periods with one 8 wk washout period in between and was conducted in the 
period from February to October 2012. The study consisted of two parallel sub studies, 
one for a low genistein isoflavone supplement (LG) vs. placebo and the other for a high 
genistein isoflavone supplement (HG) vs. placebo. The participants were randomly allocated 
to one of the sub studies and to either receive the supplement or placebo first. Stratified 
randomization was performed by an independent research assistant using a computer-
generated table of random numbers. The strata used were based on equol producer 
phenotype and participation to a previous study at the same university (ISO study, (9)). 
Researchers as well as participants were blinded to randomization until after data analysis. 
On the basis of previous nutritional intervention studies using whole-genome 
transcriptomics a sample size of 20 participants in each sub study was assumed to be 
sufficient to detect significant effects on whole-genome gene expression in adipose tissue 
(19). 
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Isoflavone supplement and placebo
Both supplements consisted of a mix of daidzein, genistein and glycitein, but contained 
comparable amounts of daidzein. Therefore, the supplement with the lowest genistein 
content was defined as a ‘low genistein supplement’ or LG supplement and the other 
supplement, which contained more genistein as a ‘high genistein supplement’ or HG 
supplement. The LG supplement was commercially available as Phytosoya forte 35mg and 
purchased from Arkopharma (Carros Cedex, France). For the placebo supplement identical 
empty capsules were provided by Arkopharma, which consisted of hydroxypropylmethyl 
cellulose (HPMC) dyed with iron oxide and titanium oxide. These were filled by Fagron 
(Nieuwerkerk a/d IJssel, the Netherlands) with microcrystalline cellulose. The participants in 
this sub study consumed 100 mg isoflavone/day (in aglycone equivalents; 56 mg daidzein, 
16 mg genistein and 28 mg glycitein) for which the participants were asked to consume 
four capsules a day: two in the morning and two in the evening. The HG supplement was 
provided by Springfield Nutraceuticals (Oud-Beijerland, the Netherlands) based on the 
commercially available supplement Mega Soja. The identical-looking placebo capsules were 
also provided by this supplier; these consisted of HPMC, were not coloured and were filled 
with microcrystalline cellulose. These participants consumed 104 mg isoflavones daily (in 
aglycone equivalents; 51 mg daidzein, 43 mg genistein and 10 mg glycitein) for which the 
participants consumed two capsules a day: one in the morning and one in the evening. 
The supplement composition was measured at our lab and is reported in Table 3.1. All 
participants were asked not to eat soy foods for 4 wk before the trial as well as during the 
trial. To this aid, a detailed list of isoflavone-containing foods was provided to direct the 
participants. At the end of each 8 wk intervention period the participants were asked to 
fill out a 125-item semi-quantitative food frequency questionnaire (FFQ) to monitor their 
eating habits during these periods (20).
Table 3.1 Isoflavone supplement composition in aglycone equivalents (mg/day)
Low genistein supplement 
(mg/day)
High genistein supplement
(mg/day)
Daidzin 52.0 50.8
Daidzein 3.7 0.5
Genistin 16.5 42.0
Genistein 0 0.7
Glycitin 26.3 9.8
Glycitein 1.5 0.4
Total isoflavones 100.1 104.2
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Blood sampling and adipose tissue biopsies
The participants came to the research venue at Wageningen University four times after an 
overnight fast; at the start and end of each intervention period. At each visit, venous plasma 
and serum samples were obtained as described before (9). The subcutaneous adipose 
tissue samples were obtained by needle biopsy from the periumbilical area under local 
anaesthesia. The samples were rinsed to eliminate blood and were immediately frozen in 
liquid nitrogen. All samples were stored in aliquots at -80°C.
Plasma samples were analysed for isoflavone concentrations using HPLC with electrochemi-
cal detection as previously described (9, 21). For this method the limit of detection and 
limit of quantification were 0.11 and 0.22 µmol/L for glycitein and 0.04 and 0.08 µmol/L 
for the other isoflavones.
Serum samples were analysed for lipid profile (total cholesterol, HDL cholesterol and 
triglycerides) at the Centre for Medical Diagnostics (SHO, Velp, The Netherlands) and RBP4 
concentration at Wageningen University with ELISA and the Quantikine RBP4 immunoassay 
kit from R&D systems (R&D systems Inc., Minneapolis, USA).
RNA extraction and microarray processing
RNA was isolated from all adipose samples using Qiagen miRNeasy Mini kit (Qiagen, Venlo, 
The Netherlands) after homogenization with Trizol (Invitrogen, Breda, The Netherlands) 
and extraction with chloroform and ethanol. RNA yield was quantified and integrity was 
measured as previously described (9). Of 57 subjects, adipose tissue samples yielded 
enough RNA of sufficient quality to perform microarray analysis, resulting in a total of 114 
microarrays. RNA labeling and hybridization to GeneChip® Human Gene 1.1 ST Array was 
performed according to the manufacturers’ instructions as previously described (9).
Adipocyte size
Because of the observed effects of the LG supplement on energy metabolism-related gene 
expression in our study, adipocyte size was studied for the LG supplement sub study (n = 19). 
Frozen (-80°C) adipose tissue biopsy samples were transferred to 4% formaldehyde in phosphate 
buffered saline (PBS) for at least 24h and embedded in paraffin. Slices of 8 µm were cut using a 
microtome (model RM2355, Leica Microsystems B.V., Rijswijk, Netherlands), a hematoxylin and 
eosin staining was performed and cell size was determined using a Olympus BX41 microscope 
with CellSens Imaging software (Olympus Nederland B.V., Zoetermeer, Netherlands).
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Data analysis
Pairs of arrays performed for 55 participants yielded good quality microarray results; 
24 participants from the LG supplement sub study and 31 participants from the HG 
supplement sub study. Expression values of the microarray data were calculated using the 
Robust Multichip Average (RMA) method and normalized using quantile normalization 
(22, 23) in MADMAX (management and analysis database for multi-platform microarray 
experiments, (24)). Genes with normalized signals of > 20 on > 15 arrays were defined as 
expressed and selected for analysis. Genes were regarded as significantly changed at P < 
0.05. Further data analysis was performed using Gene Set Enrichment Analysis (GSEA, (25, 
26)) with a false discovery rate (FDR) of < 0.25 and results were visualized and clustered 
using Cytoscape (27). Upstream regulator analysis was performed using Ingenuity Pathway 
Analysis (Ingenuity Systems, Redwood City, CA, (28)). A list of estrogen-responsive genes 
derived from the Dragon Estrogen-Responsive Gene Database (ERGDB) comprising 1069 
genes from Homo Sapiens (data downloaded September 2013, (29)) was compared to the 
significantly changed genes in both sub studies.
For the 55 participants with good quality microarrays, plasma isoflavone concentrations 
and changes in eating habits (FFQ data, one missing for LG supplement) were reported. 
To further examine the effect of the isoflavone supplement on energy metabolism, data 
on serum lipid profile, serum RBP4 concentrations and body weight data were reported. 
Samples of 19 participants in the LG supplement sub study were analysed for adipocyte 
size, as this sub study showed the most pronounced effects on energy metabolism-related 
gene expression. Mean perimeters (in µm) from 20 different cells were averaged and used 
for statistical analysis. Statistical analysis for these variables was performed using paired 
t-tests (P < 0.05) for differences between supplement and placebo for the two supplements 
and also for the two supplements and the two producer phenotypes separately (SAS version 
9.3, SAS Institute, Inc., Cary, NC).
ReSULTS
In this study, 7 equol producers were identified in the LG supplement sub study (n = 
24) and 8 in the HG supplement sub study (n = 31). Baseline age, body weight and BMI 
of participants were not significantly different between the two sub studies (Table 3.2). 
Mean total isoflavone plasma concentrations after intake of the supplements ranged from 
2.18 to 2.57 µmol/L in the two sub studies per producer phenotype (Table 3.3). Plasma 
daidzein concentrations did not significantly differ between the supplements, while 
Isoflavone effect on adipose tissue gene expressionChapter 3
58
Low genistein vs. high genistein supplement
Microarray analysis of adipose tissue after intake of the LG supplement showed a significant 
change in expression of 1245 genes in adipose tissue of 24 postmenopausal women as 
compared to placebo (Figure 3.1). In adipose tissue of the 31 postmenopausal women 
taking the HG supplement, expression of 528 genes was significantly changed. The overlap 
of significantly changed genes between the two supplements was 53 genes. GSEA of this 
data showed that after exposure to the LG supplement compared to placebo, gene sets 
Table 3.2 Baseline characteristics of participants with good quality arrays per sub study
Low genistein supplement High genistein supplement
N 24 31
N equol producers (%)* 7 (29) 8 (26)
Age (years) 63.2 ± 5.5 63.0 ± 5.5
BMI (kg/m2) 25.3 ± 3.0 25.0 ± 3.7
Body weight (kg) 71.8 ± 10.1 69.7 ± 11.2
Values are means ± SDs for age, BMI and bodyweight.
There were no significant differences in subject characteristics for the two sub studies.
* Number of equol producers as determined at the end of the intervention period with the isoflavone 
supplement.
Table 3.3 Isoflavone plasma concentrations in the two sub studies after the isoflavones 
intervention separate for equol producers and non-producers with good quality arrays
Low genistein supplement High genistein supplement
EP (n = 7) NP (n = 17) EP (n = 8) NP (n = 23)
Daidzein 1.06 (± 0.84) 1.54 (± 0.74) 0.97 (± 0.50) 1.21 (± 0.65)
Equol 0.73 (± 0.61) NA 0.64 (± 0.28) NA
Genistein 0.31 (± 0.17) 0.50 (± 0.37) 0.93 (± 0.56)* 1.29 (± 0.94)*
Glycitein 0.18 (± 0.18) 0.12 (± 0.12) 0.03 (± 0.05) 0.05 (± 0.07)*
Total** 2.27 (± 0.99) 2.18 (± 0.96) 2.57 (± 1.16) 2.55 (± 1.48)
Values are means ± SDs in µmol/L, EP equol producer, NP non-producer, NA not applicable. 
** Total isoflavones as the sum of daidzein, equol, genistein and glycitein. 
* P < 0.05 for comparison between supplements separately for producer status.
genistein concentrations were significantly higher after intake of the HG supplement. 
Glycitein concentrations were significantly higher for non-producers after intake of the LG 
supplement, and equol concentrations were only detected in equol-producers. 
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related to energy metabolism, amino acid metabolism and cell cycle were downregulated, 
whereas after the HG supplement these gene sets were upregulated. In addition, after 
intake of the latter supplement an upregulation of gene sets involved in inflammation and 
estrogen signaling was observed (Figure 3.2)
Entrez IDs 19,738 
genes
Expressed:
15 arrays > 20
14,957 genes
High genistein supplement (n = 31)
528 genes regulated
Low genistein supplement (n = 24)
1245 genes regulated
Non-producers (n = 23)
547 genes regulated
Equol producers (n = 8)
631 genes regulated
Non-producers (n = 17)
883 genes regulated
Equol producers (n = 7)
1169 genes regulated
Overlapping: 53 genes
Overlapping: 32 genes Overlapping: 89 genes
Figure 3.1 Flow chart of genes from Affymetrix gene chip to genes with significantly changed 
expression after exposure to each supplement compared to placebo and further separated for 
producer status.
Figure 3.2 Results of GSEA of both supplements for all participants and separately for equol 
producers (EP) and non-producers (NP).
Gene sets in GSEA Low genistein High genistein
All NP EP All NP EP
Glucose metabolism ↓ ↓ ↓ ↑ ↑ ↓
OXPHOS ↓ ↓ ↓ ↑ ↑ ↓
TCA cycle ↓ ↓ ↓ ↑ ↑
Fatty acid metabolism ↓ ↓ ↓ ↑ ↑
Inflammation ↓ ↑ ↑ ↓ ↑
Cell cycle ↓ ↑ ↓ ↑ ↑
Amino acid metabolism ↓ ↓ ↑
Protein processing ↑ ↑ ↓
Complement & 
coagulation
↓
Estrogen signaling ↑ ↑
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effect of the equol-producing phenotype
To identify the effect of the equol-producing phenotype on gene expression changes 
in adipose tissue, data analysis were performed separately for equol producers and 
non-producers for each supplement (Figure 3.1) and showed different gene expression 
changes in both sub studies. GSEA, performed separately for each producer phenotype, 
showed similar effects of the two phenotypes on energy-related gene expression after 
intake of the LG supplement and opposite effects on inflammation and cell cycle (Figure 
3.2). Effects on amino acid metabolism were only observed for equol producers. For the 
HG supplement, opposite effects for the two phenotypes were observed for energy 
metabolism, inflammation and protein processing. Effects on cell cycle, complement and 
coagulation and estrogen signaling were only observed for non-producers after intake of 
the HG supplement. 
Gene sets related to energy metabolism and inflammation were selected for further analysis 
as these had lowest FDR values (FDR < 0.25) for both producer phenotypes in the two sub 
studies. Individual changes in expression of energy metabolism-related genes are visualized 
in heatmaps for both supplements (Supplemental Figures 3.1a and 3.1b). The number of 
genes with significantly changed expression involved in energy metabolism was 121 for 
the LG supplement and 19 for the HG supplement, indicating a more pronounced effect 
after intake of the LG supplement. To illustrate the effect of LG supplement on energy 
metabolism, a schematic representation of an adipocyte with the effects of this supplement 
on genes in pathways of glucose metabolism, TCA cycle, OXPHOS, fatty acid synthesis, 
triglyceride synthesis and cholesterol biosynthesis is shown in Figure 3.3. Individual changes 
in expression of genes in the inflammation-related gene sets are visualized in heatmaps in 
Supplemental Figures 3.2a and 3.2b. 
With Ingenuity software, potential upstream regulators of the genes with significantly 
changed expression were identified. Several upstream regulators were identified for equol 
producers after intake of the LG supplement while only a few or none were identified for the 
other groups (Table 3.4). Most upstream regulators were involved in activation or inhibition 
of energy metabolism and inflammation-related genes.
estrogen-related effects
The estrogen-responsive effects on gene expression after isoflavone supplementation were 
further explored by comparison of the genes with significantly changed expression to the 
ERGDB database. As a result, between 4.4 and 7.0% (30 to 82) of genes with significantly 
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changed expression after intake of both supplements for both producer phenotypes were 
identified as estrogen-responsive (Supplemental Figure 3.3). 
Table 3.4 Upstream regulators derived from Ingenuity analysis (-1.5 > z > 1.5, P < 0.05) with effects 
on their downstream pathways
Upstream 
regulator
z-value Overlap 
P-value
Effects on downstream pathways
Energy metabolism Inflammation
 L
ow
 g
en
is
te
in
 s
up
pl
em
en
t EP BRD4 -2.63 0.04 ↓
IL13 -2.27 0.00 ↓ ↑
SYVN1 -2.14 0.03 ↓ ↓
PPARGCA1 -1.95 0.01 ↓
KRAS -1.94 0.00 ↑
MAPK1 -1.53 0.01 ↑/↓
NEDD9 1.63 0.01 ↓
GATA1 1.98 0.00 ↑
EPO 1.98 0.00
CD40LG 2.19 0.00 ↑
FOXO3 2.59 0.00 ↑
NP KDM5D -1.67 0.04 ↓
CD24 2.45 0.04 ↑
H
ig
h 
ge
ni
st
ei
n EP IFNB1 2.00 0.00 ↑
NP none
EP, equol producer; NP, non-producer.
effects on physiological markers
Because the isoflavone-induced gene expression pointed towards a downregulation of 
glucose metabolism, TCA cycle, OXPHOS, fatty acid synthesis, triglyceride synthesis and 
cholesterol biosynthesis in adipose tissue, effects of isoflavone supplement intake on 
body weight, adipocyte size and plasma lipid profiles were also evaluated. No significant 
differences on body weight and adipocyte size were observed for supplement vs. placebo 
in producers and non-producers (Table 3.5). Furthermore, no significant differences after 
intake of the two supplements vs. placebo were observed for total, HDL and LDL cholesterol 
and triglycerides in serum of equol producers and non-producers. Additionally, expression of 
RPB4, a gene coding for an adipokine associated with energy metabolism, was significantly 
downregulated in adipose tissue of equol producers after intake of the LG supplement. 
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mitochondrium
cytosol
Glucose
Glucose-6-P
SLC2A5 ↓
SLC2A4 ↓
GADP
GPI ↓
Pyruvate
PGAM2 ↓
ENO1 ↓
GOT1 ↓
MDH1 ↓
PyruvateSLC16A1 ↓
TCA cycle
Acetyl coA
PDHA1 ↓
DLAT↓ Citrate
Citrate
Acetyl CoA
ACO2 ↓
OGDH ↓
ME1 ↓
ME2 ↓
Succinate
β-oxidation
EHHADH ↓
ACADM ↓
DECR1 ↓
ECHS1 ↓
CRAT ↓
ACSL6 ↑
Complex I
NDUF ↓
Complex III
QPC ↓
UQCR ↓
Complex IV
COX ↓
Complex V
ATP synthase ↓
CYC1 ↓
CYCS ↓
Uncoupling protein
SLC25A14 ↓
OXPHOS
Malonyl CoA Acyl CoA
FASN ↓
ACAA2 ↓
ECHS1 ↓
ECHDC1 ↓
MECR ↓
DECR1↓
SCD ↓
ACSL6 ↑
ACACA ↓
FASN ↓
Triglyceride synthesis
DGAT2 ↓
Cholesterol
biosynthesis
APOE ↓
APOA1 ↓
NSDHL ↓
CYP22A4 ↓
DHCR24 ↓
Glycolysis
Fatty acid 
synthesis
Adenine nucleotide 
translocator
SLC25A5 ↓
SLC25A1 ↓
MVD↓
LSS ↓
NPC1L1 ↓
NR1H3 ↓
CYP46 ↓
Figure 3.3 Significantly changed genes related to energy metabolism, i.e. the pathways of glucose 
metabolism, TCA cycle, oxidative phosphorylation, fatty acid synthesis, triglyceride synthesis and 
cholesterol biosynthesis, after exposure to the low genistein supplement depicted in a schematic 
adipocyte. Bold genes are significantly changed in adipose tissue of equol producers, italic genes 
in adipose tissue of non-producers and underlined genes in both phenotypes, P < 0.05. 
ACAA2, acetyl-CoA acyltransferase 2; ACACA, acetyl-CoA carboxylase alpha; ACADM, acyl-CoA dehydrogenase; 
ACO2, aconitase 2, mitochondrial; ACSL6, acyl-CoA synthetase long-chain family member 6; APOA1, apolipoprotein 
A-I; APOE,  apolipoprotein E; COX , cytochrome c oxidase; CRAT, carnitine O-acetyltransferase; CYC1,  cytochrome 
c-1; CYCS,  cytochrome c, somatic; CYP22A4 and CYP46, cytochrome P450 22A4 and 46;  DECR1, 2,4-dienoyl CoA 
reductase 1, mitochondrial; DGAT2, diacylglycerol O-acyltransferase 2; DHCR24,  24-dehydrocholesterol reductase; 
DLAT, dihydrolipoamide S-acetyltransferase; ECHDC1, enoyl CoA hydratase domain containing 1; ECHS1, enoyl 
CoA hydratase, short chain, 1, mitochondrial; EHHADH, enoyl-CoA, hydratase/3-hydroxyacyl CoA dehydrogenase; 
ENO1, enolase 1, (alpha); FASN, fatty acid synthase; GOT1, glutamic-oxaloacetic transaminase 1, soluble (aspartate 
aminotransferase 1); GPI, glucose-6-phosphate isomerase; LSS, lanosterol synthase (2,3-oxidosqualene-lanosterol 
cyclase); MDH1, malate dehydrogenase 1, NAD (soluble); ME1, malic enzyme 1, NADP(+)-dependent, cytosolic; 
ME2, malic enzyme 2, NAD(+)-dependent, mitochondrial; MECR, mitochondrial trans-2-enoyl-CoA reductase; 
MVD, mevalonate (diphospho) decarboxylase; NDUF, NADH dehydrogenase; NPC1L1,  Niemann-Pick disease, 
type C1-like 1; NR1H3, nuclear receptor subfamily 1, group H, member 3; NSDHL, NAD(P) dependent steroid 
dehydrogenase-like; OGDH, oxoglutarate (alpha-ketoglutarate) dehydrogenase (lipoamide); PDHA1, pyruvate 
dehydrogenase (lipoamide) alpha 1; PGAM2, phosphoglycerate mutase 2 (muscle); QPC, glutaminyl-peptide 
cyclotransferase; SCD, stearoyl-CoA desaturase (delta-9-desaturase); SLC16A1, SLC25A1, SLC25A14, SLC25A5 , 
SLC2A4, SLC2A5, solute carrier family; UQCR, ubiquinol-cytochrome c reductase.
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Therefore, serum RPB4 was measured in the total study population. No statistical significant 
effects of the isoflavone supplements vs. placebo were observed on this marker for each 
producer phenotype (Table 3.5). 
Table 3.5 Plasma markers for lipid profile and RBP4
Low genistein supplement
(EP n = 7, NP n = 17)
High genistein supplement
(EP n = 8, NP n = 23)
Supplement Placebo Supplement Placebo
Cholesterol (mmol/L) EP 6.52 ± 0.58 6.81 ± 1.49 6.04 ± 0.80 5.98 ± 0.57
NP 5.98 ± 0.91 6.09 ± 0.90 5.84 ± 0.92 5.81 ± 0.95
HDL (mmol/L) EP 1.99 ± 0.49 2.05 ± 0.60 1.74 ± 0.35 1.79 ± 0.57
NP 1.75 ± 0.59 1.80 ± 0.59 1.84 ± 0.43 1.88 ± 0.50
LDL (mmol/L) EP 3.98 ± 0.63 4.12 ± 1.35 3.67 ± 0.78 3.64 ± 0.62
NP 3.67 ± 0.85 3.72 ± 0.85 3.51 ± 0.97 3.42 ± 0.93
Triglycerides (mmol/L) EP 1.23 ± 0.28 1.43 ± 0.92 1.40 ± 0.51 1.23 ± 0.44
NP 1.24 ± 0.53 1.27 ± 0.51 1.09 ± 0.47 1.12 ± 0.45
RBP4 (µmol/L) EP 1.16 ± 0.44 1.50 ± 0.42 1.10 ± 0.38 1.10 ± 0.38
NP 1.19 ± 0.40 1.13 ± 0.38 1.07 ± 0.44 1.02 ± 0.34
Body weight (kg) EP 65.9 ± 10.0 65.5 ± 10.3 70.7 ± 14.7 70.8 ± 14.1
NP 73.7 ± 9.7 73.5 ± 10.1 68.2 ± 10.5 68.3 ± 10.3
Adipocyte size* (µm) EP 357.8 ± 33.9 378.0 ± 25.3 - -
NP 331.4 ± 42.0 330.0 ± 44.1 - -
Values are means ± SDs for all variables.
No significant differences were observed after supplement compared to placebo for both supplements and 
producer phenotypes (paired t-test, P < 0.05).
*Adipocyte size was only measured in the sub study with the low genistein supplement for n = 4 equol 
producers and n=15 non-producers.
RPB4, Retinol Binding Protein 4; EP, equol producer; NP, non-producer.
FFQ results
There were no significant differences in energy-adjusted carbohydrate and fat intake by the 
participants during the supplement and placebo intervention periods for both supplements 
(results not shown). Mean energy intake by the participants was significantly higher (+ 
579kJ) during the supplement than the placebo intervention period for the HG supplement 
sub study. Energy-adjusted protein intake was significantly higher (+ 1 energy%) during 
the supplement than the placebo intervention period for the LG supplement sub study.   
DISCUSSION
Isoflavone supplement intake for 8 weeks affected gene expression in adipose tissue of 
postmenopausal women. The effects were dependent on the isoflavone supplement-type 
consumed and the equol-producing phenotype of the participants. Expression of energy 
metabolism-related genes was downregulated after intake of the LG supplement for both 
phenotypes and oppositely regulated for equol producers (down) and non-producers 
(up) after intake of the HG supplement. Expression of inflammation-related genes was 
upregulated in equol producers, while downregulated in non-producers, independent of 
supplement type (Figure 3.2).
After consumption of the LG supplement, the downregulated expression of several genes 
within connecting metabolic pathways of glucose metabolism, TCA cycle, OXPHOS, fatty acid 
synthesis, triglyceride and cholesterol metabolism pointed towards a reduction in energy 
metabolism. One of the identified upstream regulators was PGC-1α, which was significantly 
downregulated in equol producers and is known to be involved in the regulation of OXPHOS 
(30). A previous study examining adipose tissue of female OVX Sprague-Dawley rats after 
intake of an isoflavone supplement, similar to the LG supplement, in combination with a high 
fat diet as compared to effects after a high fat diet only, also resulted in a downregulation 
of gene expression related to energy metabolism (31). The observed downregulation in 
gene expression of PGC-1α- and energy-related pathways in adipose tissue is also very well 
known as a consequence of caloric restriction (32, 33). In caloric restriction, these expression 
changes are paralleled by a reduction in adipocyte size and subsequent weight loss. In 
our study we could not identify a significant decrease in adipocyte size or body weight. 
This could be due to the relatively short 8 wk exposure period, because the mild effects of 
isoflavones might require longer exposure to isoflavones to induce changes in adipocyte 
size and body weight. In addition, adipocyte size was assessed in subcutaneous adipose 
tissue, while effects might have shown in visceral adipose tissue. Furthermore, changes 
in body fat distribution were not assessed, while this might have been affected without 
changing body weight. Also, isoflavone-induced effects on gene expression of RBP4 and 
of genes related to cholesterol metabolism were not reflected by changes in serum RBP4 
and cholesterol (total, HDL and triglycerides) concentrations.  
Besides a role as energy-storing organ, adipose tissue is an active tissue in the regulation 
of immunity and inflammation (34-36). Intake of the two supplements also resulted in the 
significant upregulation of genesets involved in inflammation for the equol producers. 
However, further analysis identified an inhibition of upstream regulators known to play 
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a role in activating inflammation, such as MAPK1 and KRAS. In addition, expression 
of the receptor for the anti-inflammatory interleukin 10 (IL10RA) and NFKBIA were 
upregulated, while pro-inflammatory IRAK2 was downregulated. Although first analyses 
suggested an upregulation of inflammation, more in depth analysis pointed towards a 
predominance of the anti-inflammatory response after intake of the LG supplement in 
equol producers. Intake of the HG supplement by equol producers resulted in activation 
of the upstream regulator interferon β (IFNB1). Activation of this cytokine is suggested 
to lead to inhibition of the NLRP1b and NLRP3 inflammasomes via upregulation of STAT1 
(37). Although expression of specific inflammasome-related genes was not changed, 
STAT1 was significantly upregulated which may point towards an anti-inflammatory 
response after intake of the HG supplement by equol producers. In contrast to this more 
anti-inflammatory response in adipose tissue of equol producers after intake of both 
supplements, specific pro- or anti-inflammatory responses could not be elucidated in 
adipose tissue of non-producers.
Isoflavones are known to induce estrogen-related effects because of their structural 
similarity with 17β-estradiol. In this study, the effects of isoflavone supplementation 
were studied in adipose tissue, an endocrine organ (38), therefore estrogen receptor-
mediated effects were expected to be prominent. We observed that only about 4.4 to 
7% of the genes with significantly changed expression in our study were known to be 
estrogen-responsive. This indicates that, next to estrogen-responsive effects, the majority 
of isoflavone-induced gene expression effects (93%) are most likely regulated via other 
ways than activation of the ERs in these postmenopausal women. The limited effects 
of isoflavones via the ERs might be due to lower expression of the estrogen receptor in 
postmenopausal women compared to premenopausal women, although we previously did 
not find differences in the gene expression levels of pre- and postmenopausal women (9). 
However, their protein levels might still be reduced. Furthermore, isoflavones might induce 
more estrogen-responsive effects in other estrogen-responsive tissues such as breast and 
uterus tissue.
The gene expression effects in this study were separately analysed for both producer 
phenotypes, which explained some of the variation in response, but large inter-individual 
differences in response were still observed. This might be explained by other effect 
modifiers for isoflavones that were not taken into account, such as production of other 
gut-metabolites of daidzein; for instance production of O-desmethylangolensin (O-DMA) 
(39). But other factors might also be responsible for the individual variation in response, 
like ER polymorphisms (40, 41) and DNA methylation of certain genes (42). 
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To our knowledge, effects of isoflavone supplementation on whole-genome gene 
expression in human adipose tissue have not been published so far. In this study, the two 
supplements were well-characterized with regard to isoflavone content and the equol-
producing phenotypes were identified prior to the study to allow stratification. Another 
strength of our study was the sample size (n = 24 and 31), as crossover studies involving 
whole-genome gene expression are often performed with lesser participants (43, 44). 
No differences in baseline characteristics between the two sub studies and the producer 
phenotypes were observed. However, the estimated energy and protein intake based 
upon FFQ during the intervention periods differed between supplement and placebo for 
the HG and LG supplement, respectively. The daily dose of both commercially-available 
supplements (100 mg/day) was relevant with regard to effects of over-the-counter 
isoflavone supplements. Compliance to the study was confirmed by returned pill count (> 
94.5% compliant, results not shown) and by the reflection of the isoflavone content of the 
supplement in plasma concentrations. The two commercial supplements were soy extracts, 
differing not only in genistein content but also in glycitein content. Considering that the 
estrogen-responsive effects were limited in our study, the higher glycitein concentration 
might also be responsible for the more prominent effects of the LG supplement. 
Furthermore, potential competition or interaction of the four isoflavones for other receptors 
or transcriptional regulators might also play a role in the observed effects. Because the 
responsible isoflavone, isoflavone ratio or molecular pathway cannot be elucidated from 
this study, further investigation on these is required before any conclusion can be drawn 
regarding health effects of isoflavone supplementation.
Altogether, the current study showed that isoflavone supplementation induced molecular 
effects on energy metabolism and inflammation which were only partly induced via the 
classical ER-related pathways, but were highly influenced by supplement composition 
and equol-producing phenotype. Consumption of the LG isoflavone supplement by 
postmenopausal women resulted in a caloric restriction-like gene expression profile 
in adipose tissue and pointed towards a potential beneficial effect of this supplement, 
while intake of both supplements induced anti-inflammatory gene expression in equol 
producers.
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SLC2A5 6518         -0.27 -0.69   
SLC25A1 6576               -0.15 -0.17   
G6PD 2539               -0.10 -0.20   
STRN4 29888         -0.08 -0.04   
SLC25A11 8402         -0.08 -0.19   
ENO1 2023         -0.07 -0.21   
PYGM 5837         -0.07 -0.23   
GPI 2821         -0.06 -0.13   
NUP188 23511         -0.03 -0.14   
PGK1 5230         0.00 -0.12   
SEH1L 81929         0.01 -0.17   
NUP88 4927         0.01 -0.12   
GYG1 2992         0.02 -0.13   
GBE1 2632         0.03 -0.12   
LDHA 3939         0.05 -0.11   
PDHA1 5160         -0.01 -0.24     
MDH1 4190         0.00 -0.15     
DLAT 1737         0.00 -0.40     
ACO2 50         -0.09 -0.17   
OGDH 4967         -0.09 -0.13   
SLC16A1 6566         -0.03 -0.24   
ME2 4200         0.07 -0.13   
ATP5D 513         -0.13 -0.11   
ATP6V0E2 155066         -0.12 -0.01   
COX4I2 84701         -0.12 -0.03   
MAPT 4137         -0.11 -0.02   
NDUFS7 374291         -0.11 -0.21   
SLC25A5 292         -0.11 -0.15   
NDUFA3 4696         -0.11 -0.19   
CLTB 1212         -0.10 -0.09   
COX8A 1351         -0.09 -0.31   
NDUFS8 4728         -0.09 -0.23   
ATP6V1F 9296         -0.08 -0.06   
NDUFA2 4695         -0.08 -0.15   
COX10 1352         -0.08 -0.19   
CYC1 1537         -0.08 -0.24   
COX7B 1349         -0.07 -0.52   
UQCR11 10975         -0.06 -0.22   
ATP5A1 498         -0.06 -0.18   
ATP5J2 9551         -0.05 -0.26   
COX5A 9377         -0.05 -0.19   
HTRA2 27429         -0.05 -0.13   
NDUFA1 4694         -0.04 -0.16   
UQCRQ 27089         -0.04 -0.13   
COX6B1 1340         -0.04 -0.15   
NDUFA4 4697         -0.04 -0.16   
COX4I1 1327         -0.04 -0.12   
NDUFA7 4701         -0.04 -0.18   
CYCS 54205         -0.03 -0.24   
NDUFS2 4720         -0.03 -0.14   
Supplemental Figure 3.1a Energy metabolism Low genistein supplement
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NDUFB6 4712         -0.03 -0.23   
SLC25A14 9016         -0.03 -0.23   
NDUFS4 4724         -0.02 -0.16   
COX6A2 1339         -0.02 -0.19   
ITPR2 3709         -0.02 -0.18   
POLR2C 5432         -0.02 -0.15   
ATP5G1 516         -0.01 -0.18   
ATP5J 522         -0.01 -0.20   
ATP6V1D 51382         0.01 -0.26   
ATP5F1 515         0.01 -0.15   
NDUFA6 4700         0.01 -0.17   
CDK5 1020         0.03 -0.18   
POLR2B 5431         0.05 -0.14   
DLG4 1742         0.08 -0.20   
APOE 348        -0.09 -0.35     
ETFB 2109         -0.03 -0.17     
FADS1 3992         -0.23 -0.53   
FASN 2194         -0.22 -0.37   
NPC1L1 29881         -0.18 0.06   
FADS2 9415         -0.17 -0.64   
ACACA 31         -0.17 -0.41   
ACSS2 55902         -0.16 -0.05   
MVD 4597         -0.16 -0.12   
SLC25A1 6576         -0.15 -0.17   
PLA2G2E 30814         -0.15 -0.05   
SCD 6319         -0.14 -0.35   
CYP46A1 10858         -0.14 0.02   
ECHS1 1892         -0.13 -0.19   
LSS 4047         -0.12 0.01   
NR1H3 10062         -0.11 -0.03   
DHCR24 1718         -0.11 -0.24   
ACSL6 23305         -0.11 0.27   
TBL1X 6907         -0.11 0.05   
PLA2G6 8398         -0.10 -0.23   
PPARA 5465         -0.10 0.00   
RXRB 6257         -0.10 0.12   
CRAT 1384         -0.09 -0.10   
ABAT 18         -0.08 0.16   
ASS1 445         -0.08 -0.07   
MECR 51102         -0.08 -0.22   
DGAT2 84649         -0.07 -0.30   
SDC1 59274         -0.06 -0.19   
ACSL3 2181         -0.05 -0.17   
NSDHL 50814         -0.05 -0.21   
MGLL 11343         -0.05 -0.14   
ACAA2 10449         -0.04 -0.21   
ACADM 34         -0.03 -0.22   
CYP4A22 284541         -0.03 -0.37   
HSD17B1
2 51144                             -0.02 -0.22      
PLA2G4A 5321         -0.02 -0.26   
Supplemental Figure 3.1a Energy metabolism Low genistein supplement
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RDH11 51109         -0.01 -0.13   
CERS6 253782         -0.01 -0.15   
EHHADH 1962         -0.01 -0.22   
APOA1 335         0.00 -0.13   
SGPL1 8879         0.00 -0.13   
VLDLR 7436         0.00 -0.24   
DECR1 1666         0.01 -0.13   
RXRG 6258         0.01 -0.29   
ELOVL2 54898         0.01 -0.26   
ACAD8 27034         0.01 -0.16   
ECHDC1 55862         0.02 -0.35   
AGT 183         0.06 -0.39   
ACACA 31         -0.17 -0.41     
ME1 4199         -0.05 -0.35     
ALDH1B1 219         -0.04 -0.28       
ALDH9A1 223         -0.02 -0.18       
PRKACA 5566         -0.04 -0.19     
GOT1 2805                                                 -0.11 -0.15     
 
Supplemental Figure 3.1a Heatmap of significantly expressed genes in postmenopausal women 
involved in energy metabolism after eight weeks exposure to the low genistein supplement 
compared to placebo. Bold SLRs are significantly expressed, SLR signal log ratio, EP equol producer, 
NP non producer.
Supplemental Figure 3.1a Energy metabolism Low genistein supplement
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PIK3CA 5290         0.00 0.14   
ENO3 2027         0.02 -0.22   
PGM1 5236         0.09 -0.08   
SLC25A11 8402         0.10 -0.04   
MRPL12 6182         0.12 -0.11   
ALDH3A2 224         0.04 -0.11   
NDUFB9 4715         0.04 -0.17   
CYCS 54205         0.12 0.18   
NDUFS6 4726         0.12 -0.04   
ATP5E 514         0.12 0.17   
MGLL 11343         0.07 -0.06   
SLC27A4 10999         0.11 -0.04   
AGPAT3 56894         0.14 0.03   
HPD 3242         0.15 0.00   
PLA2G4A 5321         0.15 0.06   
VLDLR 7436         0.18 -0.04   
APOB 338         0.19 0.14   
ACSS2 55902         0.13 -0.08       
ALDH9A1 223                                                               0.10 -0.07       
 
Supplemental Figure 3.1b Energy metabolism High genistein supplement
Supplemental Figure 3.1b Heatmap of significantly expressed genes in postemenopausal women 
involved in energy metabolism after eight weeks exposure to the high gensitein supplement 
compared to placebo. Bold SLRs are signficantly expressed, SLR signal log ratio, EP equol producer, 
NP non producer.
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LBP 3069         -0.15 -0.51   
TGFB3 7043         -0.15 -0.34   
IRAK2 3656         -0.09 -0.26   
CALR 811         0.04 -0.21   
FBXW5 54461         -0.09 -0.18   
MLST8 64223         -0.08 -0.14   
NFKB1 4790         0.10 -0.02   
PPARA 5465         -0.10 0.00   
RELA 5970         -0.09 0.03   
CFLAR 8837         0.06 0.15   
MITF 4286         0.06 0.16   
C1S 716         0.03 0.17   
FHL2 2274         0.04 0.20   
ITGB3 3690         -0.01 0.33   
PLCB2 5330         -0.10 0.33   
TLR6 10333         -0.05 0.46   
MTOR 2475         -0.02 -0.14     
CD247 919         0.05 0.31         
CD3E 916         0.05 0.53       
NFATC2 4773         0.07 0.23       
NFKBIA 4792         0.02 0.24         
TNFAIP3 7128         0.03 0.18     
CASP8 841         0.01 0.22     
PLCG2 5336         -0.01 0.20     
FCGR2B 2213         0.06 0.24     
ITGB2 3689         -0.08 0.48     
NCF2 4688         -0.05 0.70     
ETV5 2119         -0.01 -0.36   
CCND1 595         -0.08 -0.26   
SPRY1 10252         -0.03 -0.15   
MAP2K2 5605         -0.14 -0.03   
KRAS 3845         0.12 0.01   
FOXO3 2309         -0.15 0.05   
CBL 867         -0.08 0.05   
MPL 4352         -0.04 0.14   
CDKN1B 1027         0.02 0.14   
JAK2 3717         0.10 0.14   
IL15RA 3601         0.00 0.19   
IL6R 3570         -0.03 0.25   
GADD45
G 10912                             0.03 0.28       
IL10RA 3587         -0.04 0.37   
STAT5B 6777         -0.05 0.11     
BCL2L1 598         -0.07 0.26     
UBE2V1 7335         0.04 -0.31   
DUSP3 1845         0.00 -0.24   
STK39 27347         -0.01 -0.15   
STIM1 6786         -0.04 -0.14   
Supplemental Figure 3.2a Inflammation Low genistein supplement
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YWHAQ 10971         0.01 -0.11   
WASF2 10163         0.01 0.17   
SLA 6503         -0.09 0.42   
RASGRP1 10125         -0.05 0.48   
RASSF5 83593         0.02 0.58   
TRAT1 50852         -0.18 0.73   
PTPRC 5788         -0.05 0.66     
ITK 3702         -0.04 0.71     
HSP90B1 7184         0.07 -0.13   
TXNIP 10628         0.03 0.11   
PRDM1 639         -0.03 0.25   
NCR3 259197         0.02 -0.26   
PLA2G4A 5321         -0.02 -0.26   
KIR3DL2 3812         0.08 -0.24   
PIP5K1C 23396         -0.07 -0.20   
S1PR1 1901         0.09 0.14   
PTPN18 26469         0.03 0.16   
HCLS1 3059         -0.07 0.27   
KLRD1 3924         0.01 0.44   
KLRC4-
KLRK1 100528032                             0.06 0.55       
CD48 962                                                 -0.15 0.84   
 
Supplemental Figure 3.2a Inflammation Low genistein supplement
Supplemental Figure 3.2a Heatmap of significantly expressed genes involved in inflammation 
in adipose tissue of postmenopausal women after eight weeks exposure to the low genistein 
supplement compared to placebo. Bold SLRs are significantly expressed, SLR signal log ratio, EP 
equol producer, NP non producer. Genes are identified in genesets related to Toll-like receptor 
signaling, T-cell receptor signaling, Nod-like receptor signaling, Natural killer cell and B-cell 
signaling.
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KLRC2 3822         -0.12 0.30   
TEC 7006         -0.10 -0.02       
IL1RN 3557         -0.23 0.08       
CCL3 6348         -0.24 0.11         
PIK3CA 5290         0.00 0.14       
STAT1 6772         0.03 0.18       
NRAS 4893         -0.09 -0.02     
ICAM1 3383         -0.10 0.05       
B2M 567         -0.09 0.07       
IL4R 3566         -0.01 0.17     
PAK2 5062         0.01 0.12     
KIR2DL4 3805         -0.05 0.16     
JAK2 3717         -0.06 0.17     
CASP3 836         -0.01 0.17     
IRF1 3659         -0.08 0.31     
LY96 23643         -0.15 0.13   
JUNB 3726         -0.02 0.36   
IRF5 3663         -0.14 0.03       
CD86 942         -0.15 0.11     
EDN1 1906         -0.17 -0.57   
CHRM4 1132         -0.06 -0.26   
DRD5 1816         -0.05 -0.22   
CXCL12 6387         -0.06 -0.20   
KISS1 3814         -0.06 -0.16   
HGF 3082         -0.14 -0.16   
GNAQ 2776         -0.04 -0.15   
GNG5 2787         -0.06 -0.14   
ADCY2 108         -0.11 -0.13   
OPRL1 4987         -0.10 -0.12   
ATP8A1 10396         -0.11 -0.05   
LTB4R 1241         -0.12 -0.03   
UTS2D 257313         -0.19 -0.02   
CDC42 998         -0.10 -0.01   
HLA-DOA 3111         -0.12 0.00   
F2R 2149         -0.09 0.02   
RELT 84957         -0.11 0.12   
CHRM1 1128         -0.12 0.16   
GPBAR1 151306         0.09 0.21   
PRKCD 5580         0.12 0.23   
CCBP2 1238         -0.10 0.23   
CCR2 729230         -0.17 0.38   
TNFRSF21 27242         0.03 0.15     
CCL25 6370         0.02 0.18     
CCL27 10850         -0.06 0.26     
VEGFA 7422         0.01 0.29     
PTAFR 5724         -0.08 0.30     
CCR1 1230         -0.11 0.48     
CD59 966         -0.07 -0.03   
RFX5 5993         -0.08 -0.02   
ATP6V0B 533         -0.11 0.06   
FCER1A 2205         -0.15 0.08   
BIRC2 329         0.00 0.11   
CD1C 911         -0.14 0.16   
Supplemental Figure 3.2b Inflammation High genistein supplement
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Supplemental Figure 3.2b Heatmap of significantly expressed genes in postmenopausal women 
involved in inflammation after eight weeks exposure to the high genistein supplement compared 
to placebo. Bold SLRs are signficantly expressed, SLR signal log ratio, EP equol producer, NP non 
producer. Genes are identified in gene sets related to interleukin, Toll like receptor, G-protein 
coupled receptor signalling and immune response.
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LAX1 54900         -0.12 0.20   
ISG20 3669         0.01 0.31   
CR1 1378                                                               -0.22 0.53   
 
Supplemental Figure 3.2b Inflammation High genistein supplement
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Low 
genistein 
supplement 
High 
genistein 
supplement 
Gene Description 
SLR 
NP 
SLR 
EP 
SLR 
NP 
SLR 
EP 
KRT6B keratin 6B -0.25       
TPX2 TPX2, microtubule-associated, homolog (Xenopus laevis) -0.22       
NR4A1 nuclear receptor subfamily 4, group A, member 1 -0.21 -0.35     
ADRB1 adrenoceptor beta 1 -0.21       
ZWINT ZW10 interactor -0.19       
NME2 NME/NM23 nucleoside diphosphate kinase 2 -0.18       
RET ret proto-oncogene -0.18 -0.21     
MUC1 mucin 1, cell surface associated -0.16       
EGR3 early growth response 3 -0.16       
TK1 thymidine kinase 1, soluble -0.15 -0.21     
TGFB3 transforming growth factor, beta 3 -0.15 -0.34   -0.18 
CORO2B coronin, actin binding protein, 2B -0.15       
SSNA1 Sjogren syndrome nuclear autoantigen 1 -0.13       
NOS3 nitric oxide synthase 3 (endothelial cell) -0.13 -0.25     
BIK BCL2-interacting killer (apoptosis-inducing) -0.12       
GOT1 glutamic-oxaloacetic transaminase 1, soluble (aspartate aminotransferase 1) -0.11 -0.15     
FGF18 fibroblast growth factor 18 -0.11   0.12   
SLC25A5 solute carrier family 25 (mitochondrial carrier ///  adenine nucleotide translocator), -0.11       
CTBP1 C-terminal binding protein 1 -0.10       
CELSR2 cadherin, EGF LAG seven-pass G-type receptor 2 (flamingo homolog, Drosophila) -0.08       
TMED2 transmembrane emp24 domain trafficking protein 2 0.06       
sep-02 septin 2 0.07       
MAN1A1 mannosidase, alpha, class 1A, member 1 0.07       
RIF1 RAP1 interacting factor homolog (yeast) 0.08       
WDR43 WD repeat domain 43 0.09       
NR2C1 nuclear receptor subfamily 2, group C, member 1 0.09       
LRRFIP2 leucine rich repeat (in FLII) interacting protein 2 0.09       
KIFAP3 kinesin-associated protein 3 0.09       
OLFM1 olfactomedin 1 0.10       
APOA2 apolipoprotein A-II 0.10       
RPL15 ribosomal protein L15 0.11       
EIF5 eukaryotic translation initiation factor 5 0.12       
LRRC49 leucine rich repeat containing 49 0.12       
TMED7 transmembrane emp24 protein transport domain containing 7 0.12       
ABCE1 ATP-binding cassette, sub-family E (OABP), member 1 0.12       
RBBP8 retinoblastoma binding protein 8 0.13       
ZNF230 zinc finger protein 230 0.16       
FXYD2 FXYD domain containing ion transport regulator 2 0.20       
GPRC5A G protein-coupled receptor, family C, group 5, member A 0.21       
TNC tenascin C   -0.44     
IGF2 insulin-like growth factor 2 (somatomedin A)   -0.44     
PPIF peptidylprolyl isomerase F   -0.36     
ME1 malic enzyme 1, NADP(+)-dependent, cytosolic   -0.35     
NME1 NME/NM23 nucleoside diphosphate kinase 1   -0.34     
TUBG1 tubulin, gamma 1   -0.31     
THBD thrombomodulin   -0.31     
NCAM2 neural cell adhesion molecule 2   -0.30     
KITLG KIT ligand   -0.27     
Supplemental Figure 3.3 Estrogen-responsive genes
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Low 
genistein 
supplement 
High 
genistein 
supplement 
Gene Description 
SLR 
NP 
SLR 
EP 
SLR 
NP 
SLR 
EP 
ELOVL2 ELOVL fatty acid elongase 2   -0.26     
CCND1 cyclin D1   -0.26     
CNKSR3 CNKSR family member 3   -0.25     
CYCS cytochrome c, somatic   -0.24     
DHCR24 24-dehydrocholesterol reductase   -0.24     
KIR3DL2 killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 2   -0.24     
PAICS phosphoribosylaminoimidazole carboxylase, phosphoribosylaminoimidazole succinocarboxami   -0.23     
TFF1 trefoil factor 1   -0.23     
HSPD1 heat shock 60kDa protein 1 (chaperonin)   -0.23     
KPNA2 karyopherin alpha 2 (RAG cohort 1, importin alpha 1)   -0.22     
ARMCX3 armadillo repeat containing, X-linked 3   -0.22     
ENO1 enolase 1, (alpha)   -0.21     
SGCD sarcoglycan, delta (35kDa dystrophin-associated glycoprotein)   -0.20     
SEMA5B sema domain, seven thrombospondin repeats (type 1 and type 1-like), 
transmembrane domai 
  -0.20     
G6PD glucose-6-phosphate dehydrogenase   -0.20     
RAMP3 receptor (G protein-coupled) activity modifying protein 3   -0.19     
AURKB aurora kinase B   -0.19     
ESR2 estrogen receptor 2 (ER beta)   -0.18     
C1QBP complement component 1, q subcomponent binding protein   -0.18     
CENPA centromere protein A   -0.18     
ACO2 aconitase 2, mitochondrial   -0.17     
RUNX1 runt-related transcription factor 1   -0.17     
MCM4 minichromosome maintenance complex component 4   -0.17     
NR4A3 nuclear receptor subfamily 4, group A, member 3   -0.16     
FOXF1 forkhead box F1   -0.16     
ORMDL2 ORM1-like 2 (S. cerevisiae)   -0.15     
MARCKS myristoylated alanine-rich protein kinase C substrate   -0.15     
SLC12A2 solute carrier family 12 (sodium/potassium/chloride transporters), member 2   -0.15     
SPRY1 sprouty homolog 1, antagonist of FGF signaling (Drosophila)   -0.15     
GARS glycyl-tRNA synthetase   -0.15     
RPA3 replication protein A3, 14kDa   -0.14     
STMN1 stathmin 1   -0.14     
IARS isoleucyl-tRNA synthetase   -0.14     
ITGAV integrin, alpha V   -0.12     
NUP88 nucleoporin 88kDa   -0.12     
TXNIP thioredoxin interacting protein   0.11     
NRF1 nuclear respiratory factor 1   0.13     
ECE1 endothelin converting enzyme 1   0.13     
EFEMP1 EGF containing fibulin-like extracellular matrix protein 1   0.13     
MPL myeloproliferative leukemia virus oncogene   0.14     
GSTO1 glutathione S-transferase omega 1   0.15     
HIP1R huntingtin interacting protein 1 related   0.16   -0.19 
PAX8 paired box 8   0.16     
PTPN18 protein tyrosine phosphatase, non-receptor type 18 (brain-derived)   0.16     
WSB1 WD repeat and SOCS box containing 1   0.17 -0.11   
IGF1R insulin-like growth factor 1 receptor   0.17   -0.15 
GNG7 guanine nucleotide binding protein (G protein), gamma 7   0.17     
Supplemental Figure 3.3 Estrogen-responsive genes
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Low 
genistein 
supplement 
High 
genistein 
supplement 
Gene Description 
SLR 
NP 
SLR 
EP 
SLR 
NP 
SLR 
EP 
SFRP1 secreted frizzled-related protein 1   0.18     
MCM7 minichromosome maintenance complex component 7   0.18     
SATB1 SATB homeobox 1   0.18     
INPP4B inositol polyphosphate-4-phosphatase, type II, 105kDa   0.20     
THBS2 thrombospondin 2   0.20     
PTGER2 prostaglandin E receptor 2 (subtype EP2), 53kDa   0.21     
WISP2 WNT1 inducible signaling pathway protein 2   0.22   -0.21 
BCL2L11 BCL2-like 11 (apoptosis facilitator)   0.22     
ABCB1 ATP-binding cassette, sub-family B (MDR/TAP), member 1   0.23     
TSC22D3 TSC22 domain family, member 3   0.24     
NFKBIA nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha   0.24     
ANKRD44 ankyrin repeat domain 44   0.25     
CTNND1 catenin (cadherin-associated protein), delta 1   0.25     
BCL2L1 BCL2-like 1   0.26     
TNFSF8 tumor necrosis factor (ligand) superfamily, member 8   0.26     
CCNG2 cyclin G2   0.26     
FKBP8 FK506 binding protein 8, 38kDa   0.26     
ZFP36L2 zinc finger protein 36, C3H type-like 2   0.27     
SLA Src-like-adaptor   0.42     
S100P S100 calcium binding protein P   0.51     
CD86 CD86 molecule     -0.15   
GNRH1 gonadotropin-releasing hormone 1 (luteinizing-releasing hormone)     -0.14   
PLAT plasminogen activator, tissue     -0.12   
HMGB2 high mobility group box 2     -0.12   
TFPI tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor)     -0.11   
ICAM1 intercellular adhesion molecule 1     -0.10   
PDLIM5 PDZ and LIM domain 5     -0.09   
LRCH3 leucine-rich repeats and calponin homology (CH) domain containing 3     -0.09   
PTPRO protein tyrosine phosphatase, receptor type, O     -0.09   
NRAS neuroblastoma RAS viral (v-ras) oncogene homolog     -0.09   
PPP2CA protein phosphatase 2, catalytic subunit, alpha isozyme     -0.08   
PSMD11 proteasome (prosome, macropain) 26S subunit, non-ATPase, 11     0.05   
EIF2S1 eukaryotic translation initiation factor 2, subunit 1 alpha, 35kDa     0.06 0.10 
TSN translin     0.08   
CSTF2 cleavage stimulation factor, 3' pre-RNA, subunit 2, 64kDa     0.08   
PVR poliovirus receptor     0.08   
SND1 staphylococcal nuclease and tudor domain containing 1     0.09   
ACTN1 actinin, alpha 1     0.09   
MRPL3 mitochondrial ribosomal protein L3     0.09   
VPS37C vacuolar protein sorting 37 homolog C (S. cerevisiae)     0.09   
HOXD4 homeobox D4     0.10   
CACYBP calcyclin binding protein     0.10   
SLC22A1 solute carrier family 22 (organic cation transporter), member 1     0.10   
BLVRB biliverdin reductase B (flavin reductase (NADPH))     0.11   
PRKCD protein kinase C, delta     0.12 0.23 
HSPB8 heat shock 22kDa protein 8     0.13   
PGR progesterone receptor     0.14   
FKBP4 FK506 binding protein 4, 59kDa     0.15   
Supplemental Figure 3.3 Estrogen-responsive genes
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Low 
genistein 
supplement 
High 
genistein 
supplement 
Gene Description 
SLR 
NP 
SLR 
EP 
SLR 
NP 
SLR 
EP 
APOB apolipoprotein B (including Ag(x) antigen)     0.19   
EDN1 endothelin 1       -0.57 
NTRK3 neurotrophic tyrosine kinase, receptor, type 3       -0.40 
MAB21L1 mab-21-like 1 (C. elegans)       -0.26 
FST follistatin       -0.24 
PGM5 phosphoglucomutase 5       -0.23 
ENO3 enolase 3 (beta, muscle)       -0.22 
LAMA3 laminin, alpha 3       -0.21 
CXCL12 chemokine (C-X-C motif) ligand 12       -0.20 
SYTL2 synaptotagmin-like 2       -0.18 
PLXNA3 plexin A3       -0.18 
PRKCE protein kinase C, epsilon       -0.18 
CACNA1C calcium channel, voltage-dependent, L type, alpha 1C subunit       -0.18 
CITED2 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2       -0.18 
SVIL supervillin       -0.17 
TOP3B topoisomerase (DNA) III beta       -0.16 
KLF6 Kruppel-like factor 6       -0.15 
PDIA4 protein disulfide isomerase family A, member 4       -0.14 
EXOSC10 exosome component 10       -0.14 
PDE3A phosphodiesterase 3A, cGMP-inhibited       -0.13 
ZFYVE26 zinc finger, FYVE domain containing 26       -0.13 
HDAC6 histone deacetylase 6       -0.12 
DLC1 deleted in liver cancer 1       -0.11 
HUWE1 HECT, UBA and WWE domain containing 1, E3 ubiquitin protein ligase       -0.10 
GNB1 guanine nucleotide binding protein (G protein), beta polypeptide 1       -0.10 
DNAJA2 DnaJ (Hsp40) homolog, subfamily A, member 2       0.13 
PHF7 PHD finger protein 7       0.14 
CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1)       0.17 
RHOU ras homolog family member U       0.20 
PLOD2 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2       0.24 
ZNF267 zinc finger protein 267       0.26 
ISG20 interferon stimulated exonuclease gene 20kDa       0.31 
BAK1 BCL2-antagonist/killer 1       0.33 
JUNB jun B proto-oncogene       0.36 
CCR2 chemokine (C-C motif) receptor 2       0.38 
CCR1 chemokine (C-C motif) receptor 1       0.48 
Number of significantly regulated estrogen responsive genes 39 82 30 41 
% of estrogen responsive genes relative to all regulated genes 4.4 7.0 5.5 6.5 
 
Supplemental Figure 3.3 Estrogen-responsive genes
Supplemental Figure 3.3 Significantly changed estrogen responsive genes. Expression of 
estrogen-responsive genes according to the ERGDB signficantly changed after eight weeks 
exposure to each supplement compared to placebo.
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ABSTRACT
Background: Isoflavones are present in soy foods and soy-based supplements. Despite 
low plasma isoflavone concentrations in the general Western population, concentrations 
in supplement users exceed those suggested to be beneficial for health in Asian 
populations, raising concerns for adverse effects. To aid risk assessment, quantification 
of the relation between isoflavone intake and plasma concentrations is essential.
Methods: Plasma samples were collected from postmenopausal women in three 
placebo-controlled crossover studies with eight-week periods for supplements (2 
studies, ~100 mg isoflavones/day, n = 88) or four-week periods for soy foods (1 study, 
~48 mg isoflavones/day, n = 15). Plasma isoflavone concentrations (daidzein, equol, 
genistein and glycitein) were quantified with HPLC and electrochemical detection. 
The association between plasma concentrations and isoflavone intake, equol producer 
status, intake-producer interaction and background dietary intake was assessed based 
on the assumption of a log-linear relation. 
Results: Median plasma total isoflavone concentrations after the soy food and 
supplement interventions were respectively 2.16 and 3.47 µmol/L for equol producers 
and 1.30 and 2.39 µmol/L for non-producers. Regression analysis showed that doubling 
isoflavone intake increased plasma concentrations by 55-62% (± SE 1-2%, R2 > 0.87) for 
daidzein, genistein, equol (only for producers) and total isoflavones; for glycitein the 
association was weaker (15 ± 1%, R2 = 0.48). Adjustments for energy, carbohydrate and 
fat intake did not affect these estimates. Inter-individual variation, estimated based on 
repeated measures in one of the studies, was 30-96%.
Conclusions: Although the relation between isoflavone intake and plasma concentrations 
was adequately quantified, the use of isoflavone intake data for risk assessment needs 
caution due to large inter-individual variation in plasma concentrations. 
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INTRODUCTION
Isoflavones, present in soy products, are suggested to relieve menopausal complaints (1, 2) 
and to have a number of other beneficial health effects, such as prevention of osteoporosis 
and cardiovascular disease (3-5). At higher doses, uncertainty exists regarding potentially 
detrimental effects on thyroid function and risk of breast and endometrium cancer, because 
long-term human trials are currently lacking (6-8).
The glucosides daidzin, genistin and glycitin are the main isoflavones in soy, whereas their 
malonyl and acetyl equivalents as well as the aglycones daidzein, genistein and glycitein 
occur in much lower quantities (9). The various isoflavones have specific pharmacokinetic 
characteristics: e.g. isoflavone glucosides are more bioavailable than their aglycones (10); 
daidzein is rapidly excreted in urine, whereas genistein enters enterohepatic recycling (10, 
11). Additionally, 20-30% of the Western population are so-called equol producers; they 
can convert daidzein into the more active metabolite equol by their gut bacteria (12). 
Furthermore, isoflavone plasma concentrations can be influenced by isoflavone source, 
food matrix, diet, frequency of ingestion, gender and age (10). 
Mean isoflavone intake is low (0.5-0.8 mg/day) across the European population and remains 
well below the intake in Asian countries even for vegetarians and vegans (22.4 mg/day) 
(13). In Japan, mean intakes of daidzein and genistein are 18.3 and 31.4 mg/day resulting in 
plasma concentrations of 0.12 and 0.48 µmol/L, respectively (14). On average, supplement 
users in Western countries consume 50 mg of isoflavones/day, but soy-based supplements 
can contain up to 107 mg aglycone equivalents of isoflavones (15-17). Two intervention 
studies demonstrated that an intake of 100 mg isoflavones/day resulted in total circulating 
isoflavones of 1.12 and 4.50 µmol/L (18, 19). This illustrates that postmenopausal women 
taking isoflavone supplements e.g. to relieve their menopausal complaints can be exposed 
to higher isoflavone concentrations than Asians who regularly consume soy products. 
For risk assessment, insight in isoflavone plasma concentrations resulting from these higher 
isoflavone intake ranges is important. Isoflavone pharmacokinetics as well as positive 
correlations and dose-response curves between intake and circulating isoflavones have 
previously been thoroughly characterized (20-25). However, because of the small sample 
sizes (n = 10-18) these data are not suitable for risk assessment and a quantitative description 
of the relation between isoflavone intake and plasma concentrations in a much larger group 
of postmenopausal women is needed. We aimed to quantify this relation based on intakes 
of two different isoflavone supplements and a soy food, taking into account relevant factors 
like equol-producing phenotype and background dietary intake.
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SUBjeCTS AND MeThODS
Trials and subjects
For this study, data from three randomized crossover trials were used: the ISO study, the 
ISO II study and the SOY study. All studies were conducted at the department of Human 
Nutrition of Wageningen University and were performed according to the guidelines laid 
down in the Declaration of Helsinki. All procedures were approved by the medical ethical 
review board of this University and written informed consent was obtained from all subjects.
Thirty postmenopausal women participated in the double-blind ISO study of which all 
participants were equol producers, characterized at screening. The study was registered at 
clinicaltrials.gov under NCT01232751. The ISO II study, hereafter named the GD (genistein/
daidzein) study, was a double-blind trial with two arms in which 72 postmenopausal women 
participated, 36 in each arm. The two arms were either a low genistein, high daidzein 
supplement (LG) or a high genistein, high daidzein supplement (HG), both against placebo. 
Equol producers, characterized at screening, were randomized over the two arms. The study 
was registered at clinicaltrials.gov under NCT01556737. Both double-blind trials included 
two eight-week intervention periods with one eight-week washout period in between 
and had the same in- and exclusion criteria, previously reported in (26). In the ISO study, 
postmenopausal status was defined as 3 months absence of menses and if shorter than 1 
year this was complemented with an FSH test. For the GD study 1 year absence of menses 
defined postmenopausal status (see Table 4.1 for details on subjects). The SOY study was 
a strictly-controlled dietary intervention with a soy protein diet. Sixteen postmenopausal 
women with abdominal obesity, as defined by a waist circumference ≥ 80 cm, were included. 
During each four week intervention period the participants consumed a soy protein-rich 
diet or a mixed protein diet (control diet), with a four week washout period in between. 
The study was registered at clinicaltrials.gov under NCT01694056.
Equol-producing capacity of the participants of the ISO and the GD study was verified 
before entering the study by a three-day challenge with the daidzein-rich supplement, after 
which equol was detected in a spot urine sample. For exact criteria used, see van der Velpen 
et al., 2013 (26). In the ISO study, 42 equol producers (27%) out of 150 postmenopausal 
women were characterized of which 30 producers entered the study. In the GD study, 73 
postmenopausal women were screened and 17 (23%) were equol producers; 16 producers 
and 54 non-producers were included in the study. At the end of the isoflavone intervention 
of the GD study 2 non-producers switched producer status. In the SOY study, 4 of 15 women 
(27%) were characterized as equol producers after the soy diet intervention period.
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Isoflavone intervention
The isoflavone supplements of the ISO study (October 2010) which were also used in the 
LG-arm of the GD study (November 2011) were previously described (26). The capsules 
from the two different batches contained 14 mg daidzein, 3-4 mg genistein and 6-7 mg 
glycitein (aglycone equivalents) per supplement, as quantified in our laboratory (Table 
4.1). The participants were asked to consume four capsules/day, two in the morning and 
two in the evening.
Table 4.1 Subject characteristics, isoflavone content of supplements and soy foods and 
background dietary intake
ISO 
(n = 21)
GD LG 
(n = 32)
GD HG 
(n = 35)
SOY 
(n = 15)
Mean SD Mean SD Mean SD Mean SD
Age (years)1 60.3 6.2 62.2 5.3 62.7 5.4 61.2 5.4
BMI (kg/m2) 25.7 4.0 25.2 3.1 25.0 3.6 25.4 4.1
Body weight (kg) 73.0 13.3 71.4 9.8 69.5 11.0 69.4 12.6
No of equol producers (%)2 21 100 8 25 9 26 4 27
Total isoflavone intake (mg/day)3 93.9 100.1 104.2 48.3
Daidzin 53.2 52.0 50.8 15.9
Daidzein 3.2 3.7 0.5 2.3
Genistin 11.4 16.5 42.0 21.4
Genistein 0.4 0 0.7 6.0
Glycitin 23.8 26.3 9.8 2.3
Glycitein 2.0 1.5 0.4 0.5
Energy intake4 (kJ/day)
Intervention 8726 2304 7626 2244 7869 1946 9126 1801
Placebo 8377 2264 7819 2675 7359 1938 9021 1674
Carbohydrate intake (g/day)
Intervention 237 62 197 67 217 65 263 57
Placebo 228 60 208 80 203 62 274 55
Fat intake (g/day)
Intervention 87 32 73 29 73 27 67 13
Placebo 81 32 76 32 68 24 63 12
1 Age, BMI and body weight are determined at the start of the studies.
2 No of equol producers as determined at the end of the intervention.
3 Glucosides daidzin, genistin and glycitin calculated as aglycone equivalents.
4 Diet data for GD LG arm for n = 31.
The supplements in the HG-arm of the GD study were provided by Springfield Nutraceuticals 
(Oud-Beijerland, the Netherlands) based on the commercially available supplement Mega 
Soja with an isoflavone content of 25 mg daidzein, 21 mg genistein and 5 mg glycitein per 
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supplement (aglycone equivalents, Table 4.1). The identical-looking placebo capsules were 
provided by the same supplier; these consisted of hydroxypropylmethyl cellulose (HPMC), 
were not coloured and were filled with microcrystalline cellulose. The participants in this 
study consumed two capsules/day, one in the morning and one in the evening. A run-in 
period of 4 weeks proceeded both studies. The participants were asked not to eat soy foods 
during the run-in and the study period.
Before the strictly controlled dietary intervention (SOY study), participants were assigned to 
an energy group based on the results of a validated 177-item FFQ (27) and their height and 
weight. The soy and mixed protein diet were iso-energetic with the same macronutrient 
composition (21 energy% protein, 26 energy% fat and 51 energy% carbohydrates). The 
soy protein diet contained approximately 30 gram of soy protein/day, in the form of soy 
based meat analogues and soy nuts provided by Alpro (Gent, Belgium) containing ~48 
mg isoflavones (18 mg daidzein, 26 mg genistein, 3 mg glycitein, Table 4.1). During the 
one week run-in period and the 4 week washout period participants were not allowed 
to eat soy foods.
Background dietary intake
To monitor background dietary intake during the ISO and GD study, the participants were 
asked to fill out a semi-quantitative validated FFQ consisting of 125 items at the end of 
each eight week intervention period (27). Background dietary intake in the SOY study was 
derived from duplicate portions of both experimental diets in which energy, fat, protein, ash 
and dry matter content was analysed. Carbohydrate content was calculated by subtracting 
protein, fat, ash and moisture content from the total sample weight. Mean energy and 
nutrient intake per participant was calculated from food tables (28) and adjusted for the 
duplicate diet analysis. 
Sample collection 
In the ISO study, plasma samples were collected halfway and at the end of each 8 week 
intervention period. During the GD study and SOY study, plasma was collected after each 
intervention period. Fasted venous blood samples were collected into 6 ml EDTA vacutainers 
(Becton Dickinson (BD), Breda, the Netherlands) and centrifuged for ten minutes at 1190 
g at a temperature of 4°C to obtain plasma. The samples were stored at -80°C in aliquots 
until analysis.
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hPLC analysis of isoflavones 
Isoflavones in plasma, supplements and soy foods were determined after enzymatic 
deconjugation using reversed phase HPLC with electrochemical detection as previously 
described for the ISO study (26). For all isoflavones, except glycitein, the limit of detection 
(LOD) and limit of quantification were 0.04 and 0.08 µmol/L, respectively. For glycitein these 
values were 0.11 and 0.22 µmol/L, respectively. The within-run and between-run variability 
coefficients of variation (CV in %) were 7.6 and 16.8% respectively for daidzein, 7.6 and 
23.8% for equol, 14.7 and 30.6% for genistein and 24.2 and 28.0% for glycitein.    
Data analysis
In the ISO study, one outlier was detected for all plasma concentrations (8 SD from mean) 
and excluded from the analysis. The GD study had three dropouts and the SOY study had one 
dropout. Ten subjects participated in more than one of the studies; these were excluded from 
the study with most equol producers, i.e. ISO study, resulting in 103 subjects. Each subject 
contributed two data points (206 observations), one after the placebo or mixed protein 
period (unexposed) and one after the intervention period of each trial (exposed). Although 
these data are paired, they were considered statistically independent because plasma 
concentrations for unexposed were close to zero and not correlated to the concentration 
for exposed and there was no overlap in study subjects.
Linear regression analysis was used to explain total and component-specific concentrations 
of isoflavones in plasma by intake (in µmol/kg bw). Both dose and plasma concentrations 
(µmol/L) were loge transformed and all models were adjusted for study (ISO study, GD study, 
SOY study). For daidzein, equol and total isoflavones the model also accounted for equol 
producer status (prod; 1 for producer, 0 for non-producer) and its interaction with intake:
loge(conc) = β0 + β1* loge(dose) + β2 * prod + β3 * prod * loge(dose) + ε
When original values for concentration were zero, 0.5 times the LOD was used to enable loge 
transformation of the data, i.e. 0.02 for daidzein, equol, genistein and total isoflavones and 
0.055 for glycitein. When intake was zero, a dose of 0.01 µmol/kg bw was used. To account 
for the role of the background diet, a second model was further adjusted for energy intake 
(continuous in kJ/day), carbohydrate intake (g/day) and fat intake (g/day). Dietary intake 
data from 1 participant in the GD LG-arm was missing.
To estimate inter- and intra-individual variation at a high supplement dose, loge transformed 
plasma isoflavone concentrations after four and eight weeks of isoflavone supplementation 
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were used (ISO study, n = 29). Variance between subjects and total variance was obtained 
by the varcomp procedure and the mean square error of the regression model (MSEmodel). 
Coefficients of variation were obtained as CVbetween (%) = sqrt(exp
(Variancebetween) – 1)) * 100 and 
analogously for CVtotal and MSEmodel (29). Differences between plasma concentrations after 
four and eight weeks of exposure to 94 mg isoflavones/day in the ISO study were tested 
with a paired t-test (P-value < 0.05, SAS, v9.2, SAS Institute Inc., Cary, NC, USA).
ReSULTS
In the studies with isoflavone supplements (~100 mg/day), the mean total isoflavone 
concentration after eight weeks exposure to isoflavones (daidzein, equol, genistein and 
glycitein) was 3.47 µmol/L for equol producers (n = 38) and 2.39 µmol/L for non-producers (n 
= 50). After the four week intervention with soy protein (~48 mg isoflavones/day) the mean 
total isoflavone concentration was 2.16 µmol/L for equol producers (n = 4) and 1.30 µmol/L 
for non-producers (n = 11, Table 4.2). For all studies at the end of the placebo or mixed protein 
period, 86% of the measured daidzein concentrations were below the quantification limit 
of the method, this was respectively 99%, 96%, and 100% for equol, genistein and glycitein. 
Table 4.2 Mean (± SD) plasma isoflavone concentrations in equol producers and non-producers 
after the interventions
ISO study2 GD study LG GD study HG SOY study
(EP n = 21) (EP n = 8, 
NP n = 24)
(EP n = 9, 
NP n = 26)
(EP n = 4, 
NP n = 11)
Mean 
(µmol/L)
SD Mean 
(µmol/L)
SD Mean 
(µmol/L)
SD Mean 
(µmol/L)
SD
Daidzein EP 1.75 0.79 1.22 1.06 1.07 0.56 0.60 0.40
NP NA 1.53 0.64 1.27 0.69 0.43 0.19
Equol EP 1.20 0.52 0.72 0.58 0.61 0.28 0.39 0.15
NP NA NA NA NA
Genistein EP 0.69 0.52 0.40 0.30 1.19 0.95 1.16 1.08
NP NA 0.43 0.33 1.33 0.90 0.87 0.64
Glycitein EP 0.44 0.40 0.19 0.17 0.02 0.05 0.00 0.00
NP NA 0.15 0.12 0.06 0.08 0.00 0.00
Total1 EP 4.08 1.55 2.53 1.25 2.90 1.48 2.16 1.48
NP NA 2.11 0.84 2.65 1.49 1.30 0.80
1 Total isoflavones is the sum of daidzein, equol, genistein and glycitein. 
2 The ISO and GD study provided ~100 mg isoflavones/d (aglycone equivalents) as supplements for 8 wk, 
the SOY study provided ~48 mg/d as soy protein diet for 4 wk.
EP, equol producer; NP, non-producer.
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Significant linear associations between natural logarithm (loge) of plasma concentration 
versus loge of intake per kg bw (dose) were observed in non-producers for daidzein (β1 = 
0.66), genistein (β1 = 0.70), glycitein (β1 = 0.20) and total isoflavones (β1 = 0.67, Table 4.3). 
In these non-producers the regression coefficient of equol concentration after daidzein 
intake was β1 = 0.0, while in equol producers this was β1 + β3 = 0.63. Furthermore for 
equol producers, the association between plasma daidzein and intake was β1 + β3 = 0.64 
and for total isoflavones it was β1 + β3 = 0.74. This linear model on the loge-loge scale can 
be interpreted on a normal scale as concentration = eβ0+β2 * doseβ1+β3, with β0 (intercept) 
and β1 (dose, Figure 4.1). β2 (producer status) and β3 (intake-producer status interaction) 
were only relevant for equol producers for daidzein, equol and total isoflavone plasma 
concentrations. When isoflavone intake doubles from 1.5 to 3 µmol/kg bw, the equation is 
as follows (1.5/3.0)β1 = (2)0.67 = 1.59 fold or 59%. So, total isoflavone plasma concentrations 
increase with 59% when its intake doubles.
Except for glycitein (R2 = 0.48), the explained variances of the models were higher than 0.87.
Inclusion of energy (kJ/day), carbohydrate and fat intake (g/day) in the model as background 
dietary intake did not change the associations (data not shown).
Figure 4.2 shows that the relation between intake and plasma concentration, calculated 
as the concentration divided by the dose, for soy foods is not different than for isoflavone 
supplements.
Table 4.3 Outcomes of the linear regression model on loge transformed intake (µmol/kg bw) and 
loge transformed plasma concentrations (µmol/L)
1
Non-producers2 Producers3
β0 95% CI β1 * dose 95% CI β0 + β2 95% CI (β1 + β3) * dose 95% CI R
2
Daidzein -0.54 -0.70,
-0.38
0.66 0.61, 
0.71
-0.49 -0.74,
-0.24
0.64 0.59,
0.70
0.87
Equol -3.92 -3.98,
-3.85
0.00 -0.02, 
0.02
-1.12 -1.23,
-1.02
0.63 0.61,
0.66
0.96
Genistein -0.66 -0.78,
-0.54
0.70 0.67, 
0.74
0.90
Glycitein -2.14 -2.26,
-2.01
0.20 0.17, 
0.24
0.48
Total -0.39 -0.55,
-0.23
0.67 0.63, 
0.72
-0.06 -0.31,
0.18
0.74 0.68,
0.79
0.90
1 The log-linear regression model: loge(conc) = β0 + β1 * loge(dose) + β2 * prod + β3 * prod * loge(dose) + ε.
2 The model was adjusted for study (ISO, GD or SOY).
3 The model was adjusted for study (ISO, GD or SOY), equol producer status (β2) and loge-transformed intake 
* producer status interaction (β3).
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Among the equol-producing women in the ISO study, plasma concentrations of the 
individual isoflavones after four and eight weeks of exposure were similar (results not 
shown). In this study, within person CV is smaller than between person CV for all individual 
and total isoflavones, resulting in a large intraclass correlation coefficient (ICC, Table 4.4). 
The CVs between persons were 30-45% for all isoflavones except for genistein (96%). The 
CVs for MSEmodel, comprising the inter- and intra-individual variation, was 31% for equol 
and ranged from 59 to 87% for the other isoflavones.  
Figure 4.1 Exponential regression lines for the association between isoflavone intake (µmol/kg 
bw) and plasma concentration (µmol/L) combined with individual data. Isoflavone intake and 
plasma concentration on the x- and y-axis refer to specific isoflavones; panel A shows daidzein 
intake with daidzein plasma concentration and daidzein intake with plasma equol concentration; 
panel B shows genistein intake with genistein concentration and total isoflavone intake with total 
isoflavone concentration.
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DISCUSSION
In this study, plasma isoflavone concentrations from 103 postmenopausal women par-
ticipating in three intervention studies were evaluated after exposure to either isoflavone 
supplements or soy foods. A log-linear regression model showed that over a range of total 
isoflavone intakes from 0 to 100 mg/day, doubling of the dose (per kg bw) increased plasma 
concentrations with 55-62% (± SE 1-2%) for daidzein, genistein, equol (only in producers) 
Figure 4.2 Relative plasma isoflavone concentrations of equol producers (panel A) and non-
producers (panel B) in the three studies. Relative concentrations were calculated by dividing plasma 
concentrations in µmol/L by intake in µmol/kg bw. The bar for equol concentration is placed on top 
of the bar for daidzein concentration. DAI, low genistein (LG) arm; GEN, high genistein (HG) arm.
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Table 4.4 Between person and total variance, coefficient of variation (%) and ICC of isoflavone 
concentrations 4 and 8 wk after supplementation with 94 mg isoflavones (aglycone equivalents) 
in the ISO study in 29 equol-producing postmenopausal women
Varbetween Vartotal ICC MSE model
2
CVbetween
1 % CVtotal % CV %
Daidzein 0.18 44 0.27 56 0.67 0.52 83
Equol 0.18 45 0.27 56 0.67 0.09 31
Genistein 0.65 96 0.81 112 0.80 0.32 61
Glycitein 0.19 46 0.56 87 0.34 0.30 59
Total 0.09 30 0.14 39 0.64 0.56 87
1 Coefficient of variation between persons from loge-transformed concentration data, calculated as the square 
root of the exponent of the variance minus 1. 
2 For comparison of the coefficients of the ISO study, the MSE of the linear regression model is shown.
ICC, intra class correlation; CV, coefficient of variation; MSE, mean square error.
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and total isoflavones (R2 > 0.87). For glycitein, with an intake range of 0 to 28 mg/day, the 
observed increase was much smaller (15% ± 1%, R2 = 0.47). Including background dietary 
intake in the model did not affect the associations. Both visual inspection of the regression 
model and quantification with ISO study data, indicated large inter-individual variation of 
isoflavone plasma concentrations at this intake range. 
We studied the isoflavone dose-concentration relation among 103 postmenopausal 
women, which is a relatively large sample size compared to other studies (n = 39-76) (18, 
19). The percentage of equol producers in the studies (23-27%) was similar to literature 
data (12). Results from three intervention studies are presented, covering isoflavone intake 
from 0 to 100 mg/day. The three studies, having small differences in duration and dose, 
are comparable because they were conducted in postmenopausal women using similar 
determination of isoflavones with regard to lab, methods and reference materials. We 
demonstrated that data from four and eight weeks of exposure could be combined in the 
repeated measurements of the ISO study, also supported by calculations from literature 
(30), and that food matrix did not influence the comparability of the studies. 
The outcomes of our model suggested that production of equol did not affect daidzein 
plasma concentrations as these concentrations increased equally for producers and non-
producers (56 and 58%, respectively) at doubling daidzein intake (Table 4.3). Equol plasma 
concentrations, only relevant for producers, did depend on daidzein intake as doubling 
intake increased plasma equol concentration by 55%. Together this resulted in higher 
increases in total plasma isoflavone concentrations in equol producers (67%) than in non-
producers (59%) at doubling daidzein intake. Previous literature is not consistent on whether 
equol is produced at the expense of daidzein plasma concentrations (31-33), which might 
partly be explained by differences in the pharmacokinetics of daidzein and equol (34). 
In the model we assumed that the ability to produce equol would influence daidzein, 
equol and total isoflavone concentrations and that a linear relation between the natural 
logarithms of intake and plasma concentrations existed. By using loge transformations of 
both intake and concentration, homogeneity of the variance of error terms was allowed 
for, while the back transformed curve flattened down at higher doses. Without these loge 
transformations and inclusion of the unexposed data the model fit would be less (data not 
shown). The high explained variances of the models (R2 > 0.87) indicated a good model 
fit except for glycitein (Table 4.3), although plasma isoflavone concentrations varied 
substantially between individuals (Figure 4.1). This variation proved to be large when 
quantified by CV and ICC with ISO study data and the MSEmodel for the regression model 
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(Table 4.4). Differences between these measures of variance can be explained by the 
number of studies and therefore supplements included. In previous studies with isoflavone 
supplements, inter-individual variation in plasma isoflavone concentrations was quantified 
as 162 to 1596-fold for the individual isoflavones (18, 19). Inter-individual variation might 
be caused by differences in uptake efficiency and metabolism, which in turn might be 
influenced by microbiota (10) or genetic variation in transporter genes (35). Other studies 
hypothesized that fat, carbohydrate and fibre intake could explain inter-individual variation 
(36, 37). Therefore we complemented our model with energy, fat and carbohydrate intake 
data. Fibre intake data could not be extracted from the FFQ used. This adjustment did not 
change the observed associations and suggests that background dietary intake did not 
explain the observed inter-individual variation. 
Postmenopausal women produce little endogenous estradiol and are therefore considered 
susceptible to the potentially beneficial or even adverse health effects of isoflavones when 
using these supplements. Our study confirmed that supplement intake by postmenopausal 
women led to high concentrations of circulating isoflavones compared with soy food 
intake in Japanese populations (14). For risk assessment purposes, plasma isoflavone 
concentrations from 103 postmenopausal women in this study could be explained 
by isoflavone intake and equol producer status at a relevant intake range of 0-100 mg 
isoflavones/day. 
Despite the adequate explanation of plasma isoflavone concentrations over this intake 
range, the large inter-individual variation will restrict the use of this model for future risk 
assessment to the population level and cannot be applied to predict plasma concentrations 
in individuals.
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ABSTRACT
Background: In risk assessment, potential adverse health effects in humans are often 
extrapolated from animal experiments, this extrapolation represents an important source 
of uncertainty. Transcriptomics may be a powerful tool to evaluate effects in different 
tissues and species and might reduce this uncertainty in risk assessment.
Objective: We aimed to quantify gene expression effects of isoflavone supplementation 
and to compare these in peripheral blood mononuclear cells (PBMCs) and white adipose 
tissue (WAT) of postmenopausal women and ovariectomized F344 rats.
Methods: Gene expression effects were quantified after 8wk isoflavone supplementation 
compared to placebo. The women were exposed to a supplement containing ~100 
mg isoflavones/day (~1.5 mg/kg body weight) and the rats to ~0.42 mg/day (~2.1 mg/
kg body weight) with the following composition: ~58% daidzein, ~14% genistein and 
~28% glycitein. Gene expression, measured using Affymetrix gene chips, was compared 
between tissues and species with gene set enrichment analysis (GSEA) and multivariate 
regression modeling. 
Results: Multivariate analysis showed a change in gene expression after isoflavone 
supplementation of 8% in human PBMCs and 7% in human WAT and of 24% and 34% in 
these tissues in rats, respectively. For both tissues and species, GSEA revealed changes 
in similar gene sets, i.e. energy metabolism, inflammation and cell cycle. Interspecies 
correlations were only significant for estrogen-responsive genes in WAT (r = 0.31) and 
for OXPHOS genes in PBMCs (r = 0.33). Intertissue correlations were only significant for 
estrogen-responsive genes and cell cycle-related genes in both tissues.
Conclusion: Our model can be used to quantify gene expression effect size for selected 
gene sets and to quantitatively compare these between tissues and species. This model 
provides an important tool to contribute to advancing use of transcriptomics in the 
parallelogram approach for risk assessment. 
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INTRODUCTION
In current risk assessment practices, estimation of potential adverse health effects in humans 
is often based on results of animal experiments. Extrapolation of effects from animal to man 
is one of several sources of variability and uncertainty in risk assessment (1). Traditionally 
used uncertainty factors for extrapolation are 10 for intraspecies differences and 10 for 
interspecies differences, applied to a dose experimentally determined as safe in animals (2). 
Application of new techniques, like quantitative structure-activity relationship modelling, 
physiologically based biokinetic modelling and transcriptomics, might enable better 
quantification of interspecies differences (3). Especially the latter is promising, because 
transcriptomics can be used in animal experiments as well as in human intervention studies. 
Furthermore, transcriptomics can be considered as a powerful tool for detection of early 
effect markers, especially when changes in gene expression are considered within biological 
pathways (4) as done with computational methods, like gene set enrichment analysis (GSEA 
(5)). However, the interpretation is often restricted to qualitative evaluation of up- versus 
downregulation of gene expression, instead of considering effect size. In two recent studies, 
transcriptomics were qualitatively compared for risk assessment using the parallelogram 
approach (6, 7). The parallelogram approach enables comparison of effects in two species, 
for instance humans and animals, and a subsequent extrapolation to an intermediate or 
clinically relevant outcome in humans. For transcriptomics, this would imply comparison of 
gene expression data from similar tissues in animals and humans and animal target tissue 
to predict the effects in human target tissue. To reduce uncertainty in extrapolation from 
animal to human, it is important to quantitatively compare gene expression effects within 
and between species. Therefore, our study focusses on quantification of these effects after 
isoflavone supplementation in humans and animals for use in risk assessment. 
Isoflavones are phytoestrogens present in soy (products) and the main isoflavones are 
daidzein, genistein and glycitein. Epidemiological studies in Asian countries suggest that 
isoflavones are beneficial for health, because in these studies high soy consumption was 
associated with lower incidence of several types of cancer, osteoporosis and cardiovascular 
disease (8). However, results from in vitro and animal studies still raise doubts about the 
safety of isoflavone intake (9-11), especially because isoflavones are hypothesized to activate 
estrogen receptors (ER) in the same way as estrogens and estrogens are known to increase 
breast cancer risk (9). Peri- and postmenopausal women are a potentially vulnerable group 
for these adverse effects because they have reduced competition by endogenous estrogens 
for the ERs and potentially frequently use isoflavone supplements with high doses to relieve 
their menopausal complaints. This vulnerability might be enhanced in a subgroup of so-
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called equol-producing individuals. These individuals, comprising 20-30% of the Western 
population, harbour specific intestinal bacteria that can convert daidzein into the more 
active metabolite equol (12).
In this paper, isoflavones are studied to explore the intertissue and interspecies comparability 
of gene expression, in peripheral blood mononuclear cells (PBMCs) and white adipose tissue 
(WAT), by quantitative analysis of aligned experiments in rats and humans (Figure 5.1).
Figure 5.1 Quantification of gene expression effects after isoflavone supplementation and 
intertissue and interspecies comparisons in peripheral blood mononuclear cells (PBMCs) and white 
adipose tissue (WAT) in postmenopausal women and OVX F344 rats. Solid lines indicate effects 
of isoflavone intake on PBMCs and WAT, dotted lines indicate correlations between the estimates 
of these effects, i.e. intertissue (between tissues, within species) and interspecies (within tissues, 
between species).
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Quantification and comparison of gene expression effects after isoflavone intake was 
performed using data from two human intervention studies and one rat experiment. These 
studies were aligned for dose, duration and target group, and standardized laboratory 
methods were used.
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human intervention studies
The two human intervention studies were conducted at the Division of Human Nutrition 
of Wageningen University, approved by the Medical Ethical Committee of this university 
and have been described earlier by Van der Velpen et al. (13, 14). Both studies were double-
blind placebo-controlled crossover studies with two eight week intervention periods and 
an eight week washout period in between. All participants received both supplement and 
placebo treatment.
In the ISO study, the effects of a low genistein, high daidzein (LG) on PBMC gene expression 
were studied in 27 equol-producing postmenopausal women. The ISO II study consisted of 
2 sub studies that compared the same LG supplement vs. placebo in one sub study. This 
sub study was conducted in 36 postmenopausal women, both equol producers and non-
producers. For our analysis, data from 24 postmenopausal women was used. The exact in- and 
exclusion criteria for both the ISO study and the ISO II study, as well as the screening procedure 
for equol producers have previously been described (13, 14). The studies were registered at 
clinicaltrials.gov under NCT01232751 (ISO study) and NCT01556737 (ISO II study).
Rat experiment
The rat experiment was performed at the Centre for Laboratory Animals (CKP, Wageningen) 
in compliance with the Dutch Act on animal experimentation (Stb, 1977, 67; Stb 1996, 
565, revised February 5, 1997) and was approved by the ethical committee on animal 
experimentation of Wageningen University. All procedures were considered to avoid 
and minimize animal discomfort. For our analysis, data from 10 eight-week-old female 
inbred ovariectomized (OVX) F344 rats were used, all equol producers. Further detailed 
experimental conditions are described by Islam et al. (15). 
Oral gavage stock of the LG supplement was daily and freshly prepared in 10 ml water 
containing 1% dimethyl sulfoxide. After eight weeks, the animals were anesthetized with 
a mixture of isofluorene and oxygen and blood was removed from the dorsal aorta. PBMCs 
were isolated from the blood and stored at -20°C and abdominal WAT was collected in liquid 
nitrogen during sacrifice and stored at -80°C until further analysis. 
Supplements and doses
The studies were performed with the same LG supplement which contained 60% daidzein, 
13% genistein and 27% glycitein for the supplements used in the ISO study, originating 
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from a batch bought in October 2010. The supplements from the ISO II study and the rat 
experiment originated from a batch bought in November 2011 and contained 56% daidzein, 
16% genistein and 28% glycitein (absolute contents in Table 5.1).
The postmenopausal women in the two studies received ~100 mg isoflavones/day 
calculated in aglycone equivalents, for which two supplements were administered twice 
daily. For the animal study, the intake was scaled to body weight. For the women, the daily 
dose was 0.88-1.81 mg/kg bw/day as their body weights ranged from 55 to 107 kg. For 
the rats this was ~2.1 mg/kg bw/day, which is equivalent to ~0.42 mg/day for a 200 g rat. 
Table 5.1 Daily isoflavone intake in the two human intervention studies (ISO study and ISO II study) 
and the rat experiment in mg isoflavone per day and mg/kg bw calculated as aglycone equivalents
ISO study1 ISO II study1 Rat experiment2
mg/day mg/
kg bw/day
mg/day mg/
kg bw/day
mg/day mg/
kg bw/day
Total isoflavone 93.9 0.88-1.70 100.1 0.94-1.81 0.42 2.10
Daidzin 53.2 0.50-0.96 52.0 0.49-0.94 0.22 1.10
Daidzein 3.2 0.03-0.06 3.7 0.03-0.07 0.02 0.10
Genistin 11.4 0.11-0.21 16.5 0.15-0.30 0.07 0.35
Genistein 0.4 0.00-0.01 0 0 0 0.00
Glycitin 23.8 0.22-0.43 26.3 0.25-0.48 0.11 0.55
Glycitein 2.0 0.02-0.04 1.5 0.01-0.03 0.01 0.05
1 In the human intervention studies, the absolute amount per day was the same for every participant; the dose 
per kg bw is shown for the range between the lowest (i.e. 55.2 kg) and the highest bodyweight (i.e.107.0 kg).
2 In the rat experiment, the dose per kg bw was similar for each rat; for calculation of the total dose a bodyweight 
of 200 g was assumed.
Transcriptomics
In the human studies, gene expression after both supplement and placebo treatment 
was measured in PBMCs (n = 27, all equol producers of the ISO study) and WAT (n = 24; 
7 equol producers and 17 non-producers of the ISO II study) by Affymetrix human gene 
1.1 ST arrays (13, 14). In the rat experiment, the gene expression in PBMCs and WAT (n = 
10, all equol producers) was measured by Affymetrix rat gene 1.1 ST arrays. Five rats were 
exposed to the supplement, five other rats to the placebo and both PBMCs and WAT were 
collected from all rats.
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Data analysis
Data from the Affymetrix chips were normalized using CDF17 with MADMAX software (16). 
Filtering of results was done according to number of arrays in the original study; for the 
ISO study with intensity 20 on > 5 arrays, for the ISO II study this was intensity 20 on > 15 
arrays, for the rat data this was intensity 20 on > 4 arrays. To compare rat and human gene 
expression, the rat genes were recoded into human genes using the Homologene database 
(http://www.ncbi.nlm.nih.gov/homologene) and all duplicate genes were removed. After 
this, 80.7% of the rat genes in PBMCs and 81.5% genes in WAT that passed filtering remained 
as human homologs for analysis.
To study whether effects on gene expression in humans were similar to rats, genes with 
significantly changed expression in PBMCs (n = 27) and WAT (n = 7) from equol-producing 
postmenopausal women were compared to the differentially expressed human homologs 
in PBMCs and WAT from OVX F344 rats (n = 10). Subsequently, GSEA was performed on 
gene expression results for the same four groups of PBMCs and WAT in humans and rats. 
The significant gene sets (FDR < 0.25) were visualised using Cytoscape.
To study alleged estrogen-responsive effects of isoflavone supplementation, the human 
genes with significantly changed expression (separate for equol producers and non-
producers in human WAT) and differentially expressed human homologs in rats were 
compared to the human estrogen-responsive genes registered in the estrogen-responsive 
gene database (ERGDB, data downloaded September 2013, (17)).
To quantify gene expression effects in PBMCs and WAT of postmenopausal women and 
OVX rats, multivariate regression models were run with sets of log-transformed gene 
expression intensities from human and rat PBMCs and WAT as dependent variables. The 
multivariate analysis was performed using redundancy analysis (RDA), also known as least-
squares reduced-rank regression (18, 19). Like principal component analysis (PCA), RDA 
can handle any number of response variables (20), but has the advantage over PCA that it 
can focus on the effects of explanatory variables by constraining the components (axes) 
by the explanatory variables. In our case, the explanatory variables were the isoflavone 
supplement and the two tissues. All constrained components were used in reporting the 
results, and thus reduced-rank was not used because treatment effects were present on 
all axes, as judged by the relative magnitude of the eigenvalues of the constrained axes. 
The human model focused on the within-person tissue-dependent effects of isoflavone 
supplementation compared to placebo with the following model formula (21):
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[Expression of group of genes] = (supplement + supplement.tissue) | person, tissue
where  .  denotes “interaction” and  |  means “conditional on”.
Supplement and tissue have two levels each; LG and placebo for supplement and PBMC 
and WAT for tissue. Person is used as a covariate to correct for the paired measurements 
(supplement and placebo) within persons. Tissue is contained in the factor person, because 
each person provided only one of the two tissues, therefore tissue is superfluous as a 
covariate. 
The rat model also focused on the tissue-dependent effects of the isoflavone supplement 
compared to placebo:
[Expression of group of genes] = (supplement + supplement.tissue ) | tissue
This model has the same levels for supplement and tissue as the human model and tissue 
as a covariate to correct for the PBMCs and WAT collected from the same rats. 
The models were run separately for humans and rats using Canoco 5.03 (20); both jointly 
and separately for PBMC and WAT samples. In the joint analysis, RDA estimated coefficients 
for each gene (dependent variable) and each explanatory variable for each (constrained) 
axis. This resulted in an explained variance (R2 in %) of the model. The effect sizes of the 
intake on gene expression were summarized by the root mean square effect (RMSE) on the 
loge-scale and shown as the summary effect size (SES in % = 100 * (e
RMSE-1)). The separate 
analysis for each tissue was used to evaluate significance of the SES using permutation 
tests producing a pseudo-F test statistic (P < 0.05 and P < 0.10). In the permutation tests, 
the human samples were shuffled within person, while for the rat model unrestricted 
permutations were used. In addition, intertissue correlations were derived to compare gene 
expression effects between PBMC and WAT within each of the species. Similarly, interspecies 
correlations were determined to compare gene expression effects between rats and humans 
for each tissue separately. Correlation coefficients were calculated between the regression 
coefficients of the individual genes estimated by the separate models for PBMCs and WAT 
using SAS (SAS, version 9.3, SAS Institute, Inc., Cary, NC, USA).
Four different sets of genes were used as dependent variables in the multivariate analysis; 
1) all genes with significantly changed expression in human PBMCs, 2) all genes with 
significantly changed expression in human WAT, 3) all differentially expressed human 
homologs in rat PBMCs, and 4) all differentially expressed human homologs in WAT of rats. 
Furthermore, genes from the ERGDB with significant gene expression in both species were 
used as dependent variable in the multivariate analysis. This was also done for three gene 
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sets identified with GSEA, i.e. energy metabolism, inflammation and cell cycle. Therefore, 
groups of genes with significantly changed expression in women or differentially expressed 
genes in rats related to oxidative phosphorylation (OXPHOS), interleukin signalling and 
mitotic cell cycle were selected as representative for these biological pathways.
ReSULTS
The overlap between significant gene expression effects in PBMCs of equol-producing 
postmenopausal women (n = 339 genes) and PBMCs of rats (n = 540), was only 12 genes. 
Between significant gene expression effects in WAT of equol-producing postmenopausal 
women (n = 1169) and rats (n = 1237), the overlap was 86 genes (Figure 5.2 and Supple-
mental Table 5.1). 
Figure 5.2 Overlap between genes with significantly changed expression in peripheral blood 
mononuclear cells (PBMCs, n = 27) of postmenopausal equol-producing women and differentially 
expressed human homologs in OVX F344 rat PBMCs (n = 10) and the overlap between these genes 
in white adipose tissue (WAT) of equol-producing women (n = 7) and rat (n = 10).
WAT
Human
Rat
327
528
12
1083
1151
86
Differentially expressed 
human homologs
Genes with significantly 
changed expressionPBMC
Next to evaluating effects of isoflavones on expression of single genes, the overall gene 
expression effect was quantified in a multivariate regression model. When genes with 
significantly changed expression in human PBMCs were used as dependent variables in 
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this model, the SES indicated 8.1% change of gene expression (P < 0.05) in these PBMCs. 
Similarly, a significant SES was obtained for human WAT (SES = 7.0%) with significant gene 
expression WAT as dependent variable, which was also observed for differentially expressed 
human homologs in the rat model for both PBMCs (SES = 23.9%) and WAT (SES = 34.0%). 
For the four analyses with significant gene expression as dependent variable, the SES was 
smaller and did not reach statistical significance in the other tissue in the same model, i.e. 
the tissue on which the selection of genes was not based (Table 5.2).
Table 5.2 Summary effect sizes (SES) of isoflavone supplementation for significantly changed gene 
expression in PBMCs and WAT, separate for the human intervention trials and the rat experiment
Significant gene 
expression in1
Within-subject changes in gene 
expression in human intervention 
studies2
Between-group differences in gene 
expression in rat experiment3
Ngenes PBMC
4 
(%)
WAT 
(%)
R2model 
(%)
Ngenes PBMC 
(%)
WAT 
(%)
R2model  
(%)
PBMC 328 8.14‡ 4.18 11.0 536 23.9‡ 19.2 30.3
WAT 1158 3.16 7.01‡ 6.9 1231 10.9 34.0‡ 35.1
1 Significant gene expression in PBMCs and WAT in humans and rats as mentioned in Figure 5.2. 
2 Based on two human crossover intervention trials, with 27 equol producing women for PBMCs, and 24 
women (7 equol producers) for WAT.
3 Two groups (placebo and supplement) with 5 rats each, PBMCs and WAT collected from all rats.
4 Summary effect size (SES) in % calculated as exp((τ*sqrt(β1st axis
2 + β2nd axis
2)/SD)-1)*100) and interpreted as 
follows: if the exposure changes from placebo to supplement, gene expression for this selected group of 
genes changes with SES %.
‡ Significance determined by the separate models for each tissue (P < 0.05).
PBMC, peripheral blood mononuclear cell; WAT, white adipose tissue.
GSEA on the gene expression in the two tissues of equol producers in both species resulted 
in enriched gene sets related to energy metabolism, inflammation, cell cycle and nuclear 
receptor signalling, but not in gene sets related to estrogen signalling (Table 5.3). Gene 
sets which were significantly enriched, but could not be categorized in one of the previous 
pathways, were specified as ‘other’. Gene sets involving estrogen signalling were not identified 
with GSEA, but all genes with significantly changed expression (in humans) and differentially 
expressed human homologs (in rats) were compared to the 1069 estrogen-responsive genes 
from the ERGDB (Supplemental Table 5.2). This analysis showed that 19 of the 339 genes 
(5.6%) with significantly changed expression in human PBMCs were estrogen-responsive. In 
WAT of equol producers, 82 out of 1169 genes (7.0%) with significantly changed expression 
were estrogen-responsive, whereas 39 out of 883 genes (4.4%) in WAT of non-producers were 
estrogen-responsive. In rats, 35 out of the 540 differentially expressed human homologs 
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Table 5.3 Results of gene set enrichment analysis on gene expression after isoflavone supplement 
intake performed for both PBMCs and WAT in postmenopausal women and OVX F344 rats
Human1 Rat2
Groups Groups of gene sets PBMC WAT PBMC WAT
Energy metabolism Glucose metabolism *↓ ↓ ↓
OXPHOS ↓ ↓ ↑ ↓
TCA cycle *↓ ↓ ↑
Lipid metabolism ↓
Cholesterol biosynthesis ↓
Amino acid metabolism ↓
Inflammation T-cell signalling ↑ ↓
B-cell signalling ↑ ↓
Toll-like receptor signalling ↓ ↑ ↓
Interleukin signalling ↑ ↓ ↓
Nod-like signalling ↓ ↑
Cytokine signalling ↑ ↓ *↓
MAPK signalling ↓
GPCR signalling ↓ *↓
NFκB signalling ↓
Interferon signalling ↓ ↓
NGF signalling *↓
Auto immune response ↓ ↓ ↓
Adaptive immunity ↑ ↓
Cell cycle Mitotic cell cycle ↓ ↓ ↑
Proteasome *↓ ↓ ↑ ↓
Cyclin signalling ↓ ↑ ↓
mRNA metabolism ↑
mRNA processing ↑
Nucleosome assembly ↑
tRNA amino acylation ↓
Nucleotide excision repair *↓ ↑
Metabolism of proteins ↑
Apoptosis ↓ ↓
Protein folding ↓ ↑
WNT signalling ↑
Nuclear receptors Nuclear receptor signalling ↓ ↓ ↓
PPAR signalling ↓ ↓
Other Synaptic transmission ↓
Complement and coagulation ↓
VEGF / Integrin pathway ↓ ↑ ↓
Hemostasis and platelet function *↑
1 GSEA on human data is performed for PBMCs with n = 27 and for WAT with n = 7, all equol producers.
2 GSEA on rat data is performed for n = 10 (n = 5 supplement, n = 5 placebo) for both PBMCs and WAT.
↓ downregulation of effects, ↑ upregulation of effects as shown by GSEA, * effects upregulated or downregu-
lated in only one or two within the group of gene sets.
PBMC, peripheral blood mononuclear cell; WAT, white adipose tissue; ER, estrogen responsive; OXPHOS, 
oxidative phosphorylation; TCA cycle, tricarboxylic acid cycle; MAPK, mitogen-activated protein kinase; 
GPCR, G protein-coupled receptor; NFκB, nuclear factor kappa B; NGF, nerve growth factor; PPAR, peroxisome 
proliferator-activated receptors; VEGF, vascular endothelial growth factor.
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(6.5%) in PBMCs and 84 out of 1237 genes (6.8%) in WAT were estrogen-responsive. Between 
the tissues and the species, only few overlapping genes were observed. 
In the multivariate analysis, genes in the biological pathways from Table 5.3 were selected to 
obtain a pathway-specific effect size of gene expression in PBMCs and WAT of humans and 
rats (Table 5.4). As observed for the gene sets with significantly changed gene expression 
(Table 5.2), the SES in the biological pathways in rats was larger than the SES in humans. 
For the estrogen-responsive effects, the SES was 5.5% (P < 0.05) in WAT of postmenopausal 
women and in OVX rats the SES in this tissue was 26.7%. For genes related to OXPHOS, the 
SES were not significant. Effects on interleukin genes were only significant for rats with an 
effect size of 20.2% for PBMCs and 18.2% for WAT. Effects on mitotic cell cycle were only 
marginally significant (P < 0.1) for human WAT (4.0%) and rat PBMCs (11.5%) and WAT (10.6%). 
Table 5.4 Summary effect sizes (SES) of gene expression in PBMCs and WAT after isoflavone 
supplementation for estrogen-responsive genes and genes related to energy metabolism, 
inflammation and cell cycle
Genes in biological 
pathway1
Ngenes Within-subject changes in 
gene expression in human 
intervention studies2
Between-group differences 
in gene expression in rat 
experiment3
PBMC4 
(%)
WAT 
(%)
R2model 
(%)
PBMC 
(%)
WAT 
(%)
R2model 
(%)
ER 170 3.80* 5.52** 6.2 15.9 26.7** 24.9
OXPHOS 58 4.02 6.73 6.3 13.5 26.1 16.0
Interleukin 16 4.27 3.73 3.3 20.2** 18.2** 36.2
Mitotic cell cycle 30 4.35 4.00* 5.2 11.5* 10.6* 19.6
1 Group of genes involved in biological pathways (estrogen-responsive, energy metabolism, inflammation and 
cell cycle) with significant changed expression in two human intervention studies or differentially expressed 
human homologs in the rat experiment.
2 Based on two human crossover intervention trials, with 27 subjects for PBMCs, 24 subjects for WAT.
3 Two groups with 5 rats each, all providing both PBMCs and WAT.
4 Summary effect size (SES) in % calculated as exp((τ*sqrt(β1st axis
2 + β2nd axis
2)/SD)-1)*100) and interpreted as 
follows: if the exposure changes from placebo to supplement, gene expression for this selected group of 
genes changes with SES %.
** Significance determined by the separate models for each tissue with P < 0.05 or *  for P < 0.10.
PBMC, peripheral blood mononuclear cell; WAT, white adipose tissue; ER, estrogen responsive; OXPHOS, 
oxidative phosphorylation.
The interspecies correlation within the biological pathways was only significant for WAT 
with regard to the estrogen-responsive genes (r = 0.31) and for PBMCs for the OXPHOS 
genes (r = 0.33). The intertissue correlation between PBMCs and WAT was statistically 
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significant for estrogen-responsive genes with r = 0.23 in humans and r = 0.22 in rats, and 
for cell cycle genes with r = 0.39 in humans and r = 0.47 in rats (Table 5.5). For the other 
biological pathways, gene expression effects between the tissues and the species were 
not significantly correlated.  
Table 5.5 Intertissue and interspecies correlation coefficients for effect estimates from separate 
multivariate models for each tissue for estrogen-responsive genes and genes related to energy 
metabolism, inflammation and cell cycle
Genes in biological 
pathway1
Intertissue correlation 
between PBMC and WAT2
Interspecies correlation
between human and rat2
Human Rat PBMC WAT
Ngenes R 
(95% CI)
Ngenes R
(95% CI)
Ngenes R 
(95% CI)
Ngenes R 
(95% CI)
ER 136 0.23
(0.06-0.38)
146 0.22
(0.05-0.36)
129 0.05
(-0.13-0.22)
166 0.31
(0.16-0.44)
OXPHOS 57 0.05
(-0.21-0.30)
57 0.17
(-0.09-0.41)
56 0.33
(0.07-0.55)
58 0.08
(-0.18-0.33)
Interleukin 15 -0.33
(-0.72-0.23)
15 0.29
(-0.27-0.70)
15 0.32
(-0.24-0.71)
15 0.11
(-0.43-0.59)
Mitotic cell cycle 30 0.39
(0.03-0.67)
30 0.47
(0.13-0.71)
30 0.03
(-0.33-0.39)
30 0.14
(-0.23-0.48)
1 Group of genes involved in biological pathways (estrogen-responsive, energy metabolism, inflammation and 
cell cycle) with significant changed expression in two human intervention studies or differentially expressed 
human homologs in the rat experiment.
2 Intertissue and interspecies correlation calculated from separate models by correlating regression coefficients 
for the genes for both species.
PBMC, peripheral blood mononuclear cell; WAT, white adipose tissue; ER, estrogen responsive; OXPHOS, 
oxidative phosphorylation.
DISCUSSION
In this study, gene expression effects after isoflavone supplementation vs. placebo were 
quantified and compared in PBMCs and WAT of postmenopausal women and OVX rats. In 
PBMCs and WAT of humans, the gene expression after isoflavone supplementation changed 
on average with ~8% and this effect size was 3-4 fold stronger in rats (24% change in 
expression in PBMCs and 31% in WAT). Similar effect sizes were found for ER-related genes 
in WAT for both species and the gene expression effects correlated significantly between 
species for WAT (r = 0.31), and between the two tissues (r ~ 0.23) for the two species. For 
OXPHOS, none of the SES was significant, but the interspecies correlation (r = 0.33) pointed 
towards similar effects in human and rat PBMCs. For interleukin, significant SES were 
observed in rats only, but these effects did not correlate between tissues or species. For 
mitotic cell cycle, the SES were marginally significant for WAT in humans and both tissues 
in rat. For this geneset, the intertissue correlation was high (r = 0.39 for human and r = 
0.47 for rat).
In this study, a multivariate regression model was used to quantify gene expression changes 
in PBMCs and WAT of human and rat after exposure to isoflavones. This quantification can 
potentially be used in addition to the usual qualitative evaluation of gene expression effects 
with an up- or downregulation in pathways or gene sets, because the multivariate model 
summarizes the effect size (SES) of a group of genes. A 3-4 fold larger effect size and larger 
explained variance of the model was observed in rats compared to humans (Table 5.2). 
Although the dose and duration of exposure to isoflavones was similar, this difference is in 
line with previously observed gene expression effects in genetically homogeneous inbred 
rat strains and genetically independent women (22).
GSEA revealed more similarities in effects between rats and humans on gene sets like 
energy metabolism, inflammation and cell cycle (Table 5.3) than direct comparison of gene 
expression of all individual genes (Figure 5.2). Effect sizes of significant gene expression in 
a selection of these biological pathways were successfully quantified with the multivariate 
regression model, but data were not always consistent between tissues or species (Table 
5.4). For the estrogen-responsive genes, the effect size was significant in WAT in both species 
and significant correlations between the two tissues and the two species were observed. 
Adipose tissue is known as an estrogen-responsive tissue and despite the fact that PBMCs 
display ERs they are not particularly known as estrogen responsive (23, 24). The similarity 
of the intertissue correlation coefficients in human (r = 0.23) and rat (r = 0.22) for these 
effects is interesting, given that for humans PBMCs and WAT were not collected from the 
same individuals, which was the case for the rats. The estrogens are known to induce gene 
expression via the ERs and this gene set consists of particular ER target genes, which might 
explain part of the observed effects and correlations. However, it must be noted that the 
percentage of estrogen-responsive genes compared to the other genes with significantly 
changed expression is low (< 7%) in PBMCs and WAT. 
To our knowledge, this is the first study that compared gene expression data from human 
intervention trials with a rat experiment in which the dose (~1.5 mg/kg bw vs 2.1 mg/
kg bw), duration (8 weeks) and target group (postmenopausal women vs OVX rats) were 
aligned and the same methods in the same lab were used for measurement of gene 
expression. Despite this, effect sizes and correlations may be influenced by choices made 
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in aligning the human studies and rat experiment; with regard to duration, scaling for 
life expectancy could have been used and with regard to dose, scaling for metabolic rate 
could have been used. These estimates are also highly influenced by the selection of the 
groups of genes as dependent variables and by the loss of almost 20% of the rat genes 
because of recoding of the rat genes to human homologs. With regard to the model, the 
difference in study design for the human and rat experiment with regard to data pairing 
complicated the modelling, but by choosing different covariates, unbiased estimates of 
the supplement effects were obtained. Another important issue is that rats are known to 
be equol producers (25), while this is only the case for 20-30% of Western populations (12) 
and that differences are observed in gene expression between the equol-producers and 
non-producers in human intervention studies (14, 26). The gene expression data of human 
WAT was available for only a small number of equol producers (n = 7) compared to non-
producers (n = 17). However, equol-producing phenotype was not used as a covariate in 
the multivariate regression model to maintain the similarity of the human and rat model. 
Thus, if effects would be stronger and specific for equol producers, the inclusion of non-
producers may have weakened our effect estimates in humans. 
For risk assessment, it is important to quantitatively compare effects within and between 
species to reduce uncertainty in extrapolation from animal to human. While two 
previous studies qualitatively compared gene expression effects across species using the 
parallelogram approach (6, 7), our research showed the use of a multivariate model for 
quantification of gene expression effects and subsequent quantitative comparison of these 
effects between tissues and species. Despite this, the estimated intertissue and interspecies 
correlations cannot be directly used for risk assessment, because this would also require 
data on gene expression in target tissue, i.e. breast and uterus, and its relation to health 
endpoints. Nevertheless, this model provides an important tool to further explore intertissue 
and interspecies similarities and might contribute to advancing use of transcriptomics in 
the parallelogram approach for risk assessment.
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Supplemental Table 5.1 Overlap of differentially expressed genes in rats after the isoflavone 
supplement compared to placebo with significantly changed genes in humans with the same 
treatment compared to placebo
PBMC WAT
Human Rat Human Rat
N significantly changed genes 
(human) /
N differentially expressed human 
homologs (rat)
339 540 1169 1237
N upregulated 165 110 577 840
N downregulated 174 430 592 397
PBMC WAT
N overlapping genes 12 86
N upregulated 2 38
N downregulated 7 15
Upregulated overlapping genes 
(gene name, EntrezID)
CABP5, 56344
SUMO1, 7341
CYBRD1, 79901
VCPIP1, 80124
MYOF, 26509
CASP8AP2, 9994
FAM180A, 389558
RGS22, 26166
GALNT15, 117248
TC2N, 123036
FHL2, 2274
IL6R, 3570
HMCN1, 83872
PRPF40A, 55660
DENND2D, 79961
C10orf137, 26098
CD200R1, 131450
PSPC1, 55269
ATOH8, 84913
FAM210B, 116151
KDM5A, 5927
SPOCK2, 9806
POLI, 11201
GALNT12, 79695
PPL, 5493
OSBP2, 23762
DSG2, 1829
EFEMP1, 2202
MBNL3, 55796
FMO2, 2327
PLAC8, 51316
PHF20, 51230
WISP2, 8839
MEIS1, 4211
PNISR, 25957
ZBTB26, 57684
ARFIP1, 27236
ATXN3, 4287
TMEM178A, 130733
AMZ1, 155185
Downregulated overlapping genes 
(gene name, EntrezID)
STYXL1, 51657
LRG1, 116844
SIGLEC10, 89790
FGD6, 55785
TP53I11, 9537
MTMR11, 10903
SNX30, 401548
DPP9, 91039
BCKDK, 10295
NR4A1, 3164
FAM171A2, 284069
ACSL3, 2181
S1PR3, 1903
PRKACA, 5566
HIPK4, 147746
sep-11, 55752
TRPM4, 54795
CLASRP, 11129
PRDX5, 25824
RUNX1, 861
PGP, 283871
PKM, 5315 
Supplemental Table 5.1 continues on next page
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Supplemental Table 5.1 Continued
PBMC WAT
Human Rat Human Rat
Other overlapping (gene name, 
EntrezID)
ISG20L2, 81875
CACYBP, 27101
GNG5, 2787
MRPL33, 9553
EFHD1, 80303
SLC16A1, 6566
LSR, 51599 
KITLG, 4254
LDLRAP1, 26119
ANPEP, 290
KNSTRN, 90417
PTH1R, 5745
WDR66, 144406
ALDH1A2, 8854
RASSF5, 83593
SSC5D, 284297
LMOD1, 25802
BPGM, 669 
C10orf35, 219738
SELPLG, 6404
CD3E, 916 
MYO18A, 399687
WNT5B, 81029
C12orf45, 121053
RAPGEF5, 9771
RARS2, 57038
XPNPEP2, 7512
NDUFA4, 4697
RPP25, 54913
MYO5B, 4645
SLC25A32, 81034
SLC25A14, 9016
HP, 3240 
SLCO3A1, 28232
DECR1, 1666
RAMP3, 10268
The gene expression data for rats is recoded into human homologs; for PBMCs 670 differentially expressed, but 
540 have human homologs and for WAT 1486 differentially expressed, but 1236 have human homologs. WAT 
human data are significantly changed genes for equol producers receiving the isoflavone supplement, n = 7.
PBMC, peripheral blood mononuclear cells; WAT white adipose tissue.
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Supplemental Table 5.2 continues on next page
Gene name Description Human Rat 
 PBMC WAT EP WAT NP PBMC WAT 
CTNND1 catenin (cadherin-associated protein), delta 1 -1.13 1.19 
NME2 NME/NM23 nucleoside diphosphate kinase 2 -1.12 -1.13 
SPRED1 sprouty-related, EVH1 domain containing 1 -1.11 
NRP1 neuropilin 1 -1.10 
STAB1 stabilin 1 -1.09 
HSPA1A heat shock 70kDa protein 1A -1.08 
PTPRO protein tyrosine phosphatase, receptor type, O -1.07 
TIMELESS timeless circadian clock -1.07 
SLC25A5 solute carrier family 25 (mitochondrial carrier 
///  adenine nucleotide translocator), member 5 
-1.05  -1.08   
CACYBP calcyclin binding protein -1.05 1.40 
PSMD8 proteasome (prosome, macropain) 26S 
subunit, non-ATPase, 8 
-1.04 
    
EDEM1 
ER degradation enhancer, mannosidase alpha-
like 1 1.05     
FOXP1 forkhead box P1 1.05 
MYB v-myb myeloblastosis viral oncogene homolog 
(avian) 
1.05 
    
BCL2L1 BCL2-like 1 1.06 1.19 
STXBP1 syntaxin binding protein 1 1.07 
MUC1 mucin 1, cell surface associated 1.07 -1.12 
FKBP5 FK506 binding protein 5 1.08 
ERBB2 
v-erb-b2 erythroblastic leukemia viral 
oncogene homolog 2, neuro/glioblastoma 
derived oncogene homolog (avian) 
1.08 
    
TNC tenascin C -1.36 
IGF2 insulin-like growth factor 2 (somatomedin A) -1.35 
PPIF peptidylprolyl isomerase F -1.28 
ME1 malic enzyme 1, NADP(+)-dependent, cytosolic -1.27 
NR4A1 nuclear receptor subfamily 4, group A, member 
1  
-1.27 -1.16 -1.25 -2.44 
NME1 NME/NM23 nucleoside diphosphate kinase 1 -1.27 
TGFB3 transforming growth factor, beta 3 -1.26 -1.11 
TUBG1 tubulin, gamma 1 -1.24 
THBD thrombomodulin -1.24 
NCAM2 neural cell adhesion molecule 2 -1.23 
KITLG KIT ligand -1.20 1.18 
ELOVL2 ELOVL fatty acid elongase 2 -1.20 
CCND1 cyclin D1 -1.20 
NOS3 nitric oxide synthase 3 (endothelial cell) -1.19 -1.09 
CNKSR3 CNKSR family member 3 -1.19 
CYCS cytochrome c, somatic -1.18 
DHCR24 24-dehydrocholesterol reductase -1.18 
KIR3DL2 killer cell immunoglobulin-like receptor, three 
domains, long cytoplasmic tail, 2  
-1.18 
   
PAICS 
phosphoribosylaminoimidazole carboxylase, 
phosphoribosylaminoimidazole 
succinocarboxamide synthetase 
 -1.18    
TFF1 trefoil factor 1 -1.18 
HSPD1 heat shock 60kDa protein 1 (chaperonin) -1.17 
Supplemental Table 5.2 Estrogen responsive  genes with significantly changed expression and 
differentially expressed human homologs of PBMC and WAT in humans and rats. Data compared 
to ERGDB database. 
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Gene name Description Human Rat 
 PBMC WAT EP WAT NP PBMC WAT 
KPNA2 karyopherin alpha 2 (RAG cohort 1, importin 
alpha 1)  
-1.16 
   
ARMCX3 armadillo repeat containing, X-linked 3 -1.16 
ENO1 enolase 1, (alpha) -1.16 
TK1 thymidine kinase 1, soluble -1.15 -1.11 
RET ret proto-oncogene -1.15 -1.13 
SGCD 
sarcoglycan, delta (35kDa dystrophin-
associated glycoprotein)  
-1.15 
   
SEMA5B 
sema domain, seven thrombospondin repeats 
(type 1 and type 1-like), transmembrane 
domain (TM) and short cytoplasmic domain, 
(semaphorin) 5B 
 -1.15    
G6PD glucose-6-phosphate dehydrogenase -1.15 
RAMP3 
receptor (G protein-coupled) activity modifying 
protein 3  
-1.14 
  
1.74 
AURKB aurora kinase B -1.14 
ESR2 estrogen receptor 2 (ER beta) -1.13 
C1QBP complement component 1, q subcomponent 
binding protein  
-1.13 
   
CENPA centromere protein A -1.13 
ACO2 aconitase 2, mitochondrial -1.13 
RUNX1 runt-related transcription factor 1 -1.12 -1.15 
MCM4 minichromosome maintenance complex 
component 4  
-1.12 
   
NR4A3 
nuclear receptor subfamily 4, group A, member 
3  -1.12    
FOXF1 forkhead box F1 -1.12 
GOT1 glutamic-oxaloacetic transaminase 1, soluble 
(aspartate aminotransferase 1)  
-1.11 -1.08 
  
ORMDL2 ORM1-like 2 (S. cerevisiae) -1.11 
MARCKS myristoylated alanine-rich protein kinase C 
substrate  
-1.11 
   
SLC12A2 
solute carrier family 12 
(sodium/potassium/chloride transporters), 
member 2 
 -1.11    
SPRY1 sprouty homolog 1, antagonist of FGF signaling 
(Drosophila)  
-1.11 
   
GARS glycyl-tRNA synthetase -1.11 
RPA3 replication protein A3, 14kDa -1.10 
STMN1 stathmin 1 -1.10 
IARS isoleucyl-tRNA synthetase -1.10 
ITGAV integrin, alpha V -1.09 
NUP88 nucleoporin 88kDa -1.08 
TXNIP thioredoxin interacting protein 1.08 
NRF1 nuclear respiratory factor 1 1.09 
ECE1 endothelin converting enzyme 1 1.09 -1.13 
EFEMP1 
EGF containing fibulin-like extracellular matrix 
protein 1  
1.10   1.30 
MPL myeloproliferative leukemia virus oncogene 1.10 
GSTO1 glutathione S-transferase omega 1 1.11 
HIP1R huntingtin interacting protein 1 related 1.11 
PAX8 paired box 8 1.12 
PTPN18 protein tyrosine phosphatase, non-receptor 
type 18 (brain-derived)  
1.12 
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Supplemental Table 5.2 continues on next page
Gene name Description Human Rat 
 PBMC WAT EP WAT NP PBMC WAT 
WSB1 WD repeat and SOCS box containing 1 1.12 
IGF1R insulin-like growth factor 1 receptor 1.13 
GNG7 guanine nucleotide binding protein (G 
protein), gamma 7  
1.13 
   
SFRP1 secreted frizzled-related protein 1 1.13 
MCM7 minichromosome maintenance complex 
component 7  
1.13 
   
SATB1 SATB homeobox 1 1.14 
INPP4B 
inositol polyphosphate-4-phosphatase, type II, 
105kDa  
1.15 
   
THBS2 thrombospondin 2 1.15 
PTGER2 
prostaglandin E receptor 2 (subtype EP2), 
53kDa  
1.15 
   
WISP2 WNT1 inducible signaling pathway protein 2 1.16 1.81 
BCL2L11 BCL2-like 11 (apoptosis facilitator) 1.17 
ABCB1 
ATP-binding cassette, sub-family B (MDR/TAP), 
member 1  
1.17 
   
TSC22D3 TSC22 domain family, member 3 1.18 
NFKBIA nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, alpha  
1.18 
   
ANKRD44 ankyrin repeat domain 44 1.19 
TNFSF8 tumor necrosis factor (ligand) superfamily, 
member 8  
1.19 
   
CCNG2 cyclin G2 1.20 
FKBP8 FK506 binding protein 8, 38kDa 1.20 
ZFP36L2 ZFP36 ring finger protein-like 2 1.21 
SLA Src-like-adaptor 1.34 
S100P S100 calcium binding protein P 1.42 
KRT6B keratin 6B -1.19 
TPX2 TPX2, microtubule-associated, homolog 
(Xenopus laevis)   
-1.17 
  
ADRB1 adrenoceptor beta 1 -1.15 
ZWINT ZW10 interactor, kinetochore protein -1.14 
EGR3 early growth response 3 -1.12 -1.21 
CORO2B coronin, actin binding protein, 2B -1.11 
SSNA1 Sjogren syndrome nuclear autoantigen 1 -1.09 
BIK BCL2-interacting killer (apoptosis-inducing) -1.09 
FGF18 fibroblast growth factor 18 -1.08 
CTBP1 C-terminal binding protein 1 -1.07 
CELSR2 cadherin, EGF LAG seven-pass G-type receptor 
2   
-1.06 
  
TMED2 
transmembrane emp24 domain trafficking 
protein 2   1.04   
sep-02 septin 2 1.05 
MAN1A1 mannosidase, alpha, class 1A, member 1 1.05 
RIF1 RAP1 interacting factor homolog (yeast) 1.05 
WDR43 WD repeat domain 43 1.06 1.16 
NR2C1 nuclear receptor subfamily 2, group C, member 
1   
1.06 
  
LRRFIP2 leucine rich repeat (in FLII) interacting protein 2 1.06 
KIFAP3 kinesin-associated protein 3 1.07 
OLFM1 olfactomedin 1 1.07 
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 PBMC WAT EP WAT NP PBMC WAT 
APOA2 apolipoprotein A-II 1.08 1.34 
RPL15 ribosomal protein L15 1.08 1.22 
EIF5 eukaryotic translation initiation factor 5 1.09 
LRRC49 leucine rich repeat containing 49 1.09 1.36 
TMED7 transmembrane emp24 protein transport 
domain containing 7   
1.09 
  
ABCE1 
ATP-binding cassette, sub-family E (OABP), 
member 1   
1.09 
  
RBBP8 retinoblastoma binding protein 8 1.09 
ZNF230 zinc finger protein 230 1.12 
FXYD2 
FXYD domain containing ion transport 
regulator 2   
1.15 
  
GPRC5A 
G protein-coupled receptor, family C, group 5, 
member A   
1.16 
 
1.58 
BLNK B-cell linker -1.47 
IL6 interleukin 6 (interferon, beta 2) -1.42 
KYNU kynureninase -1.39 
P2RY6 pyrimidinergic receptor P2Y, G-protein 
coupled, 6    
-1.39  
FAIM3 Fas apoptotic inhibitory molecule 3 -1.37 
KRT8 keratin 8 -1.30 
MYO1E myosin IE -1.29 
NRP2 neuropilin 2 -1.28 
HLA-DRB1 major histocompatibility complex, class II, DR 
beta 1    
-1.28  
PRKCE protein kinase C, epsilon -1.25 -1.23 
SLC16A7 solute carrier family 16, member 7 
(monocarboxylic acid transporter 2)    
-1.25  
SH3BP5 SH3-domain binding protein 5 (BTK-associated) -1.24 
ZFP36 ZFP36 ring finger protein -1.22 
GDF15 growth differentiation factor 15 -1.21 
PKIB protein kinase (cAMP-dependent, catalytic) 
inhibitor beta     
-1.18  
PSEN2 presenilin 2 (Alzheimer disease 4) -1.18 
GPR18 G protein-coupled receptor 18  -1.18 
GADD45B growth arrest and DNA-damage-inducible, 
beta    
-1.16  
TRPS1 trichorhinophalangeal syndrome I -1.16 
AIM1 absent in melanoma 1 -1.14 1.26 
ULK1 unc-51-like kinase 1 (C. elegans) -1.11 
EIF2S1 
eukaryotic translation initiation factor 2, 
subunit 1 alpha, 35kDa    1.16  
EIF1AY eukaryotic translation initiation factor 1A, Y-
linked    
1.16 
 
TRIP13 thyroid hormone receptor interactor  1.16 
PLAA phospholipase A2-activating protein 1.17 
PDIA4 protein disulfide isomerase family A, member 4 1.17 
ATAD2 ATPase family, AAA domain containing 2 1.17 1.20 
PLEKHF2 pleckstrin homology domain containing, family 
F (with FYVE domain) member 2    
1.20  
SSR3 
signal sequence receptor, gamma (translocon-
associated protein gamma)    
1.21 1.16 
SFPQ splicing factor proline/glutamine-rich 1.23 
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Gene name Description Human Rat 
 PBMC WAT EP WAT NP PBMC WAT 
CRP C-reactive protein, pentraxin-related  1.25 
FOS FBJ murine osteosarcoma viral oncogene 
homolog     
-2.53 
JUNB jun B proto-oncogene -1.45 
SERPINA3 serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 3     
-1.32 
MMP16 
matrix metallopeptidase 16 (membrane-
inserted)     -1.29 
PTGES prostaglandin E synthase -1.28 
IGFBP5 insulin-like growth factor binding protein 5 -1.26 
FLT4 fms-related tyrosine kinase 4 -1.26 
PGM5 phosphoglucomutase 5 -1.24 
DNASE1 deoxyribonuclease I -1.24 
GRID2 glutamate receptor, ionotropic, delta 2 -1.23 
TOB1 transducer of ERBB2, 1 -1.23 
SOCS3 suppressor of cytokine signaling 3 -1.22 
IER2 immediate early response 2 -1.21 
BTG2 BTG family, member 2 -1.21 
ZNF703 zinc finger protein 703 -1.20 
WNT10B wingless-type MMTV integration site family, 
member 10B     
-1.19 
PREX1 phosphatidylinositol-3,4,5-trisphosphate-
dependent Rac exchange factor 1     
-1.19 
POLA2 polymerase (DNA directed), alpha 2, accessory 
subunit     
-1.18 
IRS1 insulin receptor substrate 1 -1.18 
MYBL2 v-myb myeloblastosis viral oncogene homolog 
(avian)-like 2     
-1.17 
JUN jun proto-oncogene -1.17 
HES1 hairy and enhancer of split 1, (Drosophila) -1.16 
L1CAM L1 cell adhesion molecule -1.15 
HMGCR 3-hydroxy-3-methylglutaryl-CoA reductase -1.15 
SEMA4A 
sema domain, immunoglobulin domain (Ig), 
transmembrane domain (TM) and short 
cytoplasmic domain, (semaphorin) 4A     
-1.13 
RXRA retinoid X receptor, alpha -1.11 
SLC7A5 solute carrier family 7 (amino acid transporter 
light chain, L system), member 5     
-1.10 
GNB1 guanine nucleotide binding protein (G 
protein), beta polypeptide 1     
1.14 
SLC1A2 solute carrier family 1 (glial high affinity 
glutamate transporter), member 2     
1.16 
IGFBP4 insulin-like growth factor binding protein 4 1.16 
NDRG1 N-myc downstream regulated 1 1.18 
TPBG trophoblast glycoprotein 1.18 
SLC38A1 solute carrier family 38, member 1 1.19 
RAB18 RAB18, member RAS oncogene family 1.19 
HUNK 
hormonally up-regulated Neu-associated 
kinase     
1.19 
AR androgen receptor 1.20 
TRA2A transformer 2 alpha homolog (Drosophila) 1.20 
HAT1 histone acetyltransferase 1 1.22 
SLC7A1 
solute carrier family 7 (cationic amino acid 
transporter, y+ system), member 1     
1.23 
Supplemental Table 5.2 Continued 
Supplemental Table 5.2 continues on next page
Gene expression profile comparison for risk assessmentChapter 5
124
Gene name Description Human Rat 
 PBMC WAT EP WAT NP PBMC WAT 
SF3A3 splicing factor 3a, subunit 3, 60kDa 1.23 
IL1R1 interleukin 1 receptor, type I 1.23 
NUCB2 nucleobindin 2 1.23 
SEMA3C 
sema domain, immunoglobulin domain (Ig), 
short basic domain, secreted, (semaphorin) 3C     
1.25 
TSPAN5 tetraspanin 5 1.27 
ITGBL1 integrin, beta-like 1 (with EGF-like repeat 
domains)     
1.27 
GALNT4 
UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgalactosaminyltransferase 4 (GalNAc-T4) 
    1.27 
PTPRU protein tyrosine phosphatase, receptor type, U 1.29 
LHFP lipoma HMGIC fusion partner 1.33 
TGFA transforming growth factor, alpha  1.33 
ANXA3 annexin A3 1.38 
PRSS23 protease, serine, 23 1.42 
PTGS2 
prostaglandin-endoperoxide synthase 2 
(prostaglandin G/H synthase and 
cyclooxygenase)     
1.43 
PARD6B par-6 partitioning defective 6 homolog beta (C. 
elegans)     
1.44 
ALB albumin 1.47 
BICD1 bicaudal D homolog 1 (Drosophila) 1.48 
OPRK1 opioid receptor, kappa 1  1.49 
SLC39A8 solute carrier family 39 (zinc transporter), 
member 8     
1.53 
OLR1 
oxidized low density lipoprotein (lectin-like) 
receptor 1     1.58 
KRT7 keratin 7 1.58 
KRT19 keratin 19 1.59 
PKP2 plakophilin 2 1.60 
MSX2 msh homeobox 2 1.60 
PTGS1 
prostaglandin-endoperoxide synthase 1 
(prostaglandin G/H synthase and 
cyclooxygenase)     
1.69 
PLOD2 
procollagen-lysine, 2-oxoglutarate 5-
dioxygenase 2     1.84 
ARNT2 aryl-hydrocarbon receptor nuclear translocator 
2     
1.98 
SLC26A3 solute carrier family 26 (anion exchanger), 
member 3     
2.01 
CDH11 cadherin 11, type 2, OB-cadherin (osteoblast) 2.61 
CXADR coxsackie virus and adenovirus receptor 2.69 
AHSG alpha-2-HS-glycoprotein  4.85 
# sign changed 
ER genes   19 82 39 35 84 
# sign changed 
genes   339 1169 883 540 1237 
% estrogen 
responsive   5.60 7.01 4.42 6.48 6.79 
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General discussion
Chapter 6
General discussionChapter 6
126
In this thesis, it was hypothesized that alignment and standardization of exposure and early 
effect markers in nutritional epidemiology and toxicological research would enable an 
integrated approach for improved risk assessment (Figure 6.1). Following this framework, 
epidemiology could contribute importantly to defining dietary intake and biomarkers 
for exposure and early effects in the population. Toxicology could complement this by 
measuring similar markers and by defining disease pathways and health endpoints resulting 
from exposure. 
Figure 6.1 The concept of integrating toxicological and epidemiological approaches to improve 
risk assessment.
Epidemiology 
Two human intervention studies
Toxicology 
One rat experiment
Intake
Exposure 
markers
Early effect 
markers
Health 
endpoints
The practical application of this concept was further developed using isoflavones as a case 
study. This topic was chosen because the safety of isoflavone consumption at higher doses 
is still under debate (1-3) and the European Food Safety Authority (EFSA) has expressed 
concerns on effects of isoflavones on tumour promotion and thyroid function (4). 
Two human intervention studies were conducted to assess effects of isoflavone supple-
mentation on gene expression in peripheral blood mononuclear cells (PBMCs, chapter 2) 
and white adipose tissue (WAT, chapter 3) of postmenopausal women. For improvement 
of risk assessment, data from human intervention studies were used to model the relation 
between intake and exposure markers (chapter 4) and the two intervention studies were 
aligned with a rat experiment to model the relation between supplemental isoflavone 
intake and early effect markers in both species (chapter 5).
In this discussion, the results of the two intervention studies with isoflavone supplements 
in postmenopausal women will be addressed first. Subsequently, the parallelogram 
approach for aligning studies in epidemiology and toxicology will be used as a framework 
for evaluating the contribution of our results to improvement of risk assessment (Figure 
6.2). 
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Molecular eFFects oF isoFlavones
rationale for the human intervention studies
Because isoflavone intake is low in the general Western population (5), observational 
studies that can be used to assess the association between isoflavone intake and disease 
endpoints are scarce (6, 7). Therefore, human health effects of isoflavone supplementation 
in the Western population are often determined using intervention trials. The generalization 
of the results of these intervention studies is complicated because the group of isoflavones 
consists of 4 different important members; genistein, daidzein, glycitein and the daidzein-
metabolite equol. The first three are often supplied as supplements or in food products from 
which the isoflavone content and dose are not always properly defined (8). In the two human 
intervention studies in this thesis, isoflavone composition and dose were systematically 
determined by HPLC analysis. Both intervention studies focused on whole-genome gene 
expression effects of isoflavone supplementation of ~100 mg/day; in the ISO study with 
a “low genistein, high daidzein” (LG) supplement, and in the ISO II study with the same LG 
supplement in one sub study and a “high genistein, high daidzein” (HG) supplement in the 
other paralleled sub study. Both studies had a similar placebo-controlled crossover design 
with two intervention periods of eight weeks and an eight week washout in between.
In our two studies, postmenopausal women were selected as potential high risk group, 
because they produce only little endogenous estradiol to compete with isoflavones for 
the estrogen receptors (ERs). Furthermore, the equol-producing phenotype can be an 
important modifier of effects, because equol has higher binding affinity on ERs than its 
precursor daidzein (9, 10). Only 20-30% of the Western population is equol producer (10) 
and this phenotype is often not adequately characterized in intervention studies (8). For 
the ISO study, only equol-producing postmenopausal women were recruited, because it 
was hypothesized that they might be a specific high risk group. The ISO II study focused 
on the effect of two isoflavone supplements in a general postmenopausal population, 
which made it possible to compare results between equol producers and non-producers. 
In the ISO study, gene expression effects were studied in peripheral blood mononuclear 
cells (PBMCs) and in the ISO II study these effects were studied in adipose tissue. PBMCs 
are easily accessible and previous studies have shown that those cells can be used to 
study nutrition-induced effects on gene expression (11). Because the ISO study indicated 
a lack of estrogen-responsive effects in PBMCs, the ISO II study was conducted with the 
more estrogen-responsive and also accessible abdominal adipose tissue (12, 13). Use of 
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whole-genome gene expression as early effect marker measured by microarrays enabled 
the exploration of the whole spectrum of possible effects of isoflavone supplementation, 
including the estrogen-responsive effects of isoflavones, instead of focusing on a few 
intermediate markers of specific health effects. The exposure duration of 8 weeks 
represented a moderate to long-term period at which plasma isoflavone concentrations 
have reached steady state.
effects of isoflavones on gene expression in PBMcs and adipose tissue
In the ISO study, expression of a total of 357 genes was significantly changed in PBMCs 
of equol-producing postmenopausal women after exposure to the LG supplement and 
these effects were related to oxidative phosphorylation (OXPHOS), inflammation and cell 
cycle. In the ISO II study, expression of 883 and 1169 genes was significantly changed in 
adipose tissue of non-producers and equol producers, respectively, after intake of the LG 
supplement. For the HG supplement, expression of 547 and 631 genes was significantly 
changed in adipose tissue of non-producers and equol producers, respectively, and effects 
of both isoflavone supplements were found on energy metabolism and inflammation. In this 
paragraph the observed effects in the two intervention studies on the biological pathways 
of energy metabolism, inflammation and cell cycle will be discussed.
Energy metabolism
In PBMCs of equol-producing postmenopausal women in the ISO study, downregulation 
of OXPHOS was observed after intake of the LG supplement. This was mainly driven by 
downregulation of several NADH dehydrogenase ubiquinone flavoprotein (NDUF) genes, 
which may result in reduced reactive oxygen species (ROS) production and oxidative 
stress. As these processes have the potential to induce DNA damage as a precursor for 
cancer (37), beneficial effects might be expected from downregulation of OXPHOS. In 
adipose tissue of both equol-producing and non-producing postmenopausal women 
in the ISO II study, expression of OXPHOS was also downregulated in addition to other 
energy metabolism-related genes after intake of the LG supplement, while these genes 
were marginally upregulated after intake of the HG supplement. The effects of the LG 
supplement on gene expression related to energy metabolism may be beneficial because 
of their resemblance with gene expression effects of caloric restriction, which is known to 
be beneficial for longevity (14). The downregulation in expression of energy metabolism-
related genes by the LG supplement, might have induced phenotypical effects, for instance 
on adipocyte cell size, body fat distribution or body weight. Effects on body weight and 
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adipocyte size in subcuteaneous adipose tissue were not observed in our study, while 
effects on body fat distribution were not assessed. However, our study size and duration 
were not designed to evaluate effects on these phenotypic markers. This could also be the 
reason why isoflavone-induced decrease in gene expression of RBP4 and in expression of 
genes related to cholesterol metabolism in adipose tissue were not reflected by changes 
in serum RBP4 and cholesterol (total, HDL and triglycerides) concentrations. It should be 
noted, however, that for these markers adipose tissue is not the main organ for production, 
as they are very well known to be produced in the liver. 
Inflammation
In both PBMCs and adipose tissue, gene expression effects of isoflavone supplementation on 
inflammation were found. More specifically, in PBMCs of equol-producing postmenopausal 
women downregulation of gene sets related to toll-like receptor (TLR) signaling and 
complement and coagulation were observed. In adipose tissue, the effects were dependent 
on supplement-type (LG or HG) as well as on equol producer status. After intake of the 
LG supplement, expression of genes in inflammation-related gene sets were significantly 
upregulated in equol producers. The inflammation-related effects in PBMCs and adipose 
tissue seem opposite, which could be explained by the fact that inflammation plays a 
different role in these tissues; PBMCs are a group of cells that mediate immune responses 
(15), while inflammation in adipose tissue only starts playing a role when fat mass is 
increasing (16-18). Analysis of the specific genes involved, suggested that the gene 
expression changes in PBMCs and in adipose tissue after isoflavone supplementation may 
be beneficial with regard to inflammation, although this might only be the case for equol 
producers. 
Cell cycle
With regard to cell cycle effects, expression of histones and histone-like genes was 
downregulated in PBMCs of equol-producing postmenopausal women after intake of the 
LG supplement. These effects may contribute to the alleged effects of isoflavones on cell 
cycle arrest, which might provide time for DNA damage repair or induction of apoptosis 
and could consequently prevent replication of cells with DNA damage and formation of 
tumors. Effects on cell cycle were also observed with gene set enrichment analysis (GSEA) 
in adipose tissue of postmenopausal women after intake of both supplements, but further 
analysis revealed that only a few genes were significantly changed. 
General discussionChapter 6
130
Final considerations and conclusion
A final question is whether the observed effects on gene expression are direct effects of 
isoflavones on these tissues, or whether they are secondary to effects on another tissue, 
for instance the liver. There is no current literature on the uptake of isoflavones in PBMCs, 
but isoflavones are known to end up in both the glandular and the adipose fraction of 
breast tissue (19) and therefore they might also be present in subcutaneous adipose tissue. 
In conclusion, effects of isoflavone supplementation on gene expression might point 
towards beneficial effects on energy metabolism and inflammation in PBMCs and adipose 
tissue, and on cell cycle in PBMCs. Other important findings were the observed differences 
in effects for the two different isoflavone supplements and the two equol-producing 
phenotypes in the ISO II study, and the apparent limited estrogen-responsive gene 
expression in both studies. The latter finding will be further discussed below.
estrogen-related and other potential pathways induced by isoflavones
In our two intervention studies it was observed that the hypothesized estrogen-responsive 
effects were marginal in both PBMCs and adipose tissue as they were not identified by GSEA. 
Also, in a separate comparison of significantly changed genes with the estrogen-responsive 
gene database (ERGDB) not more than 7% of the genes with significantly changed 
expression after isoflavone supplementation were identified as estrogen-responsive genes 
in both tissues. The prevailing hypothesis with regard to ER-related effects is that isoflavones 
preferentially bind to the ERβ in the following order of binding affinity: genistein is more 
potent than or comparable to equol, and these two are more potent than daidzein. Glycitein 
binds the least strong to the ERβ (24-26). The limited estrogen-responsive effects observed in 
our studies can be explained by multiple reasons. Firstly, PBMCs are not particularly known 
as estrogen-responsive, while adipose tissue is, albeit not as estrogen-responsive as breast 
and uterus tissue (12, 13). Secondly, expression levels of the ERs are suggested to be different 
in postmenopausal compared to premenopausal women (20-22), because postmenopausal 
women produce little endogenous estradiol (23). Expression might potentially change by 
epigenetic control. To check this, expression of ERα and ERβ was verified in both PBMCs and 
WAT of post- and premenopausal women. Although the number of available samples in 
each group was low (n = 26 in total, 4-8 per group), there was no indication of a difference 
in ER expression between pre- and postmenopausal women and between PBMCs and 
WAT (unpublished results). Thirdly, isoflavones might not predominantly induce estrogen-
responsive effects, but mainly affect other molecular pathways. This might be in line with 
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the extensive phase II metabolism that isoflavones undergo and by which they are mainly 
bound to glucuronide or sulfate esters in the systemic circulation (27). This means that 
only 1-2% of the isoflavones is present as aglycones which are able to structurally bind 
to the ERs (19, 28). Therefore, the question remains which other molecular pathways are 
induced by isoflavones and could potentially explain the effects in the other 93% of the 
affected genes, observed in our studies. Animal and in vitro experiments showed that 
next to the ERs, expression of the progesterone receptor (PR), androgen receptor (AR), 
Vitamin D receptor (VDR) and Retinoic acid receptor (RAR) was changed after exposure to 
isoflavones (29). These effects were mostly related to estrogen-responsive effects, such as 
presence of estrogen-responsive elements (ERE) in promotor sequences of PRs and VDR, 
or through ER-dependent mechanisms, which is the case for the AR. With regard to human 
health effects, both peroxisome proliferator-activated receptors alpha (PPARα) and PPARγ 
are known to be induced by isoflavones (30, 31). PPARs can induce mRNA transcription via 
heterodimerization with the retinoid X receptor and involvement of the liver X receptor (LXR) 
after exposure to isoflavones. Expression of the PPARα and LXR genes were significantly 
reduced in PBMCs of equol-producing women and in adipose tissue of non-producers after 
LG isoflavone supplementation. According to GSEA, PPARα target genes were significantly 
reduced in these groups and also in adipose tissue of equol producers taking the LG 
supplement. So, activation of PPAR by isoflavones might explain part of the observed 
effects on both energy metabolism and inflammation in our studies. Lastly, also the aryl 
hydrocarbon receptor (AhR) is known to be induced after exposure to isoflavones which 
might explain the observed effect of isoflavones on cell cycle (30). The exact involvement 
of other nuclear receptors, molecular pathways and signalling routes cannot be elucidated 
from the results of the two intervention studies, but might explain the differences in effects 
between the two isoflavone supplements and between the equol-producing phenotypes. 
Finally, other factors might influence molecular effects of isoflavones, like production of 
other gut-metabolites of daidzein such as O-desmethylangolensin (O-DMA, (32)), potential 
ER polymorphisms (33, 34) and DNA methylation of certain genes (35). 
our intervention studies vs. literature
To our knowledge, in two parallel intervention studies the effects of isoflavones on whole-
genome gene expression in PBMCs of healthy postmenopausal women were earlier 
examined (9, 36), while this has not been published for adipose tissue. Niculescu et al. clearly 
observed a difference in effects after intake of a high dose (~900 mg/day) genistein-rich 
supplement for 84 days between equol producers (2 in placebo and 5 in supplement group) 
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and non-producers (10 in placebo and 11 in supplement group). These effects were observed 
on cell differentiation, cAMP signaling, G-protein-coupled metabolism and steroid hormone 
activity (9). The study of Wang et al. observed marginal effects after an 8 week intervention 
with 50 mg isoflavones (composition not defined) in 20 participants vs. 18 participants in 
the control group on genes related to nicotinamide phosphoribosyltransferase (NAMPT), 
Fc γ R-mediated phagocytosis and cytokine interactions (36). In comparison, our studies 
were crossover studies in which equol producing phenotype of the participants (n > 24) 
and isoflavone content of the supplements were well characterized. Furthermore, in our 
studies gene chips with ~20,000 genes were used to study the effects on gene expression. 
Although dose levels and study size are very different, some of the effects observed in 
these studies resemble effects observed in our studies, like effects on cell differentiation 
and cytokine interactions. 
Beneficial or adverse molecular effects?
The suggested beneficial effects on gene expression related to energy metabolism and 
inflammation in both PBMCs and adipose tissue, and cell cycle in PBMCs in our studies, are in 
line with results from human intervention studies. In literature, marginal beneficial effects are 
generally suggested on osteoporosis, cardiovascular disease, adipose tissue distribution and 
cancer risk (see introduction). Our studies showed that at the higher end of a physiological 
relevant dose of ~100 mg isoflavones/day, no indications were observed for adverse effects 
on gene expression. It should be noted that gene expression effects as such cannot predict 
beneficial or adverse effects on physiological or clinical health outcomes. This would require 
that the link between gene expression effects and health effects should be clearly established. 
To this end, studies with longer duration are needed, such as the 5-year study by Unfer et al. 
(37), in which both health endpoints and gene expression need to be studied. 
risk assessMent
the relation between isoflavone intake and exposure markers in humans
In chapter 4, plasma concentrations of daidzein, equol, genistein and total isoflavones 
after isoflavone intake were assessed by a log-linear regression model in which equol-
producing phenotype was used as a covariate. For this model, data were used from 103 
postmenopausal women, who participated in one of the two intervention studies or in 
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a similar study with soy foods. The results indicated a large degree of inter-individual 
variation which was in line with literature. This could originate from different sources, such as 
differences in uptake efficiency and metabolism of isoflavones. Also, microbiota or genetic 
variation in transporter genes might play a role in this. Other studies hypothesized that 
fat, carbohydrate and fiber intake could explain inter-individual variation, but taking into 
account background dietary intake in our model did not confirm this hypothesis. 
the relation between isoflavone intake and gene expression effects in 
human and rats
In chapter 5, gene expression effects in PBMCs and adipose tissue of postmenopausal 
women and ovariectomized (OVX) F344 rats after isoflavone supplementation vs. placebo 
were quantified and compared. The effect size of gene expression was quantified using 
multivariate log-linear regression and showed a 3-4 fold larger effect size in rats than in 
humans. The quantification of estrogen-responsive effects and effects in biological pathways 
of energy metabolism, inflammation and cell cycle enabled quantification of intertissue 
and interspecies comparability of gene expression effects. 
the parallelogram approach for improvement of risk assessment
Part of the hypothesis of the current thesis was that improvement of risk assessment can be 
achieved by standardization of markers of exposure and early effects across aligned human 
intervention studies and animal experiments (Figure 6.2). Exposure markers for the human 
and rat studies were measured in a standardized way using HPLC with electrochemical 
detection in the same laboratory with the same quality control measures. For the early effect 
markers, gene expression measured by whole-genome microarrays was also performed in 
the same laboratory and using similar data platforms. 
In this thesis, isoflavone plasma concentrations were successfully modelled by intake for 
postmenopausal women as well as gene expression effects after isoflavone intake for 
both humans and rats (black arrows in Figure 6.2). Results from the latter model were 
used to quantify effect sizes for gene expression in PBMCs and WAT of postmenopausal 
women and OVX rats; moreover, intertissue and interspecies correlations were obtained 
for the selected gene sets. These correlations were not directly generalizable and usable 
for risk assessment since they were derived for two surrogate tissues and only for the case 
of isoflavones. However, the results suggest that this can be an important tool to further 
explore intertissue and interspecies similarities and might contribute to advancing use of 
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transcriptomics in the parallelogram approach for risk assessment. In addition, the log-linear 
regression model for explaining concentrations of exposure markers from isoflavone intake, 
can be used to compare this relation between species and also advance the parallelogram 
approach for risk assessment.
Although the standardized dose is a strength of our studies, an important disadvantage is that 
only one dose (~2 mg/kg bw) and one exposure time (eight weeks) were taken into account 
and that dose-response effects on gene expression were not considered. Furthermore, in this 
thesis the full parallelogram could not be completed due to data gaps, which are insufficient 
exposure marker data for rats and missing data on target tissues for both species (grey arrows 
in Figure 6.2). Exposure marker data was only available for 6 rats for one dose, which implied 
that models for intake vs. exposure markers could not be evaluated for rats. As known from 
literature, the pharmacokinetics of isoflavones in the two species are very different (28); 
therefore modeling of this relation for rats and the relation between exposure markers vs. 
early effect markers for both humans and rats would be valuable for risk assessment. 
Figure 6.2 Parallelogram approach using transcriptomics for gaining insight in intertissue and 
interspecies differences in which the black parts represent the achieved comparisons and the grey 
parts represent comparisons for future research. OVX, ovariectomized; PBMC, peripheral blood 
mononuclear cell; WAT, white adipose tissue.
intake 
vs. 
early effect markers
PBMCIsoflavone intake
Isoflavone intake WAT
Postmenopausal 
women
OVX 
F334 rats
Exposure
markers
Exposure
markers
Target 
tissues
Target 
tissues
WAT
PBMC
intake 
vs. 
exposure markers
In
te
rs
pe
ci
es
 
co
m
pa
ris
on
s
exposure markers
vs. 
early effect markers
G
eneral discussion
Chapter 6
135
6
Because of the hypothesized estrogen-responsive effects, likely target tissues for isoflavone 
supplementation would be breast and uterus. Quantification of effects on gene expression 
in these tissues and the subsequent quantitative intertissue and interspecies comparison 
would also advance the parallelogram approach. Unfortunately, target tissues from the 
animal experiment were not available for our data analysis and comparable samples could 
not be collected in a human intervention setting from healthy women or in representative 
clinical settings.
integration of toxicological and epidemiological data for risk assessment
Next to standardization and alignment of exposure and early effect markers for improvement 
of risk assessment, the hypothesis was that epidemiology could contribute in defining 
dietary intake in the population and toxicology could complement by defining disease and 
health endpoints (Figure 6.1). In this thesis, two human intervention studies were conducted. 
In addition to these studies, data from an intervention study with soy products with an intake 
of ~50 mg isoflavones/day was used, which enabled linear regression modelling of intake 
and exposure markers. However, insight in soy and isoflavone supplement consumption 
patterns across the population is still lacking.
Disease endpoints were not studied in the current rat experiment because for instance 
cancer development is hardly expected after eight weeks of exposure to isoflavones. 
Nevertheless, incorporating hard endpoints in the parallelogram approach is essential for 
improvement of risk assessment, especially since the link between the early effect markers 
and the hard endpoints is needed for extrapolation of effects to the human situation. 
Incorporation of hard endpoints could be achieved by longer animal experiments or human 
observational studies with sufficient participants, in a population with a large intake range 
and long follow-up time.
conclusion 
isoflavone safety: case closed?
The two human intervention studies presented in this thesis suggested that the effects of 
isoflavone supplementation on gene expression in PBMCs of equol-producing and WAT 
equol-producing and non-producing postmenopausal women might be beneficial. The 
ISO II study showed that the molecular effects were highly influenced by supplement 
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composition and equol-producing phenotype, but both studies showed no distinct 
estrogen-responsive gene expression effects were present in either PBMCs or adipose 
tissue. 
If the negative effects via the ER, observed in in vitro and animal experiments, are less 
relevant for the human in vivo situation than previously assumed and if the positive effects 
generally found in human intervention studies and in this thesis are taken into account, we 
might conclude that doses up to 100 mg/day among postmenopausal women do not raise 
safety concerns. However, isoflavones might still dominantly induce estrogen-responsive 
effects in target tissues, like breast and uterus. Moreover, in our studies conclusions could 
only be drawn on molecular effects and not on phenotypical, functional or disease-related 
endpoints. Thus, although the evidence obtained in this study does not increase safety 
concerns of isoflavones, the case cannot yet be closed.
integrated risk assessment: a step forward?
With regard to integrating toxicological and epidemiological approaches for risk assessment, 
we showed the use of two models; one for quantifying the relation between intake and 
exposure markers in humans and one for quantifying the relation between intake and early 
effect markers as determined by whole-genome gene expression in humans and rats. The 
latter model also enables quantification of intertissue and interspecies similarities. Together 
these models and comparisons can be applied in the parallelogram approach to advance 
risk assessment. 
Future directions 
Although our studies did not support an urgent safety issue with isoflavones, long term 
studies to understand their beneficial or even adverse health effects are still lacking. Also, 
further research into the effects of isoflavone content and composition and equol producer 
status on the involved molecular pathways and signaling routes is recommended, especially 
with regard to estrogenic target tissue.
The quantitative models proposed in this thesis need to be validated for the case of 
isoflavones by filling the data gaps on exposure markers and target tissue in rats (Figure 
6.2). Furthermore, early effect marker data in human estrogenic target tissue, such as breast 
and uterus, can potentially be obtained in intervention studies in a clinical setting, to 
further validate the quantitative model and intertissue and interspecies comparisons in the 
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parallelogram approach. Lastly, for the actual use of these models in risk assessment, more 
dose-response data is needed and determining the quantitative relation of transcriptomics 
as early effect markers with disease endpoints is crucial.
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Dit proefschrift beschrijft een project dat tot doel had de risicobeoordeling te verbeteren 
door de kennis en expertise van toxicologie en epidemiologie beter te combineren. Deze 
samenwerking werd in de praktijk gebracht door de veiligheidsaspecten van de consumptie 
van supplementen met isoflavonen te bestuderen.
Isoflavonen zijn ook wel bekend als planten-estrogenen en de belangrijkste isoflavonen 
zijn daidzeïne, genisteïne en glyciteïne. Deze isoflavonen komen vooral voor in soja en 
sojaproducten en zijn bekend vanwege hun gunstige effecten op de gezondheid zoals 
gevonden in epidemiologische studies in Azië waar veel soja geconsumeerd wordt. Deze 
gezondheidseffecten zijn onder andere minder overgangsklachten, osteoporose, hart- en 
vaatziekten en bepaalde soorten kanker. De hypothese achter het mechanisme van de 
gezondheidseffecten van isoflavonen is dat ze dezelfde structuur als estradiol hebben en 
daardoor aan de estrogeenreceptoren binden. Via binding aan deze receptoren worden 
genen tot expressie gebracht en via regulatie van genexpressie kunnen vervolgens 
metabole en signalering routes in het lichaam worden aan- of uitgezet. Als dit op langere 
termijn regelmatig gebeurt zou dit verschillende gezondheidseffecten kunnen induceren. 
In westerse landen consumeert men niet zoveel sojaproducten, maar kunnen vrouwen die 
in de overgang zijn wel supplementen met isoflavonen gebruiken tegen overgangsklachten. 
Deze vrouwen consumeren dagelijks een relatief hoge dosis en de vraag is of deze 
supplementen bij een dergelijke hoge dosis nog steeds gunstige gezondheidseffecten 
hebben of dat eventuele schadelijke effecten de overhand krijgen. Vooral personen die 
darmbacteriën hebben die daidzeïne om kunnen zetten in het metaboliet equol, wat 
sterker werkt op de estrogeen receptoren dan daidzeïne, kunnen gevoeliger zijn voor de 
positieve maar ook de negatieve effecten van isoflavonen. 
In de traditionele risicobeoordeling worden effecten uit dierstudies vaak geëxtrapoleerd 
naar de humane situatie, wat verschillende onzekerheidsfactoren met zich meebrengt. 
Dit kan verbeterd worden door de samenwerking tussen epidemiologie (humane data) en 
toxicologie (dierexperimentele data) te versterken. Dit kan bijvoorbeeld gedaan worden door 
het meten van vroege veranderingen in het metabolisme door blootstelling aan een bepaalde 
component, een techniek die gebruikt wordt in zowel de epidemiologie als de toxicologie. Een 
techniek die staat vaker gebruikt wordt om gevoelig te meten en zo vroege veranderingen te 
detecteren is transcriptomics, oftewel het meten van genexpressie. Dit zou de mogelijkheid 
kunnen geven tot beter inzicht in de onzekerheidsfactoren binnen de risicobeoordeling.
In dit proefschift worden eerst de gezondheidseffecten van isoflavonen onderzocht in 
twee interventiestudies. Dit wordt gevolgd door de toepassing van deze data voor de 
verbetering van de risicobeoordeling. 
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In hoofdstuk 2 wordt een humane interventiestudie beschreven waarin 30 postmenopausale 
vrouwen een isoflavonensupplement hebben geconsumeerd. Dit supplement bevatte 
relatief veel daidzeïne en weinig genisteïne (LG-supplement). Deze vrouwen waren zo 
geselecteerd dat ze allemaal equol konden aanmaken uit daidzeïne. De genexpressie 
profielen in witte bloedcellen (PBMCs) lietem effecten van het supplement zien op 
inflammatie, oxidatieve phosphorylering en de celcyclus. In deze witte bloedcellen werden 
geen effecten gevonden op genen die gereguleerd worden door de oestrogeenreceptor en 
ook niet op andere groepen genen (gensets van de ‘gene set enrichment analysis’ of GSEA) 
geassocieerd met deze effecten. De genexpressie-effecten die we in deze studie vonden 
zouden kunnen wijzen op potentiële positieve effecten van isoflavonen op het ontstaan 
van kanker en hart- en vaatziekten, maar deze studie betrof genexpressie-effecten op 
witte bloedcellen, dus effecten op andere organen moeten nog beter bestudeerd worden.
In hoofdstuk 3 wordt een andere humane interventiestudie beschreven waarin 58 postme-
nopauzale vrouwen een supplement met relatief veel daidzeïne en weinig genisteïne (LG-
supplement) of een supplement met evenveel daidzeïne als genisteïne (HG-supplement) 
slikten. De gezondheidseffecten van deze supplementen werden onderzocht door te 
kijken naar genexpressieveranderingen in vetweefsel. De resultaten lieten zien dat beide 
supplementen effecten hebben op energiemetabolisme en inflammatie, maar dat zowel 
het effect als de richting van het effect erg afhankelijk zijn van de samenstelling van het 
supplement en van de vraag of de deelnemers equol konden aanmaken. Consumptie van 
het LG-supplement resulteerde in effecten op het energiemetabolisme die erg leken op 
de effecten van calorische restrictie. Daarnaast veroorzaakten beide supplementen ver-
oorzaakten anti-inflammatoire effecten in het vetweefsel van postmenopauzale vrouwen 
die equol konden aanmaken. 
In hoofdstuk 4 wordt er een start gemaakt met de verbetering van de risicobeoorde-
ling. In dit hoofdstuk worden de plasmawaarden na isoflavonenconsumptie van de twee 
hierboven beschreven studies gecombineerd met vergelijkbare data van een studie met 
sojaproducten. Deze plasmawaarden en de isoflavoneninname werden gemodelleerd 
volgens een loglineare curve. Uit deze modellering werd duidelijk dat er grote verschillen 
zijn in de plasmawaarden tussen de verschillende personen. Bovendien bleef deze vari-
atie bestaan als we het model corrigeerden voor de voedingsinname van de deelnemers. 
In hoofdstuk 5 worden de genexpressiedata van de twee interventiestudies gecombineerd 
met genexpressiedata van een dierstudie. Meer specifiek betrof het data van PBMCs en 
vetweefsel van postmenopauzale vrouwen en PBMCs en vetweefsel van ratten zonder eier-
stokken (zogenaamde geovarectomiseerde ratten, ook postmenopauzaal) na consumptie 
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van hetzelfde supplement, namelijk het supplemen dat rijk was aan daidzeïne en arm in ge-
nisteïne (LG-supplement). Deze data werd met elkaar vergeleken door ‘gene set enrichment 
analysis’, oftewel GSEA, waarin bestaande gensets worden vergeleken met de genexpressie 
door isoflavonen. Daarnaast werd de grootte van de genexpressie-effecten gekwantificeerd 
in een multivariaat model. In beide weefsels, van zowel de vrouwen als de ratten, werden 
genexpressie-effecten gevonden op energiemetabolisme, inflammatie en celcyclus. Voor 
deze effecten werd ook een kwantitatieve vergelijking van genexpressie-effecten tussen 
PBMCs en vetweefsel en tussen vrouwen en ratten gedaan. Daardoor is dit model een 
belangrijk hulpmiddel in het gebruik van transcriptomics voor de risicobeoordeling.
Beide humane interventiestudies resulteerden in aanwijzingen voor positieve gezond-
heidseffecten van het gebruik van supplementen met isoflavonen. Deze effecten worden 
beïnvloed door de samenstelling van het supplement en door het al dan niet kunnen 
omzetten van daidzeïne in equol. In beide studies werd gevonden dat de effecten via de 
estrogeenreceptor minder sterk waren dan verwacht op basis van binding aan de estrogen 
receptor en de daarop volgende gentranscriptie activatie. Op basis hiervan zou geconclu-
deerd kunnen worden dat er tot een dosis van 100 mg/dag geen negatieve gezondheidsef-
fecten te verwachten zijn van het gebruik van deze isoflavonensupplementen. Wel dient 
opgemerkt te worden dat we alleen moleculaire effecten op twee weefsels bestudeerd 
hebben en dat het mogelijk is dat effecten van isoflavonen op andere weefsels anders en 
misschien zelfs ongunstig uitpakken. In de literatuur ontbreken studies die de effecten 
van isoflavonen op langere termijn (> 5 jaar) bestuderen. Daardoor is het, ook al vinden 
wij geen aanwijzingen voor negatieve effecten van isoflavonen, niet mogelijk om een 
definitief oordeel te geven over de veiligheid van isoflavonen op basis van onze studies.
Met betrekking tot de risicobeoordeling geeft dit proefschrift richting aan de samenwerking 
tussen toxicologie en epidemiologie door het gebruik van modellen om genexpressiedata 
te integreren. Deze benadering kan in de toekomst worden gebruikt om genexpressiedata 
te kunnen vergelijken en te gebruiken voor de risicobeoordeling. Ook met betrekking 
tot isoflavonen, kan deze benadering nog verder worden uitgebreid naar zogenaamde 
doelwitorganen van estrogene activiteit, zoals borst- en baarmoederweefsel. Dit weefsel kan 
zowel bij mensen, in een klinische setting, als bij dieren verzameld worden na blootstelling 
aan isoflavonen. Voor uiteindelijk gebruik van deze modellen voor de risicobeoordeling is 
het nodig om meer dosiseffectdata te verzamelen en is het van belang dat de genexpressie-
effecten worden vertaald in daadwerkelijke gezondheidseindpunten.
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